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Abstract 
The commonest reproductive disorders of young men (namely low sperm counts, 
testicular germ cell cancer) may originate in fetal life similar to established disorders 
(cryptorchidism, hypospadias) that manifest at birth. These disorders are interlinked and 
may comprise a testicular dysgenesis syndrome (TDS), a concept supported by animal 
model studies. The latter have identified the likely time-frame within which TDS 
disorders may be induced, namely within the so-called masculinisation programming 
window (MPW). During this critical period, sufficient testosterone (androgen) must be 
produced by the fetal testis to program the male reproductive tract so that it will 
differentiate and grow normally after the MPW. Impaired androgen production or action 
within the MPW can result in smaller reproductive organs and their abnormal formation 
and function (e.g. cryptorchidism, hypospadias).  
 
The MPW is thus of fundamental importance in determining normal, or abnormal, male 
reproductive development and function for later life. There are two big unanswered 
questions about the MPW. First, what determines its timing? Second, what mechanisms 
are controlled by androgens specifically within this time-window and not at later time 
points? Three approaches were undertaken to address the first question experimentally in 
rats. First, investigation of whether the availability of androgens and or androgen 
receptors (AR) plays a role in determining the onset or ‘opening’ of the MPW. Second, 
investigation of whether the expression of AR co-regulators was a factor in determining 
androgen sensitivity during the MPW. Third, investiga on of whether prostaglandins 
played a role in mediating androgen action in the MPW, as studies in the 1980s had 
suggested this possibility. To address what mechanisms are controlled by androgens 
specifically within the MPW, the expression of selected genes in the genital tubercle was 
investigated before, during and after the MPW in fetus s that had been exposed to 
treatments that modulated androgen action. Selection of genes was based on microarray 
studies and data reported in the literature (ie candidate genes).  
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The studies reported in this thesis show that neither availability of androgens nor the AR 
are important in determining onset of the MPW, and providing exogenous androgens 
either prior to or during the MPW does not advance or nhance masculinisation. These 
studies also showed that females may have a slightly different window of susceptibility 
to androgen action than do males. Key AR co-regulators have been characterized in the 
male reproductive tract for the first time, two of which (BRG1, CBP) show changes in 
expression through development of the testis consistent with a role in Sertoli cells. 
Another AR co-regulator, RWDD1, was found to switch off in the absence of androgen 
action in the genital tubercle, pointing to a potential role during and/or after the MPW. 
Studies involving gestational exposure to indomethacin (a compound which inhibits 
prostaglandin synthesis) during the MPW showed no detectable effect on 
masculinisation. Finally, evaluation of candidate genes for mediating androgen action in 
the genital tubercle during the MPW, failed to identify their key involvement, thus they 
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1. Literature Review 
Mammalian embryos, like most species, are initially sexually indifferent and can follow 
one of two developmental courses; becoming a male or a female. This fate is determined 
by the paternal sperm which can carry either a Y or an X chromosome. This adds to the 
maternal X chromosome to produce an XY embryo (male) or an XX embryo (female) 
(Welshons and Russell 1959). Fetal sex development ca  be divided into three 
sequential stages. The first of these is the indifferent stage when the primitive structures 
develop. The second stage involves gonadal differentiation into either the testes in the 
male or the ovaries in the female. The final stage of sex development is the 
differentiation of the internal and external reproductive organs which in the presence of 
testicular hormones in the male will lead to the development of the penis, scrotum, 
prostate, seminal vesicles, vas deferens and epididymis (Fig.1.1). In the absence of 
testicular hormones, irrespective of the existence of the ovaries, the females develop a 
uterus, fallopian tubes, cervix, clitoris and labia. Thus the female sex development 
pathway is considered to be more of a default pathwy of development, whereas to 
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There are several disorders of the male reproductive tract and some studies suggest they 
are increasing in prevalence. The widely accepted Barker hypothesis (Barker, 1998) 
proposes that some common human diseases in adulthood are related to growth patterns 
during early life. Indeed there is much evidence emerging that fetal reproductive tract 
development is a highly controlled process which when disturbed can lead to disorders 
later in life. Understanding the molecular mechanisms which are employed by testicular 
Figure 1.1 Brief representation of the three stages of normal sexual differentiation. Stage 
1 shows the undifferentiated anlagen of gonads and external genitalia, identical in both 
sexes. Stage two illustrates gonadal differentiation and the genes (in green) involved in 
the formation of the testis and the ovary. The third stage is an overview of genital 
differentiation, which in males is under the influence of hormones (brown), namely 
testosterone, DHT or AMH. In the absence of testicular hormones, the female phenotype 
develops.  
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hormones in correct male reproductive tract development should aid our understanding 
of how male reproductive tract disorders occur and if they can be avoided or prevented.  
 
This review will discuss key male reproductive trac disorders, and then the timing in 
fetal life when they are thought to originate. This will be followed by a detailed 
discussion of the key testicular hormone, testosterne (i.e. androgens), the receptor to 
which androgens bind for effect, and their role in masculinisation of the fetus. 
Androgens are C-19 steroid hormones produced by the test s in males and the ovaries in 
females and to a lesser extent also by the adrenal glands in both sexes. Androgens are 
vital in male sexual differentiation. The two main a drogens required for virilisation of 
the fetus are testosterone and its derivative DHT (dihydrotestosterone). Testosterone 
elicits differentiation of the Wolffian duct into the seminal vesicles, vas deferens and 
epididymides (Berman et al, 1995) (section 1.9.1). DHT is required in the urogenital 
tract to differentiate the prostate and external genitalia (section 1.9.2). Later in life, 
correct androgen action is required at puberty and lso in the adult male. Despite the 
existence of different androgens and their role in different tissues (Luttge and Whalen 
1970), each exerts their effect through one common androgen receptor (section 1.4).   
 
The review will highlight gaps in our current knowledge of androgens and 
masculinisation and the aims at the end of this chapter will outline how some of these 
gaps have been investigated in the studies presented in his thesis.  
 
1.1 Testicular dysgenesis syndrome (TDS) 
Almost exactly a decade ago, a theory was published proposing that certain male 
reproductive tract disorders have a common origin in the fetal period. This syndrome of 
disorders was termed the testicular dysgenesis syndrome (TDS), initiated by abnormal 
fetal testis development, leading to somatic cell/hormonal malfunction, which then 
causes deficiencies in male reproductive tract differentiation (Skakkebaek et al, 2001). 
Currently, there are four disorders which are considered to share this common origin 
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(Sharpe and Skakkebaek, 2008), although it may be possible that other disorders are also 
part of the TDS. Of the identified four disorders, two manifest at birth; hypospadias and 
cryptorchidism, and the other two present in adulthood; namely low sperm counts and 
testicular germ cell tumours (TGCT). It has been suggested, based on epidemiological 
studies (Joergensen et al, 2001; Boisen et al, 2004; Boisen et al, 2005), that each of these 
disorders are risk factors for each other, consistent with them having a common origin, 
and may possibly be increasing in incidence (Sharpe nd Skakkebaek, 2008).  
 
1.1.1 Hypospadias  
Hypospadias is a congenital defect of the penis which consists of an abnormal location 
of the urethral opening (meatus) (Duckett and Baskin 1996). Hypospadias can be 
relatively ‘mild’ with the urethral opening located on the glans (near the tip) of the 
penis, in ‘moderate’ cases anywhere along the shaft, or in ‘severe’ cases in the perineal 
region (Baskin et al, 2001). Hypospadias is also comm nly associated with abnormal 
foreskin or penile curvature (Catti et al; 2008). This disorder occurs when the urethral 
folds of the penis fail to fuse correctly during penil  development. There are probably 
multiple mechanisms via which this failure can occur (Baskin et al, 2001), but the main 
cause is thought to be a defect in the action of the main hormone involved in 
masculinisation; androgens. The mechanisms by which t is might arise are discussed in 
section 1.9.3.  
 
 Many countries in Europe and cities in the US, Australia and China have reported an 
increase in occurrence of hypospadias (Paulozzi, 1999) but the data from registries is 
often considered unreliable. This is due to under-repo ting, particularly of mild cases; 
furthermore some forms of hypospadias can be masked under the foreskin and may not 
be obvious until puberty (Toppari et al, 2010). The current epidemiology data suggests 
that hypospadias occurs in 1 in every 125 live births (Baskin et al, 2001) and is usually 
identified at time of delivery; although more recently it can be determined prenatally by 
ultrasound.  
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Mutational analysis has identified genes which may be involved in hypospadias (Lin et 
al, 2009; Miyagawa et al, 2011; Wang et al, 2004). In addition, the importance of correct 
androgen action in penile development is well established and this will be discussed 
further in section 1.9.3.  However it should be noted hat for most hypospadias patients, 
there is no identifiable cause which raises the possibility that hypospadias can be 
induced by environmental factors (Baskin et al, 2001; Gray et al, 2001; reviewed by 
Kalfa et al, 2011). It is of general consensus thathypospadias is a highly heterogeneous 
condition subject to multiple genetic and environmetal factors. Indeed, many 
environmental chemicals, such as pesticides, fungicides and phthalates display anti-
androgenic properties and have been shown to induce hypospadias in rodent studies 
(Foster and Harris, 2005; Imperato-McGinley et al, 1986; McIntyre et al, 2001). The role 
of environmental chemicals as endocrine disruptors and inducers of hypospadias are 
discussed later.  
 
1.1.2 Cryptorchidism 
Cryptorchidism is the failure of one or both testes to descend into the scrotum and is the 
most common reported congenital disorder in baby boys. The position of the cryptorchid 
testes can vary from non-palpable (abdominal) to high scrotal (Boisen et al, 2004). 
Spontaneous testicular descent occurs in up to 75% of crytorchid testes during the first 
three months of life, during the period when testosterone production is elevated (Boisen 
et al, 2004; reviewed in Toppari et al, 2010). Cryptorchidism is reported to occur (on 
average) in 2-4% of boys, but it may be as high as 9% in Denmark and 6% in the UK 
(Toppari et al, 2001; Virtanen et al, 2007; Boisen et al, 2004; Hughes and Acerini, 
2008). Although some registries are reporting an increase in occurrence of 
cryptorchidism, it is not clear if incidence is changing across the globe. This uncertainty 
arises from differences in standardising the classificat on of cryptorchidism and also the 
spontaneous resolution of cryptorchid babies requirs standardization of the time of 
diagnosis (Paulozzi, 1999).   
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The descent of the testes from the abdomen into the scrotum is thought to be mediated 
either directly or indirectly by androgen action. The exact mechanism of descent, 
including the genes involved will be reviewed in section 1.2.2.3. However it should be 
noted that similar to hypospadias, it is believed that the aetiology of cryptorchidism is 
multifactorial and endocrine disruptors in the form of environmental chemicals may also 
play a role in this disorder.  
 
1.1.3 Sperm count and quality 
Concern about ‘falling sperm counts’ was raised as early as 1974 by Nelson and Bunge 
and further established by Carlsen et al in 1992, which reviewed 61 studies to reveal that 
average sperm counts appeared to have fallen from 113 million/ml to 66 million/ml 
between 1938 and 1991. Further studies published by Swan et al in 2000 updated this 
and confirmed that sperm counts had fallen in Europe, between the 1940’s and 1966 
from 170 to < 60million/ml and in North America between the 1930’s and 1996 from 
110 to 60 million/ ml. Both studies were met with scepticism based on criticisms such as 
non-uniformity of laboratory methods or statistical issues and many argue these studies 
do not prove a real decline (Jegou et al 1999). Despite the scepticism and unknowns, it is 
evident from all counts being done, there are no reports of an increase but only ever a 
decrease in sperm count. This, added to the many recent reports of an increased demand 
for assisted fertility suggests there is an adverse change occurring in sperm counts.  
 
1.1.4 Testicular germ cell tumours (TGCT) 
Of less controversy is the rise reported in TGCT, the most common cancer of young 
men. TGCT arises from carcinoma-in-situ cells (CIS) which are thought to be derived 
from primordial germ cells which did not undergo normal differentiation during the 
embryonic period (Rajpert-De Meyts et al, 1998). Many reports have shown an increase 
in TGCT occurrence in European countries and in particular in Caucasian men. 500,000 
new cases were reported worldwide in 2002 (Bray et al, 2006). TGCT is six times more 
common in developed rather than developing countries.  
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1.1.5 Anogenital Distance 
During development, the genital tubercle and genital swellings differentiate into either 
the penis and scrotum or the clitoris and labia majora in males and females respectively, 
whereas the cloacal membrane develops into the anus, giving rise to the perineum and 
the distance between the genitalia and the anus (Hsieh et al, 2008). In most mammalian 
species, this distance is longer in males than in females, suggesting it is under hormonal 
control (Salazar-Martinez et al 2004). Indeed, when females are exposed to androgens, 
the AGD increases and in males when androgen action is blocked, AGD is found to be 
decreased (Swan at al, 2005). There have been numero s experimental studies in 
animals showing that anti-androgens decrease AGD in males as well as affecting 
development of androgen dependent reproductive tissues (Gray et al, 1999; Imperato-
McGinley et al 1986, Ostby et al 1999; You et al 1998). Furthermore, it has been shown 
that AGD can be correlated with androgen action during a specific time in gestation 
when TDS disorders are thought to originate, this time being termed the masculinisation 
programming window (MacLeod et al, 2010; Welsh et al, 2008).  
 
1.1.6  The masculinisation programming window (MPW) 
In order to gain understating into the origins of reproductive disorders, studies have been 
conducted in which reproductive disorders are induce  in fetal rodents (Clark et al, 
1990; Clark et al, 1993, Foster and Harris, 2005; McIntyre et al, 2001; Welsh et al, 
2008). Such studies, combined with investigation of fetal chemical exposure in humans 
have provided insight into the time frames of critial periods of sexual differentiation in 
fetal life. It is now known that there is a specific time-frame in rats and mice, in which 
correct androgen action is necessary for normal male reproductive tract development. 
When androgen action is disturbed during this time frame, TDS disorders can result. The 
reporting of such experiments has continued to grow and now the literature has 
narrowed down the time period in sexual differentiation to be the ‘critical period of 
development’ for the male reproductive tract, during which androgen action in the male 
is most susceptible to perturbations (Welsh et al, 2008; MacLeod et al, 2010).  
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Androgens are first produced at approximately e14.5-e1 .5 in rats, consequently, the 
initial rodent studies which investigated androgen action used chemicals to block 
androgen action from e12.5 until the end of gestation (e21.5). These studies provided 
insight into the differential effects of blocking androgen production by the testis and 
blocking androgen action at the receptor. These experiments also provided insight into 
the differential roles of the two main androgens; testosterone and its more potent 
metabolite dihydrotestosterone (DHT), in masculinisation. Testosterone is converted to 
DHT by the enzyme 5α-reductase.   
 
An example of one such study exposed rats to 17β-N,Ndusopropylcarbamoyl-4-aza-
5αandrostan-3-one, also called the aza steroid, which is a competitive inhibitor of the 
5α-reductase enzyme, and thus inhibiting the formation of DHT which is important in 
masculinisation of the fetus. When rats were exposed to the aza steroid from e12.5-
e21.5, normal inhibition of nipple development in male rats was blocked and 
hypospadias was found (Imperato-McGinley et al, 1986).   
 
Flutamide is an anti-androgen which competitively binds to the androgen receptor, and 
so blocks androgen action (section 1.6.1.4.2). It was reported that exposing rats to 
flutamide from e12.5-e21.5 caused nipple retention and induced hypospadias in males 
(McIntyre et al, 2001). McIntyre et al also reported a significant decrease in AGD in 
males exposed to flutamide. This study also suggested that flutamide-mediated changes 
in AGD and nipple retention are not sensitive predictors of altered testosterone 
development in males, but more of the development which is dependent on the more 
potent androgen, dihydrotestosterone (DHT).  
Clark et al (1993) narrowed the window of treatment a d exposed rats to finasteride, 
which also inhibits 5α-reductase, with the aim of investigating the origins of 
hypospadias. Initially this study exposed rats from e15.5 until postnatal day (PND) 21. 
Surprisingly this study found that although AGD was decreased on PND1, this was 
reversed by PND22. Animals were reported to have hypospadias in addition to cleft 
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prepuce and reduced prostate weight. However, the same study then exposed animals to 
an approximately seven times higher dose of finasteride administered on successive 2 
day periods during late gestation and identified that e most sensitive period or ‘critical 
period’ was at e16.5 and e17.5, in which the most TDS like defects, for example 
hypospadias, cleft prepuce and decreased anogenital dist nce, were induced by the 
finasteride (Clark et al, 1993).  
 
Further studies have been conducted to investigate this critical period and insight has 
been gained by blocking androgen action using a single dose of flutamide, on particular 
days of gestation. This helps to elucidate which tissues of the male reproductive tract are 
being programmed on particular days of gestation and when this programming is most 
susceptible to disturbance (Foster and Harris, 2005). These studies found that blocking 
androgen action on e16.5 in rats induced a high incide e of retained nipples, epispadias 
and missing epididymal components in the male offspring. When exposed at e17.5, 
hypospadias, vaginal pouch, cleft prepuce and missing prostate lobes were reported 
more predominantly than after any other day of treatm nt. Reduced prostate size and 
abnormal kidneys were found after flutamide exposure on e18.5, and after exposure on 
e19.5 abnormal seminal vesicles were noted (Foster and Harris, 2005). There were few 
male offspring from this study which were found to have cryptorchidism, which 
suggests this disorder occurs when androgen action is blocked over multiple days of 
gestation. Nonetheless, even six years ago, it was clear that androgens act at very 
specific times during fetal life to regulate normal development of male reproductive tract 
tissues.   
 
The most defining studies with regards to androgen action in the development of the 
male reproductive tract perhaps are those published by Welsh et al in 2008. The initial 
aim of these studies was to block androgen action in four different gestational time 
windows in the rat. Using flutamide, androgen action was blocked, during an early 
window, e15.5-e17.5, a middle window, e17.5-e19.5 a late window, e19.5-e2.5 and a 
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full window from e15.5-e21.5. The results found that androgen driven masculinisation 
of all male reproductive tract tissues is mediated during the early programming window 
(e15.5-e17.5) and that deficient androgen action during this window induced 
hypospadias, cryptorchidism, and decreased AGD. This study also underlined AGD as 
being a lifelong read-out of androgen action during just e15.5-e18.5. In these studies, 
phallus length and weight were found to be differentially regulated. In parallel, another 
set of animals were exposed to testosterone during the same four windows and this study 
concluded that excess exposure to testosterone could not advance or enhance 
masculinisation and that exposure to females during the early window induced a male 
phenotype, with increased AGD. The exposure to testosterone during the various 
windows demonstrated that not only is androgen action able to virilise the female after 
exposure in a particular window, but furthermore, presumptive excess androgen in this 
time window had no discernible effect on males. This suggests that in vivo androgen 
action is at its maximum capacity during the critical time for male reproductive tract 
differentiation (Welsh et al, 2008).  
 
Another study by Welsh et al, again using flutamide, showed that adult penile size 
depends critically on androgen action during the MPW but subsequent growth depends 
on later androgen exposure after the MPW. Fetal or postnatal testosterone exposure did 
not increase adult penile size above its pre-determin d (in the MPW) length, although 
the growth towards this could be advanced by pre-pubertal testosterone treatment 
(Welsh et al, 2010).  
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These foundation studies have been built upon and it is now widely accepted that a 
masculinisation programming window (MPW) exists in rats within the period e15.5-
e18.5 (Fig1.2). During this critical period, sufficient testosterone (androgen) must be 
produced by the fetal testis to bring about ‘programming’ of the male reproductive tract 
so that it will subsequently differentiate and grow normally after the MPW. It is during 
the MPW that correct androgen action is required to program the genital tubercle (later 
penis), the Wolffian duct (later vas deferens, seminal vesicles and epidiymis), the AGD 
and the prostate (MacLeod et al, 2009), although postnatal androgen action is required to 
reach this full potential. Any impairment of androgen production or action within the 
MPW is likely to result in smaller reproductive organs and their abnormal formation and 
function (e.g. cryptorchidism, hypospadias). The MPW is an early event, occurring 
immediately after testis differentiation, so androgen production and action at this time 
can be difficult to measure directly, especially in humans (Scott et al, 2009). However, 
anogenital distance (AGD), which is longer in males than in females, provides a life-
long read-out of androgen exposure just within the MPW (Welsh et al, 2008; MacLeod 
Figure 1.2 Illustration of the timing of events in male reproductive tract programming, 
differentiation and growth in the rat with the actions of androgens during the MPW highlighted in 
the red box. Note that the (GT) genital tubercle; (VP) ventral prostate; (WD) Wolffian duct; 
(AGD) and anogenital distance are all programmed by androgens during the MPW. Adapted 
from Macleod et al, 2010.  
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et al, 2010). Based on AGD, emerging evidence for the human points towards similar 
importance of the MPW (~8-14 weeks’ gestation; (Welsh et al, 2008)) and a critical role 
for deficient androgen action in the MPW as a cause of TDS disorders (Swan et al, 2005; 
Hsieh et al, 2008; Eisenberg et al, 2011; Mendiola et l, 2011). 
 
The MPW is now commonly used as the time frame to investigate TDS disorders in 
rodent studies and this has provided an invaluable platform upon which investigations 
can be based. However there are many gaps in our knowledge about this relatively 
newly defined time-frame. The studies conducted to ate address that impaired androgen 
action during the MPW causes a failure in programming of the reproductive tract. 
However the molecular mechanisms driven by androgens during this time in normal and 
abnormal development remain to be elucidated. Evidently, there must be something 
unique about androgen action during this time frame which does not occur at any other 
point. Furthermore, the regulation of this time frame remains to be understood. The 
presumption to date is that the onset of the MPW is due to the time of onset of 
testosterone production by the testis, which happens at around e14.5 in the rat, which is 
a very reasonable presumption. However if this is true, and androgens are the substance 
controlling the ‘opening of the window’, what might be involved in ‘closing’ the MPW? 
It is well established that androgens continue to be produced after the MPW and 
throughout much of postnatal life, and development of male reproductive organs cannot 
be induced during this time frame only during the MPW. It is interesting to note that 
there is little reported in the literature about the availability of the androgen receptor 
prior to the MPW. Furthermore, if AR is present, would excess exposure to androgens 
affect the timing of the MPW? 
1.2 Determination of gonadal sex of an embryo 
Although the genetic sex of an embryo is determined at fertilization, the sexual 
differentiation of the fetus actually only begins during the period of organogenesis when 
the gonads differentiate (Brennan and Capel, 2004; Swain and Lovell-Badge, 1999). The 
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gonads initially develop in a non-sex specific manner, and are identical in XY and XX 
embryos until e12 in mice, e13.5 in rats and week 6 in humans (Brennan and Capel, 
2004; Lambrot et al, 2006). The development of the gonads can be divided into two 
phases, formation of the bipotential gonad and thenits development into a testis or an 
ovary.  
 
1.2.1 Formation of the bi-potential gonad 
The urogenital system arises from the intermediate mesoderm layer of the fetus which 
lies on either side of the embryo, filling much of the coelomic cavity between the limb 
buds. The mesoderm layer consists of three regions from anterior to posterior, the 
pronephros, mesonephros (from which the gonads arises) and the metanephros, from 







The gonads develop from a single layer of coelomic epithelium which is located on the 
ventrolateral surface of the mesonephros (Swain and Lovell-Badge, 1999 Wilhelm et al, 
2007). The coelomic epithelium thickens and proliferat s to give rise to the genital ridge, 
also called the bipotential gonad. Genetic analysis in rodents and human has identified 
some key gene pathways which are involved in the early formation of the indifferent 
Figure 1.3 Diagrammatic representation of the urogenital system (mouse at e10). Epithelial 
structures are in red and mesenchymal structures are in blue. The genital ridge is represented by 
the striped region. WD represents Wolffian duct; MT represents mesonephric tubules, MD 
represent Müllerian duct, UB represents ureteric bud and CE represent coelomic epithelia. 
Diagram from Swain and Lovell-Badge, 1999.   
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genital ridges. These include Wilms Tumour suppressor 1 (Wt1) (Nachtigal et al, 1998), 
Steroidogenic factor-1 (Sf1) (Achermann et al, 1999; Achermann et al, 2002), GATA-
binding protein 4 (Gata4) (Tevosian et al, 2002), Limhomebox protein 9 (Birk et al, 
2000), empty spiracles homologue 2 (Emx2) (Miyamoto et al, 1997) and insulin-like 
growth factor 1 receptor (Igf1r) (Brennan and Capel, 2004). Wt1 is expressed widely 
throughout the urogenital ridge, the kidney and the gonad. Wt1 encodes a nuclear zinc 
finger protein that can function as both a transcriptional activator or repressor depending 
on cell type and promoter context (Wilhelm et al, 2007). Steroidogenic factor-1 (Sf1) is 
a nuclear receptor expressed in the developing urogenital ridge but also in the 
hypothalamus and pituitary, and is thought to be important in the formation of the 
hypothalamic-pituitary-gonadal axis early in development (Sadovsky et al, 2000, 
Shinoda et al, 1995). Gonads of Sf1 mutant embryos do not develop beyond the early 
indifferent stage and fail to undergo masculinisation n XY animals (Wilhelm et al, 
2007). Limhomeobox protein 9 (Lhx9) and empty spiracles homologue 2 (Emx2) are 
both homebox genes also crucial for the initial development of the bipotential gonads. It 
has been shown that mice lacking Lhx9 show a similar phenotype to those lacking Sf1
and furthermore Lhx9 can bind to the promoter of Sf1 (Luo et al, 1994). Mutants of 
Emx2 lack a thickening of the coelomic epithelium and later lack gonads completely 
(Miyamoto et al, 1997).  
 
Originally the bipotential gonad consists of two types of cells; the somatic progenitor 
cells, which have migrated from the mesonephros and the coelomic epithelium and the 
primordial germ cells, which arise from a population of epiblast cells in the 
extraembryonic mesoderm, near the base of the allantois. The primordial germ cells 
migrate via the hindgut to the genital ridge and can give rise to the spermatogonia in the 
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1.2.2 Testes Development 
The XY bipotential gonad begins differentiation into a testis when a particular gene, 
expressed only on the Y chromosome, termed the Sry gene, is expressed (Koopman et al, 
1991). In mice this expression begins at e10, in the rat around e12.5 and in the human 
around week 6 of pregnancy. This leads to a cascade of events which results in four 
main cell types of the testis, the Sertoli cells, the Leydig cells, the peritubular myoid 
cells and the germ cells as well as formation of two compartments, the seminferous 
cords and the interstitial space and also the formation of the testis vasculature (Wilhelm 
and Koopman, 2007).  
 
1.2.2.1 SRY 
The testis determining gene, Sry, discovered in 1990 (Gubbay et al, 1990), has been 
shown to be the only gene required from the Y chromosome to establish male 
development. The loss of Sry function in XY embryos results in ovary development a d 
the gain of Sry function in an XX embryo leads to the development of estes (Lovell-
Badge et al 1990, Koopman et al 1991, Berta et al 1990, Jager et al 1990).  
 
The Sry transcription factor encodes a nuclear high mobility group (HMG) domain 
protein which can alter chromatin structure (Brennan and Capel 2004). Outside of this 
domain, Sry exhibits little sequence conservation between species. Mutations of Sry 
which produce a clinical phenotype have always been found within this domain, 
implying its importance. 
 
The main function of Sry is to induce the differentiation of Sertoli cells but the exact 
molecular mechanisms involved in achieving this arepoorly understood (Swain and 
Lovell-Badge 1999). It is believed that Sry induces Sertoli cell differentiation by 
regulating other transcription factors, the most investigated of which is the Sry-like 
HMG-box protein 9 (Sox9) (Wilhelm and Koopman, 2007; Wilhelm et al, 2007). Sox9 is 
critical in male development, and studies have shown that Sox9 alone is sufficient to 
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induce testes formation in mice (Bergstrom et al, 2009; Vidal et al, 2001). Conversely, 
null mutations in Sox9 prevent testis differentiation (Barrionuevo et al, 2005). Sox9 
expression persists in Sertoli cells throughout life a ter transient expression of Sry has 
ceased.   
 
In addition to Sox9, the following genes have also been shown to be crucial in testes 
development, namely Fgf9, Wnt4, Ptgds and Gata4 (Wilhelm et al, 2007; Brennan and 
Capel 2004). These genes contain potential Sry binding sites in their promoters but their 
direct interaction with Sry requires further investigation (Wilhelm and Koopman, 2007). 
It is also suggested that Sry represses a negative regulator that functions at the op of the 
genetic cascade to suppress testes development, and some studies propose this negative 
regulator to be Dax1 (Bardoni et al, 1994; Jordan et al, 2001; Swain et al, 1996). The 
literature concerning the role of Dax1 is contradictory. There is consensus that this X-
chromosomal gene probably interacts with Sf1and with both oestrogen receptors α and 
β, and the androgen receptor (AR) and progesterone receptor (Conde et al, 2004; Park et 
al, 2005; Zhang et al, 2011). It has been shown to be expressed in the developing adrenal 
gland, gonads, hypothalamus and pituitary, with expr ssion patterns correlating with Sf1 
(Ikeda et al, 1996). Dax1 switches off in the male mouse testis at around e12 but then re-
appears at around e15-17 (Wilhelm and Koopman, 2007). In contrast, it is constantly 
expressed in the ovary (Swain et al, 1996). Based on uplications in humans that lead to 
XY sex reversal, some literature states this to be an ovarian determining or anti-testis 
gene which, in the male, is suppressed by SRY. However, loss of function of Dax1 in 
female mice has no reproductive consequences whereas testicular development in males 
was impaired which is why some scientists do not classify this as an ovary determining 
gene (Yu et al, 1998; reviewed in Wilhelm and Koopman, 2007).  
 
Transient SRY expression occurs in a wave that begins in the centre of the genital ridge 
(e10) and then encompasses the entire gonad reaching peak expression at e11 in the 
mouse. The expression declines first in the centre, then at the poles and is undetectable 
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by e12 (Wilhelm and Koopman, 2007). The exact molecular mechanisms which regulate 
this expression are not yet fully understood. However, mice mutants have shown that 
splice variants of Wt1, Gata4 and the insulin receptor family may be involved. The 
timing of peak Sry expression is crucial and delayed expression can le d to a range of 
phenotypes from complete XY sex reversal to unilateral or bilateral ovotestes (gonads 
which have both ovarian and testicular tissue/cells) (Wilhelm et al, 2009). 
 
1.2.2.2 Sertoli Cells 
The Sertoli cells are important not only because thy are essential for early testes 
development (Swain and Lovell-Badge 1999) but also later and throughout life for germ 
cell support and spermatogenesis. Furthermore the initiation of the male pathway 
depends on the development and the threshold number of Sertoli cells (Brennan and 
Capel 2004). Once sufficient Sertoli cells have differentiated, morphological changes 
can be seen in the gonad, as the Sertoli cells and go ocytes arrange themselves into 
seminiferous cords and the proliferation of both cell types in parallel increases testes 
size. The formation of the seminiferous cords involves the Sertoli cells undergoing 
mesenchymal to epithelial cell transformation and polarization which allows aggregation 
around the germ cells. It was originally believed that the Sertoli cells then produced a 
trigger which signaled the mesonephric cells from the adjacent mesonepehros to migrate 
into the developing testis giving rise to the pertitubular myoid (PTM) cells (Brennan and 
Capel 2004), which begin to express AR during this migration (Sharpe, 2006). However, 
more recently it is believed that the PTM cells may arise from pre-existing cells in the 
gonad (Cool et al, 2008).  The PTM cells collaborate with the Sertoli cells to induce the 
basement membrane, also called the basal lamina (Swin and Lovell-Badge, 1999). This 
finalises compartmentalization of the testes into the seminiferous cords that house the  
germ and Sertoli cells and the interstitium which houses the Leydig cells responsible for 
producing masculinising hormones.   
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The Sertoli cells also have two further roles. The first of these is to produce paracrine 
factors to initiate differentiation of the Leydig cells. In addition, and very importantly, 
Sertoli cells also secrete anti- müllerian hormone (AMH) at around e12 in the mouse and 
the action of this hormone is vital in masculinising the fetus and inducing apoptosis of a 
female structure, the müllerian ducts (Sajjid, 2010). AMH is responsible for regression 
of the müllerian ducts in the male fetus, which in females, gives rise to the fallopian 
tubes, the uterus and upper third of the vagina. It is proposed that Sf1, Wt1 and possibly 
Dax1 are involved in the regulation of AMH (Shen et al, 1994; Nachtigal et al, 1998).  
 
1.2.2.3 Fetal Leydig Cells 
Approximately 24 hours after Sertoli cell differentiation, the Leydig cells begin to 
differentiate in the interstitium in the mouse and this is thought to be regulated by 
paracrine factors from the Sertoli cells. These paracrine factors include desert hedgehog 
(Dhh) (Canto et al, 2005; Yao et al, 2002), platelet derived growth factor (Pdgf) 
(Brennan et al, 2003) and aristaless-related homeobox gene (Arx) (Kitamura et al, 
2002), and defects in these factors can lead to abnormal Leydig cell differentiation 
(Barsoum and Yao et al, 2006). The Leydig cells have two distinct lineages, the fetal and 
adult Leydig cells. Fetal Leydig cells are present in he testes from e12 in the mouse 
(Brennan and Capel 2004) until shortly after birth and function primarily to produce 
testosterone to virilise both the internal and external genitalia of the fetus. The 
production of androgens is discussed in section 1.3. The Leydig cells also produce 
insulin like growth factor 3 (INSL3), a hormone whic  is essential for migration of the 
testes within the abdomen and for normal gubernaculum development (Barsoum and 
Yao, 2006).  
 
An important difference between the male and female gonads is their final location 
within the body. The testes descend into the scrotum whereas the ovaries remain 
abdominal, close to the kidney. The descent of the testes is a pre-requisite for normal 
spermatogenesis and fertility in adulthood (Klonisch et al, 2004). Testes descent is 
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dependent upon the androgen and INSL3 mediated formation of the gubernaculum (an 
embryonic structure which connects the testes to the scrotum) and occurs in two phases 
(Barteczko and Jacob, 2000). In the first phase, testes move across the abdomen to the 
entrance of the inguinal canal and this involves both testosterone and INSL3. The next 
stage is believed to involved androgens in the production of a peptide called calitonin 
gene related peptide (CGRP) which produces rhythmic contractions of the 
gubernaculum that guide the testes along the inguinal canal and into the scrotum 
(Momose et al, 1993; Terada et al, 1994;). CGRP is a 37 amino acid neuropeptide, well 
classified to be involved in neurotransmission and in this area is known to elicit effects 
through a G-protein coupled receptor (Poyner et al, 2002; Rosenfeld et al, 1983). CGRP 
is produced mainly in the dorsal root ganglia that contain the cell bodies of sensory 
nerves (Supowit et al, 2001). Mutations in genes such as Hoxa10, Hoxa11 and Dhh have 
been shown to disrupt the second phase of testicular descent whereas Insl3 mutations 
cause disruption of the initial phase (Hutson et al, 1997; Ivell et al, 2003). Thus the 
descent of the testes is clearly dependent on several different factors and when this 
descent fails to occur completely, cryptorchidism ensues. It is interesting that mice that 
are null for Insl3, have complete failure of testicular descent due to lack of development 
of the gubernaculum and over-expression of Insl3 in females results in ovaries 
‘descending’ and inguinal hernias (Sharpe, 2006).  
 
1.2.2.4 Formation of the vasculature 
Following SRY expression, vascular endothelial cells migrate into the gonad to form the 
coelomic blood vessel on the surface of the testis and the blood vessels that give rise to 
side branches in between the seminiferous cords (Jeays-Ward et al, 2003). This arterial 
network, which is identified by the arterial marker ephrin B2 and elements of the Notch 
signalling pathway, routes the blood flow through the estes (Brennan et al, 2004) and is 
important in providing oxygen to the testes as well as transporting testosterone produced 
by the Leydig cells to target organs in the body (Brennan et al, 2002). It has also been 
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suggested that formation of the vasculature plays a role in both seminiferous cord 
formation and Leydig cell differentiation (Tang et al, 2008).   
 
1.2.3 Ovary development 
The development of the ovary is well documented in the literature (Brennan and Capel, 
2004; Hirschfield, 2008; Loffler and Koopman, 2002) and will not be reviewed in detail 
here. In brief and of relevance are two key independent signaling pathways which are 
believed to work in a complementary manner to promote ovary development and repress 
male signaling and testicular development. The first of these is the R-spondin / Wnt4/ β-
catenin pathway. R-spondin is required for Wnt4 expression in XX gonads and this 
exerts its functions via stabilization of β- catenin to promote ovarian fate and block 
testes development (Chassot et al, 2008). Loss of function of R-spondin leads to sex 
reversal in an XX female. Deletion of R-spondin in mice impairs ovarian differentiation, 
triggers development of ovotestes, results in testes-lik  vascularisation, and the 
appearance of Leydig-like cells. Wnt4 is believed to act at the top of the ovarian cascade, 
and is expressed in the bipotential gonad and becoms ovary specific at e11.5 (Nef and 
Vassalli, 2009). Wnt4 signalling has been implicated in repression of the testes pathway, 
and null mutations of Wnt4 in XX mice results in partial masculinsation of the gonad 
(Vanio et al, 1999). 
 
In addition, the Foxl2 gene has been shown to be crucial for granulosa cell 
differentiation and ovarian maintenance. The expression of Foxl2 is first seen at e12.5 in 
the pre-granulosa cells. Loss of Foxl2 function leads to differing effects in different 
species. In goats, it causes sex reversal, in mice only partial sex reversal and in humans 
causes premature ovarian failure (Garcia-Ortiz et al 2009). Recently it has been reported 
that the absence of Foxl2 (in knock out models) allows for an increase in expr ssion in 
Cyp26b1 which up-regulates Sox9 and Sf1 known to be involved in testis development 
(Kashimada et al, 2011).   
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Combined loss of R-spondin and Foxl2 results in extensive gonadal XX reversal, where 
testes-like seminiferous cords form that express high levels of SOX9 and AMH and 
contain well differentiated spermatogonia (Ottolenghi et al, 2007). However, even the 
loss of both of these key pathways, does not induce complete sex reversal which 
suggests that additional factors are involved in ovarian promotion and testes suppression 
(Cederroth et al 2007). These factors may include Dax-1, which has been shown to be 
up-regulated by Wnt4, but of more relevance for this study, it has been shown to be an 
SRY repressor. Increased Wnt4 and Dax1 expression have been suggested to be involved 
in XY sex reversal (Domenice et al, 2004; Jordan et al, 2001).  
 
1.3 The production of androgens 
Steroid hormones are produced by a process called steroidogenesis in the specialised 
streoidogenic cells of the adrenals, gonads, placent  a d brain (Stocco, 2001). The first 
step of steroidogenesis is shared between glucocorticoids, mineralcorticoids and sex 
steroids (Hiort and Holterhus, 2000). As this review is concerned with male sexual 
differentiation, it will focus on the synthesis of androgens, in particular testosterone.  
 
1.3.1 Steroidogenesis 
Cholesterol, the precursor of all steroid hormones can be synthesised de novo (from 
acetate) in the testis or acquired from serum lipoproteins, in the form of high density 
lipoproteins (HDL) or low density lipoproteins (LDL) (Cao et al, 2000). In the rat, HDL 
is the main form of circulating cholesterol whereas in the humans, LDL is considered the 
principal form of circulating cholesterol (Cao et al, 2000; Carr et al, 1983; Landschulz et 
al, 1996).   
Cholesterol requires to be transferred from the outer mitochondrial membrane to the 
inner membrane. This requirement is due to the fluid filled space between the inner and 
outer membrane, filled with aqueous fluid which only allows the passage of water 
soluble molecules (Thomson et al, 2004; reviewed by Scott et al 2009). Scavenger 
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receptor class B type 1 (SRB1) is a cell surface HDL receptor, which is expressed in the 
mouse testis and which can import cholesterol from the outer mitochondrial membrane. 
Principally however, the steroidogenic acute regulatory protein (StAR) translocates the 
cholesterol from the outer mitochondrial membrane (Arakane et al, 1998; Miller, 2002; 
Stocco and Clark, 1996). Sf1 has been shown to be involved in the regulation of both 
SRB1 and StAR, as well as two enzymes which are involved in the de novo synthesis of 
cholesterol, namely HMG-CoA synthase and HMG-CoA reductase (Mascaro et al, 2000; 
reviewed in Scott et al, 2009).  
The conversion of cholesterol to testosterone requis two main categories of enzymes, 
the cytochrome p450 enzymes and the hydroxysteroid dehydrogenase (HSD) enzymes 
(Payne and Hales, 2004). The cytochrome p450 enzymes include CYP11a1 and 
CYP17a1 and these enzymes catalyse the hydroxylation nd cleavage of the steroid 
substrate by using nicotinamide adenine dinucleotid phosphate (NADPH) as an 
electron donor. The HSD enzymes include 3β-HSD and 17β-HSD and catalyse the 
oxidation and reduction of steroid hormones and requi  NAD/NADP as electron 











Figure 1.4 Simplified testosterone biosynthesis pathway in the mammalian Leydig cell, outlining 
the ∆4 and ∆5 pathways and enzymes involved.  
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On the inner mitochondrial membrane, the first of the enzymatic reactions in 
steroidogenesis can begin. This is catalysed by CYP11a1 which cleaves a six carbon 
chain from cholesterol to generate the steroid pregnenolone (Thomson et al, 2004). 
Pregnenolone then moves to the endoplasmic reticulum where the remaining 
steroidogenic reactions occur. Pregnenolone can be converted to androstenedione 
through one of two pathways, termed ∆5 and ∆4 (Coffey et al, 1972, reviewed in Scott 
et al, 2009). In the ∆5 pathway, the pregnenolone is catalysed to 17α-
hydroxypregnenolone and then to dehydroepiandrosterone by CYP17a1 and then to 
androstenedione by 3β-HSD. It is thought the ∆5 pathway is the predominant 
steroidogenic pathway in human fetal (Fluck et al, 2003) and adult testes (Hammar et al, 
1986; Rey et al; 1995). In the ∆4 pathway, pregnenolone is converted to progesterone 
and then to 17-α-hydroxyprogesterone and finally to androstendione, and each 
conversion is catalysed by CYP17a1. It is believed that the ∆4 pathway is the most 
prominently used pathway in rats (Bell et al, 1968; Kwan et al, 1988). However it is 
believed that it is possible to converge from the ∆5 pathway to the ∆4 pathway. In each 
of the pathways, androstenedione is finally converted to testosterone by 17β-HSD. There 
are multiple isoforms of 17β-HSD (O’Shaughnessy et al, 2000), of which type 3 is 
involved in testis function (Geissler et al, 1994), although type 5 has also been found in 
the fetal testis (Pelletier et al, 1999). It is interesting to note that the fetal LCs of the 
mouse do not express 17β-HSD type 3; however it is expressed in the seminiferous 
tubules. Consequently in the mouse, it is thought tha androstendione is secreted by the 
fetal LCs and is then converted into testosterone i the seminiferous tubules 
(O’Shaughnessy et al, 2000).  
 
It should be noted that there is controversy regarding the difference in concentration of 
serum testosterone between males and females. In the humans, it is believed the LCs 
begin to produce testosterone at 8 weeks of gestation nd the levels peak at weeks 12-14 
of pregnancy (reviewed in Scott et al 2009). Some studies report during week 12-20, 
testosterone levels are 3-8 fold higher in the male than female (Rodeck et al, 1985; 
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Takagi et al, 1977). However, some studies have found that at the individual level, this 
difference is not always apparent (Zondeck et al, 1977). Furthermore, some studies 
suggest there are no differences in blood testosterone between the two sexes at birth 
(Forest and Catchaird, 1975; Takagi et al, 1977) and gain, some scientists disagree 
(Simmons et al, 1994). In the male rat, plasma testosterone levels are reported to be 4 
fold higher than in females. 
  
1.3.2 The differential roles of testosterone and DHT 
Once produced in the fetal Leydig cells, testosteron  is secreted into the bloodstream 
where in humans it binds to sex hormone binding globulin (SHBG) and in rodents to 
albumin (Alfsen, 1963; Grishkovskay et al, 1999). In addition, testosterone can reach the 
Wolffian duct in relatively high concentrations whereas in other tissues, when bound to 
SHBG or albumin, it is believed to reach targets in relatively low concentrations.  
Once released from the testis, testosterone can be converted in target tissues into its 
more potent form, dihydrotestosterone (DHT) by the enzyme 5α-reductase. There are 
two isoforms of 5α-reductase, type I which is expressed in the skin and liver and type II 
which is expressed in the male reproductive tract. Defects in type II can cause 
pseudohermaphroditism and this is discussed later in section 1.6.1. Experiments have 
shown that 5α-reductase is regulated by testosterone; for example, castrated rats have a 
decreased expression of this enzyme in the prostate which can be recovered by exposure 
to testosterone (Dadras et al, 2001;Wright et al, 1999).  
 
Testosterone and DHT are differentially effective in d fferent response systems (Luttge 
and Whalen, 1970; Bentvelsen et al, 1995). Testoster ne mediates Wolffian duct 
stabilisation while differentiation of the urogenital sinus and external genitalia depends 
more upon DHT action. The differing roles of the two hormones are clearly reflected in 
individuals with 5α-reductase deficiency and this is reviewed in section 1.6.1. It should 
be noted that in the absence of DHT, testosterone, at high concentrations, can 
Chapter 1                          Literature Review 
 
Page | 25 
differentiate the external genitalia which implies both androgens work through a similar 
mechanism but less is required of the more potent DHT.  
1.3.3 Hypothalamic-pituitary-gonadal axis (HPG axis) 
As stated above, the Leydig cells, whether fetal or adult are responsible for testosterone 
production. Testosterone production is part of a feedback loop involving the 
hypothalamus, the pituitary and the gonads. In brief, the hypothalamus secretes 
gonadotrophin releasing hormone (GnRH), which travels to the pituitary and stimulates 
the production of luteinizing hormone (LH) and follicle stimulating hormone (FSH) that 
are released into the bloodstream (Kaiser et al, 1995). The steroidogenic Leydig cells of 
the male have receptors for LH and respond by producing testosterone (Griffin et al, 
2010). FSH binds to its receptors on the SCs and initiates and helps maintain 
spermatogenesis (Walker and Cheng, 2005). Once the test s have produced sufficient 
testosterone, testosterone itself acts as the negativ  feedback signal to decrease LH 
production, in males. Furthermore, in response to FSH, Sertoli cells can produce Inhibin 
B, a hormone which also acts as a specific negative feedback regulator of FSH (Goulis 
et al, 2008).  
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In humans, testosterone is produced in the fetus at approximately week 8 of pregnancy, 
with a peak in production between weeks 11-14 (Scott et al, 2009). It is interesting to 
note that the LH receptor is first reported to be detectable in the testis at week 10 in 
humans and LH is first secreted at week 12. Human chronic gonadaotrophin (hCG) is a 
glycoprotein hormone similar in structure to luteiniz g hormone that is produced by the 
placenta (in primates) and peaks in production betwe n weeks 8-12 of pregnancy. Thus 
it is accepted that testosterone production by the fetal testis is initially not under the 
control of LH but is regulated by hCG and perhaps also by paracrine factors (Scott et al, 
Figure 1.5 Diagrammatic representation of the feedback loops of the HPG axis. GnRH 
produced by the hypothalamus signals the production of gonadotrophins from the pituitary 
which stimulate the Leydig and Sertoli cells of the testis which in their turn produce 
negative feedback hormones (testosterone and inhibin B respectively) 
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2009). Rodents do not produce hCG and the standing hypothesis is that testosterone 
production by the fetal testis in rodents is regulated initially by paracrine factors. In rats, 
testosterone is first produced at e14.5, and despite the presence of LH receptor, LH is 
not secreted until e17.5 and production peaks at e20.5-e21.5, suggesting that LH-driven 
testosterone production by the fetal rat testis is not operative until the end of gestation 
(Aubert et al, 1985, Scott et al, 2009).  
 
Although the exact mechanism of early regulation of steroidogenesis has not yet been 
identified, several factors have been identified that can stimulate fetal LC 
steroidogenesis in vitro, and these include, IGF-1, VIP, ANP, CNP and BNP and the 
receptors for these have been shown to be present in the rat fetal testis from e15.5 (Scott 
et al, 2009). It should be noted that some studies have suggested that retinoic acid may 
be involved in early human steroidogenesis as it has been shown to stimulate 
testosterone production by fetal human testis explants in vitro (Lambrot et al, 2006). 
However, in fetal rodents, retinoic acid inhibits seroidogenesis (Livera et al, 2000). Of 
relevance are studies showing that absence of LH function (through decapitation) does 
not affect steroidogenic production in fetal life at least in the mouse, rat and rabbit 
(George et al, 1979; Habert and Picon, 1982; Pakarinen et al, 2002;). Chemicals which 
interfere with steroidogenesis are discussed in section 1.6.1.1. 
 
1.4 Androgen receptor  
Steroid hormones exert their effect by binding to receptors and altering gene expression. 
Steroid receptors are a large super-family of ligand ctivated transcription factors and 
this family includes oestrogen, progesterone, glucocorticoid, mineralocorticoid and 
androgen receptors (Beato and Klug, 2000). These receptors share a common molecular 
structure (Giguere, 1999; Whitfield et al, 1999) and this review will focus on the 
androgen receptor.  
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The gene for AR is located on the long arm of chromosome X at position Xq11-q12 in 
humans. It spans 90 kilobase pairs and consists of 8 exons (McEwan, 2004). Together, 
these encode a protein of 919 amino acids with a molecular mass of 110kDa (Patrao et 
al, 2009). The AR protein, like other members of its family, has four distinct functional 
domains which together mediate the genomic actions of androgens in target tissues. 
These domains are the N-terminal domain, the DNA binding domain, the ligand binding 









The N-terminal domain, encoded by exon 1 is relatively long, representing almost half 
of the functional receptor. The N-terminus is responsible for transcriptional activity and 
contains the activation function 1 (AF1) domain (Betney and McEwan, 2003). AF1 is 
responsible for almost all AR transcriptional activity and also mediates interactions with 
Figure 1.6 Diagrammatic representation of the AR gene and protein, showing the N-
terminal domain in orange, the DNA binding domain in green, including the zinc fingers, 
and the hinge and ligand binding domain in blue.  
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some co-regulators as well as with the basic transciptional machinery. Analysis of the 
amino acid sequence of the AR N-terminal domain from a diverse range of organisms 
has revealed the presence of three areas of sequence co servation; amino acids 1-30, 
224-258, and 500-541 (McEwan, 2004). The first 30 amino acids of the N-terminus are 
believed to be important for interaction with the AR ligand binding domain, perhaps 
forming a loop that is important for functional activation (Steketee et al, 2002). The 
second conserved area, 224-258 lies within the AF1 region and this sequence is highly 
conserved from fish to primates (Betney and McEwan, 2003).  
 
The DNA binding domain is encoded by exons 2 and 3 is cystein-rich and is the most 
conserved region within the nuclear receptor family, with identical amino acid 
sequences in humans, rats and mice (Heemers and Tindall, 2007). This domain contains 
two zinc finger motifs and a c-terminal extension (Heinlein and Chang, 2002). The first 
zinc finger mediates specific DNA recognition and the second finger is involved in AR 
homodimerization as well as DNA/receptor complex stabilization (Centenera et al, 
2008). Both the DNA-binding region and the hinge region contain nuclear localisation 
signals (NLS) suggesting these regions are involved in nuclear translocation of AR.  
 
The C-terminal ligand binding domain is encoded by the remaining 5 exons and 
mediates high affinity interactions between AR and its steroidal and non-steroidal 
ligands. The LBD consists of 12 α-helices that form a ligand binding pocket (Heemers 
and Tindall, 2007; MeEwan, 2004). Upon ligand binding, a conformational change is 
induced in the LBD which results in the stabilization of α-helix 12, resulting in a more 
compact structure and the formation of a functional activation function 2 (AF2) on the 
surface of this domain. The AF2 region may play a role in dimerization and also in 
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1.4.1 Androgen mode of action 
Once testosterone or DHT reaches its target cells, it diffuses through the cell membrane 
and interacts with the AR which, in the un-bound form, is located in the cytoplasm 
attached to heat shock proteins and immunophillin chaperones, including HSP90, 
HSP70, HSP56 and p23 (Eder et al, 2001; Heemers and Tindall, 2007; Kimmins and 
MacRae, 2000; McEwan, 2004). Studies suggest that the HSP chaperone machinery in 
eukaryotes functions to prevent AR misfolding and aggregation and promote refolding 
of denatured polypeptides (Chen et al, 1998; Fliss et al, 1999). Once the ligand has 
bound to the AR, the receptor undergoes conformation l changes, allowing its release 
from the multiprotein complex, unmasking the AR NLS, causing increased 
phosphorylation, nuclear translocation and homodimerization. In the nucleus, the 
activated AR-ligand homodimer complex binds to specific DNA sequences in genes, 
termed androgen response elements (ARE’s). AREs are most commonly localised in the 
promoter regions of androgen regulated genes, such as prostate specific antigen (PSA) 
(Cleutjens et al, 1997; Luke and Coffey, 1994). ARE’s can also be present in intronic 
regions of AR regulated genes. The consensus ARE sequence has been identified as a 
partial pallindromic 15 basepair element consisting of two imperfect 6 base pair indirect 
repeats with a 3 base pair space (5’-GG(A/T)ACANNNTGTTCT-3; (Patrao et al, 2009, 
McEwan 2004).  
 
AR mediated transcription of target genes requires th  recruitment of RNA polymerase-
II (RNA Pol II) to the promoter sequence of the target gene (Roeder, 1996). RNA Pol II 
recruitment is mediated through the assembly of GTFs (general transcription factors) 
and this forms the pre-initiation complex.  The first of these GTFs is TBP (TATA box-
Binding Protein) which binds near the transcriptional start site (McEwan and 
Gustafsson, 1997). TBP is part of a multi-protein complex, which also contains general 
and promoter-specific TBP-associated factors (TAFII). TBP binding induces DNA 
bending, which causes sequences of the TATA to interac  with the GTFs and steroid 
receptor-coregulator complexes. Other transcription factors, namely TFIIB and TFIIB 
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This classic genomic action of androgens is a mechanism which requires approximately 
40 minutes to alter gene expression and hours if a new gene is to be expressed (Walker, 
2009). There is increasing evidence that androgens may also initiate cellular processes 
through rapid non-genomic mechanisms, in a matter of minutes (Foradori et al, 2008). 
This is reviewed in section 1.5.  
 
1.4.2 AR expression  
The expression of androgen receptor in the developing reproductive tract has been 
investigated through immunohistichemical studies. In the male and female rat fetus, AR 
Figure 1.7 Summary of androgen receptor mode of action. Androgens disassociate from SHBG 
and bind to AR in the cytoplasm. This causes the disassociation of AR from chaperone proteins 
and the ligand-receptor complex translocates to the nucleus where it binds to target genes to 
modulate transcription via the involvement of GTFs, RNA pol II and various co-regulators 
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is present at equal levels until the onset of differentiation (Bentvelsen et al, 1995) and 
the same appears to be true in humans (Sajjid et al, 2003; Wilson and McPhaul, 1996). It 
is interesting that both males and females have similar AR expression prior to 
masculinisation of the reproductive tract as this suggests that sex specific AR expression 
does not appear to be a factor in masculinisation. It should be noted that there are some 
differences in the literature which report the timings of AR expression in rat studies, this 
may be due to differences in rat strains and or antibodies which have been used 
(Bentvelsen et al, 1995; Majdic et al, 1995).  
 
In the male reproductive tract of rats, AR is generally first expressed in the 
mesenchymal cells and later in the epithelial cells (Shannon and Cunha, 1983). An 
exception to this is displayed in the efferent ducts which express AR from e14.5 
throughout gestation in both the mesenchymal and epithelial cells (Bentvelsen et al, 
1995). In the WD, the mesenchyme is AR positive from e14.5 throughout gestation, 
however the epithelial cells only become AR positive at around e18.5 (Bentvelsen et al, 
1995; Hannema and Hughes, 2007). Furthermore the epididymal tail is AR positive in 
the mesenchyme from e18, but epithelial cells only become AR positive from postnatal 
day 2. The distal WD (later vas deferens) does not express AR until e20.5 in the 
mesenchymal cells and, similar to the epididmyal tail, epithelial cells become positive at 
PND2. The mesenchymal cells of the prostate anlagen express AR at e16 with a majority 
of epithelial cells only becoming AR positive at PND5 (Bentvelsen et al, 1995).  
 
The interstitial cells of the testis become AR positive at around e17.5 in the rat but some 
studies have reported staining as early as e15.5 in the interstitium (You and Sar, 1998); a 
similar pattern of staining has been reported in the human testis at corresponding ages 
(Boukari et al, 2009). SCs remain negative for AR until PND 5 in the rat and expression 
increases in SCs as the animal develops towards puberty (You and Sar, 1998; Bremner 
et al, 1994). The lack of AR in SC correlates with high AMH expression in the fetal 
period and, in contrast, when AR is switched on postnatally, AMH expression decreases 
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(Rey et al, 2009). The absence of AR in SCs in fetal life may be to protect the cells from 
precocious maturation and onset of pubertal spermatogenic development.  
The folds and swellings in and around the urogenital tubercle express AR at e14.5 in the 
mesenchymal cells and during development, in the male GT, the number of 
mesenchymal cells expressing AR increases progressively. The epithelial cells in the 
skin of the genital tubercle express AR from PND5 in the rat (Bentvelsen et al, 1995). 
Both the gubernaculum and perineal region express AR abundantly from e18.5 in the rat.  
 
In females, the Müllerian ducts are AR negative throughout development, after 
differentiation, females have low levels of AR expression in comparison to males in the 
urogenital sinus and tubercle (Bentvelsen et al, 1995).   
 
The expression patterns of AR in the male reproductive tract suggest that androgens 
induce epithelial differentiation of the genitalia via action in the mesenchymal cells. 
Although a full review of mesenchymal-epithelial interactions is outwith the scope of 
this review, it is accepted as fact that mesenchymal-epithelial interactions play a central 
role in the development of the male reproductive tract (Cunha et al, 1991; Donjacour and 
Cunha, 1993; Kurzrock et al, 1999) and these will be referred to where appropriate in the 
review of phenotypic differentiation. 
 
Of particular interest is the relative lack of data vailable for AR expression prior to the 
onset on androgen production in the fetus in both rdents and humans. One study of AR 
in the urogenital system of a marsupial reported that AR mRNA is present just before 
the genital ridge develops, but AR protein investigations were only carried out just prior 
to the end of gestation (Butler et al, 1998). To the best of my knowledge, there is little 
data showing the availability of AR protein in the d veloping reproductive tract prior to 
the production of androgens.  
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1.4.3. Regulation of AR expression 
Given the importance of AR in the various actions of androgens it is not surprising that 
the AR protein is regulated at multiple levels. Furthe more, AR expression is 
differentially regulated in different tissues. Perhaps the simplest way to review this is to 
separate transcriptional regulation and post-transcriptional regulation of the AR protein.  
 
At the transcriptional level, AR is auto-regulated by androgens, which have been shown 
to reduce AR mRNA in both rat tissues and LNCaP cells (Tan et al, 1998; Krongard et 
al, 1991). The stability of AR mRNA is important inthe regulation of AR protein 
expression and when RNA-binding proteins bind to a conserved UC rich element of the 
3’ untranslated region of AR mRNA, AR protein expression is altered (reviewed in 
Yeap et al, 2004). In 1994 Bentvelsen et al demonstrated fetal exposure to androgens in 
the female up-regulated AR expression and that exposure to anti-androgens during the 
fetal period, down regulated the expression of AR in males in comparison to respective 
controls (Bentvelsen et al, 1994). Another example of androgens regulating AR 
expression, is the age-dependent down-regulation of AR levels in the rat penis, which 
has been shown to be androgen dependent (Takene et al, 1990). Furthermore, androgens 
can regulate the expression of co-regulators which in turn potentiate AR signalling, 
providing another level of regulation (Urbanucci et al, 2008). Co-regulators are 
discussed further in section 1.7.1. However it should be noted that some of these co-
regulators are involved in post-translational regulation of the AR protein as well as 
enhancing or repressing AR activity. It is also important to remember that changes in 
AR mRNA do not necessarily mean a corresponding change in AR protein and generally 
the latter is increased by testosterone action.  
 
The binding of steroids to their receptors to elicit a response, is a cyclical event and 
degradation of the receptor after this event is important in order to regulate subsequent 
rounds of transcription. Ubiquitin dependent proteolysis is an important mechanism for 
controlling protein turnover and is well established as a method of regulation of various 
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transcription factors (Freiman et al, 2003, Nawaz et al, 2004). For example, both the 
oestrogen and glucocorticoid receptors have been shown to be ubiquitinlyated and 
destroyed after binding to their respective ligands, as a form of regulation. This is also 
true for AR, which can be destroyed via the 26S proteosome (Sheflin et al, 2000). 
Another example of AR being a target of ubiquitinaton regulation / destruction is 
Mdm2, the proto-oncogene which has been reported to work ith histone deacetylase 1 
(HDAC1) to de-stabalise the AR protein and reduce AR mediat  transcription 
(Gaughan et al, 2005).  
 
1.5 Oestrogens in the male 
Oestrogens are one of the sex steroid hormones, produced by steroidogenesis and 
historically are thought of as the ‘female’ hormone whereas androgens are considered 
the ‘male’ sex steroid hormone. Over the past couple of decades this perception has 
changed and it is imperative to note that not only are both sex steroids present in both 
males and females, but oestrogens can also be important for some aspects of ‘normal’ 
development of the male phenotype in some species. It i  believed that it is not the 
qualitative differences in these hormones which are involved in sexual differentiation 
but the difference in hormone concentration and differential expression of hormone 
receptors. Indeed, several studies have reported that disturbance of the androgen-
oestrogen balance can lead to disrupted development of the male phenotype (reviewed in 
Sharpe, 1998). 
 
The importance of oestrogens in males was perhaps only really noted when mice in 
which the oestrogen receptor alpha had been knocked out (ERKO) were reported to be 
infertile (Lubhan et al, 1993; Korach et al, 1996). Further studies of the knockout model 
have reported that the efferent ducts in these males ar  incapable of reabsorbing luminal 
fluids from the testis and it is hypothesised that oestrogens are responsible for the 
regulation of fluid resorption and thus increasing sperm concentration prior to their entry 
into the epididymis (Hess et al, 1997). The role of oestrogens in the testis is probably 
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one of the more investigated roles of oestrogens in the male. Unlike androgens, which 
work through one receptor, oestrogens can work through one of two receptors, ER-α and 
ER-β and the latter is more widely expressed throughout the rodent and primate body 
(Saunders et al, 1998). ER-β is expressed in all of the cell types of the testis as well as in 
the epididymis, vas deferens, seminal vesicles and the prostate. ER-α is also expressed in 
the LCs, at least in rodents. Moreover, aromatase, which converts testosterone to 
oestradiol is expressed in many of the cell types in which ER-α and ER-β are expressed 
in the male reproductive tract as well as in adipose tissue, bone, the heart and the brain. 
Ironically, oestrogens produced in the brain are thought to be involved in masculinsing 
the brain and male sexual behaviour in rodents (Miesal and Sachs, 1994) but not in 
humans. As AR, ER and aromatase are expressed in many of the same cell types, a 
balance in action between androgens and oestrogens may be important for some aspects 
of male reproductive function. One of the older and more dramatic examples is a study 
in sheep (Bennetts et al, 1946). This showed that when clover (which contains weak 
phytoestrogens) was ingested by castrated rams, it led to death due to urinary retention 
caused by overgrowth of the bulbourethral glands. However, when animals which had 
not been castrated and consequently had high levels of circulating testosterone ingested 
clover, it had no effect. Another study which exemplifies nicely the balance between 
androgens and oestrogens, involved exposure of rats to diethylstilbestrol (DES) (a 
synthetic oestrogen discussed in section 1.6.1.1.1) in two different doses. In addition 
some rats were exposed to the low dose of DES in conjunction with a GnRH antagonist 
(GnRHa) to block androgen production or flutamide to block androgen action (Rivas et 
al, 2002). Treatment with the high dose of DES drastic lly reduced the expression of AR 
in investigated tissues, which was also seen when animals were exposed to the low dose 
of DES in combination with GnRHa or flutamide. However, administration of GnRH 
alone or flutamide alone did not have this effect. DES as an anti-androgenic compound 
is discussed in section 1.6.1.1.1. Another example of a requirement for the androgen-
oestrogen balance is evidenced by gynaecomastia in males, which can be induced either 
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by exposure to oestrogens or by lowering androgens or androgen activity (which can 
occur in aging or in conjunction with abdominal obesity) (Gustafson et al, 2003).  
 
Therefore it appears that the development of the corre t male phenotype requires a fine 
balance of oestrogens and androgens in particular tissues. In addition there is some 
evidence that these sex steroids could work together. For example, oestrogens can trans-
activate the AR/ARA70 complex at high concentration (Yeh et al, 2000) and using a two 
hybrid system, co-transfection of the two receptors into CV-1 cells has demonstrated a 
mutual ability of each receptor (AR and ER) to antagonise trans-activation mediated by 
ligand binding to the other receptor (Panet-Raymond et al, 2000) 
 
1.6 Disorders of sex development in the male 
As discussed in the introduction, the sex development of an embryo can be classified 
into three sequential stages, the indifferent stage, where primitive structures develop, 
gonadal differentiation and phenotypic differentiation. Disorders of sex development can 
occur as the result of deficiencies at any of these stages and it is important to review 
these to not only understand where androgens might fit aetiologically into these sex 
differentiation disorders but also to understand them in their possible relationship to 
TDS.  
 
The exact molecular mechanisms involved in the indifferent stage of development of the 
urogenital tract remain to be fully understood. There are however, certain genes which 
have been identified to be crucial for this part of development, and mutations in these 
genes are reported to cause a variety of different disorders. For example, mutations in 
Homeobox A13 (HoxA13) have been associated with hand-foot-genital syndrome. This 
disorder is characterised by mild bilateral shortening of the thumbs and great toes and 
urogenital abnormalities including abnormalities ofthe ureters and urethra and 
Müllerian fusion in females and hypospadias of variable severity in males (Mortlock and 
Innis, 1997). Examples of genes which have been idetified at the indifferent stage to be 
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involved in disorders of sexual development include: GLI3, associated with 
hypospadias, micropenis and Pallister-Hall syndrome (Bose et al, 2002; Narumi et al, 
2010); CFTR, associated with congenital aplasia of the vas deferens (Zielenski et al, 
1995); ROR2, associated with aphallia (absent phallus); Robinow syndrome, a disorder 
characterized by short-limbed dwarfism, abnormalities n the head, face, and external 
genitalia, as well as vertebral segmentation (Bacino, 2005; van Bokhoven et al, 2000).  
 
During development of the gonad the most prominent disorder that has been reported to 
occur is hypogonadism, when functional activity of the gonads is low or absent. 
Hypogonadism can be due to whole testicular dysfunctio  or dysfunction of individual 
cell populations (Grinspon and Rey, 2010). Abnormal gonadal differentiation can cause 
hypogonadism and an example of this is ‘streak’ gonads, where the testes fail to produce 
testicular hormones. These individuals can have lowor absent serum AMH and 
testosterone in conjunction with high gonadotrophin levels (Rey et al, 1999). Partial 
forms of this disorder can present with asymmetric gonadal differentiation or ovotestis 
(reviewed in Rey et al, 2011).  
 
Mutations in certain genes at the indifferent stage can cause isolated testicular dysgensis, 
when non-reproductive organs form normally, for example mutation or deletions in SRY. 
However, most mutations do cause disorders elsewher at this early stage. This is 
illustrated by mutations of WT1, which can result in at least three well known disorders, 
Denys-Drash syndrome (affecting the renal system as well as the gonads) (Heathcott et 
al, 2002; Little et al, 1993), Frasier syndrome (associated with nephropathy as well as 
gonadal dysgenesis) (Barbaux et al, 1997; Klamt et al, 1998) and WAGR syndrome (can 
cause mental retardation as well as gonadal dysgeneis) (Almind et al, 2009; Gessler et 
al, 1993). Other than affecting the gonads, mutations n Sox9 have been shown to lead to 
skeletal malformations, also termed campomelic dysplasia (Kwok et al, 1995), 
micrognathia (Jakobsen et al, 2007) and cardiac (Akiyama et al, 2004; Montero et al, 
2002) and renal defects (Reginensi et al, 2011) .  
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1.6.1 Androgen deficiency 
Other than hypogonadism, caused by mutations in genes involved in formation of the 
testis, hypogonadism can also arise once the testis has formed and individual cell types 
do not function properly. An example of this is impaired LC function which leads to a 
decrease in virilisation due to lack of testosteron. This can mean that the WD is not 
stabilised or differentiated, the external genitalia is not masculinised, leading to varying 
severity of hypospadias and lack of testis descent. However, as the SCs continue to 
produce AMH, the Müllerian ducts and its derivatives are removed. LC dysfunction can 
be due to various factors, such as LH receptor mutations in humans, known as Leydig 
cell hypoplasia (Latronice et al, 1996; Mendonca et al, 2010), defects in steroidogenic 
enzymes such as StAR or CYP11a1 which causes lipid congenital adrenal hyperplasia 
(Miller et al, 2009). Defects of either of the HSD enzymes also result in LC dysfunction 
(Lee et al, 2007; Mendonca et al, 2010, reviewed in Rey et al, 2011).  
 
Dysfunction of the Sertoli cells can lead to a lack of AMH and this can cause persistent 
müllerian duct syndrome (PMDS), characterised by the presence of a uterus and 
fallopian tubes in XY males (Josso et al, 2005). Such ‘pseudohermaphroditic’ 
individuals are usually virilised normally as the LC produce testosterone in the normal 
range (Rey et al, 1999; Thomson et al, 1994).  
 
Incomplete masculinisation may also be caused by androgen deficiency downstream of 
the testis for example because of a lack of 5α-reductase in the target organ (Imperato-
McGinley et al, 1974). Patients with a deficiency in 5α-reductase type 2 have low 
synthesis of DHT and at birth may have an under-virilised phenotype, with ambiguous 
genitalia, bifid scrotum, and a urogenital sinus opening on the perineum (Sultan et al, 
2001). Due to normal levels of local testosterone, th  WD derivatives are normal in 
these individuals. Over 40 mutations have been identified in 5α-reductase type 2 
deficient patients but a very recent cohort investigation reported that the various 
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phenotypes displayed by patients with mutations in 5α-reductase type 2 could not be 
linked to particular genotypes (Maimoun et al, 2011).  
 
So far the deficiency in androgen production has been discussed, however 
pseudohermaphroditism can also occur when the AR protein is defective and signalling 
is abnormal despite the presence of sufficient androgens. Three pathological situations 
are well associated with AR defects, androgen insensitivity syndrome (AIS), spinal and 
bulbular muscular atrophy (also known as SBMA or Kenn dys disease) and prostate 
cancer (Brinkman, 2001).  
 
Androgen insensitivity syndrome can present itself in two forms. The more severe 
phenotype is called complete androgen insensitivity syndrome (CAIS) and the less 
severe, partial androgen insensitivity syndrome (PAIS) (Ahmed et al, 2000; Quigley et 
al, 1995). CAIS patients have a completely non-functio al AR and present with normal 
female external genitalia, a short blind ending vagin  with no uterus or fallopian tubes, 
absence of WD derived structures, absence of prostate and development of normal 
female breast tissue at puberty (gynaecomastia) (Thiele et al, 1999; Quigley et al, 1995). 
In contrast, PAIS occurs when there is incomplete loss of AR function and can present 
with a range of phenotypes ranging from a predominantly female appearance as for 
CAIS, to ambiguous genitalia to a predominantly male phenotype with disorders such as 
micropenis, hypospadias and cryptorchidism (Jaaskenain , 2011; Rey et al, 1994; 
Werner et al, 2010).  
 
Over 400 different mutations leading to AIS have ben reported (database can be found 
at http://www.mcgill.ca/androgendb) and in general these can be classified into two 
groups according to DNA and mRNA alterations. The first is loss or gain of genomic 
information such as macro and micro deletions and base pair insertions and the second is 
point mutations responsible for non-sense, mis-sense a d splice mutations (Sultan et al, 
2001). Each of these defects disturbs the ability of AR to regulate gene transcription. It 
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is interesting that the same mutation can lead to different phenotypes or alternatively 
different molecular defects can produce the same phenotype. This suggests that other 
determinants may influence androgen action within te target cell.  
 
1.6.1.1 Anti-androgenic chemicals 
There is growing concern that certain environmental chemicals can inhibit androgen 
production or action and affect virilisation (Fisher, 2004; Gray et al, 2006; Sharpe, 
2001). This has been reported in wildlife in pollutant exposed fish that have ovotestes or 
intersex genitalia, in birds that display deformities of the reproductive tract and similar 
traits have also been found in amphibians and rodents (reviewed by Sharpe, 
http://www.chemtrust.org.uk/documents/ProfRSHARPE-MaleReproductiveHealth-
CHEMTrust09.pdf). As discussed in section 1.1.4, TGC  are reported to be increasing 
in occurrence in humans and other TDS disorders are common and some believe that 
they may also be increasing in prevalence, in particular low sperm counts and associated 
infertility. The identification of sexual development disorders in wildlife and the 
increasing concern over human reproductive development has led to anti-androgenic 
environmental chemicals being studied intensively with the hypothesis that they may be 
involved in the origins of TDS and affect virilisation of the fetus. Although some genetic 
mutations have been found in patients with TDS, genetic abnormalities are not always 
found and other explanations for these disorders are sought. Moreover, TDS occurrence 
is highly linked to geography suggesting that environmental factors are involved in these 
disorders and/or that there are ethnic/genetic differences in susceptibility (Lopez-Teijon 
et al, 2008; Virtanen et al, 2005)   
 
It is extremely difficult to accurately determine the exact level of exposure of the human 
fetus to environmental chemicals and the effects this may have. In order to prove that 
environmental chemical effects are linked to TDS, the level of exposure would have to 
be determined, this would have to be linked to a mechanistic effect and then to the 
outcome disorder. This obviously has incredible obstacles because of inaccessibility of 
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the fetus. Consequently, the majority of our understanding of environmental chemicals 
and their possible role in TDS has come from experim ntal rodent studies. One criticism 
of these rodent studies is that the dose of chemicals used to induce TDS disorders are far 
in excess of what humans are generally exposed to and any adverse outcomes of these 
chemicals in rodents are unlikely at exposure levels experienced by humans (Sharpe and 
Skakkebaek, 2008). However it can also be argued that humans are exposed to mixtures 
of many different chemicals, thus higher doses of an individual chemical may mimic the 
effects of more complex mixtures (Sharpe, 2008). Nevertheless the most relevant studies 
are those which expose rodents to mixtures of chemicals n much lower doses.   
 
1.6.1.1.1 Diethylstilboestrol (DES) 
DES is a synthetic non-steroidal oestrogen which was first synthesised in 1938 and was 
used therapeutically until 1971 to prevent pregnancy complications and miscarriage. 
DES was discontinued for use when it emerged that some females exposed in utero to 
DES developed clear cell adenocarcinoma of the vagina and fertility problems (Barclay, 
1979; Fowler and Edelman, 1978; Herbst 1981). In sos exposed to DES in utero, 
testicular and reproductive tract abnormalities have been reported (Schrager and Potter, 
2004; Wilcox et al, 1995).  
 
Initially it was hypothesised that the adverse effects of DES in males was simply due to 
the oestrogen agonistic effect, but some studies suggest it is more complex than this. 
Thus, DES-induced disorders of the male reproductive tract may result more from the 
disturbance of the androgen-oestrogen balance rather than from oestrogen action alone 
(Rivas et al, 2002). Furthermore, it has been shown that altered gene expression induced 
by DES in fetal life can persist well after exposure is terminated and the permanent 
defect in gene expression does not necessarily coincide with spatial localisation of 
altered expression at acute exposure (Bromer et al, 2009). Thus, the typical endocrine 
regulation of gene expression may not account for these apparently epigenetic effects.  
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1.6.1.2 Phthalates 
Phthalates are a group of chemicals mainly used as plasticisers to soften polyvinyl 
chloride in the manufacture of various different products including pharmaceuticals, 
cosmetics, perfumes, medical equipment and toys (Heudorf et al 2007). Examples of 
phthalate chemicals include Di-n-butyl phthalate (DBP) and di-2-ethyl hexyl phthalate 
(DEHP), but many more exist. The effects of phthalates on testosterone production in 
humans is conflicting. Some studies have reported a negative correlation between fetal 
AGD in humans and the levels of phthalates reported in maternal urine (Lottrup et al, 
2006; Swan et al, 2005; Swan et al, 2008). However in contrast, other studies have found 
no association between phthalate exposure and AGD (Huang et al, 2009) although some 
effects have been noted on germ cells in vitro (Lambrot et al, 2009).  Moreover, 
phthalates have no effects in vitro on steroidogenesis by human fetal testis explants 
(Hallmarkk et al, 2007; Lambrot et al, 2008) and, more convincingly, no effect on 
steroidogenesis in a fetal testis xenograft model after chronic phthalate exposure 
(Mitchell et al, 2011, submitted). This controversy however does not exist in rat studies, 
which provide unequivocal evidence that phthalates can inhibit fetal testosterone 
production (Gray et al, 2000; McKee et al, 2006; Parks et al, 2000; Wilson et al, 2004).   
 
1.6.1.3 Fungicides and herbicides 
Certain fungicides and herbicides have also been report d to affect androgen action. 
Ketoconazole is an anti-fungal agent used in the treatment of fungal skin conditions and 
also in Cushing’s syndrome. Ketoconazole has been rported to inhibit CYP17 (Pont et 
al, 1982), vital in steroidogenesis and studies indicate that human LC steroidogenesis, 
which has a preference for the ∆5 pathway, is more susceptible to ketoconazole 
disturbance than are rat or dog Leydig cells (reviewed in Scott et al, 2009). Another 
fungicide of interest is prochloraz used in crop protection and shown in rodent studies to 
affect fetal steroidogenesis by inhibiting CYP17 conversion of progesterone to 
testosterone (Laier et al, 2006; Vinggaard et al, 2005).  
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Linuron is a urea-based herbicide and in rodents, can inhibit androgen action by 
reducing fetal testosterone production (Wilson et al 2004; Hotchkiss et al, 2004) but also 
by antagonising AR (McIntyre et al, 2000). Unlike the fungicides described above, the 




There has been substantial interest in the effect of therapeutic drugs on virilisation of the 
fetus. Glucocorticoids are used in the treatment of many different disorders, including 
those in pregnant woman, despite the fact that it is established that elevated 
glucocorticoids in response to stress can suppress testosterone production in adult males 
(Hardy et al, 2005).  
 
16.1.4.1 Indomethacin 
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which inhibits the 
production of prostaglandins. PGs are reviewed in section 1.7.3. Indomethacin works by 
competitively blocking the COX1 and COX2 enzymes (non-selectively) which inhibits 
the synthesis of prostaglandins and their effect in inflammation (Mitchell et al, 1993). 
Blocking COX2 is what makes NSAIDs effective, as this reduces inflammation; 
however, blocking COX1 can cause unwanted side effects (Bateman et al, 1994; Vane, 
1996). Prostaglandins, particularly of the E and F series are the main promoters of 
cervical ripening and myometrial contractility in pregnancy (Vladic-Stjernholm et al, 
2009). Consequently indomethacin has been used in the treatment of pre-term labour 
(Norton, 1997). Many studies have been conducted on animals and humans investigating 
the effect of prenatal exposure to indomethacin with conflicting results. Some of these 
studies have reported indomethacin exposure in utero does not produce any 
malformations in offspring in mice and rats (Klein et al 1981; Randall et al 1987). 
However studies have been published which contradict these findings. Kusang et al 
(1977) reported that exposing mice to indomethacin causes skeletal defects as well as 
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fused ribs. In addition the studies reviewed in 1.7.3 showed that Gupta et al (1986) 
found that exposing male mice to indomethacin caused incomplete virilisation of the 
external genitalia as well as decreased AGD. When rabbits were exposed to 
indomethacin there were no birth defects in the fetus s which survived but an increase in 
resorption of developing embryos was reported (O’Grady et al, 1972). Studies using 8 
rhesus monkeys reported that exposure to indomethacin was associated with 
oligohydramnios (deficiency of amniotic fluid) and also reported a 50% fetal mortality 
rate (Novy, 1978). Exposure at various doses, can also lead to constriction of the fetal 
ductus arteriosus (Arishima et al 1991; Sharpe et al, 1975).  
 
In humans, exposure to indomethacin in the first trimester does not generally produce 
fetal malformations (Aselton et al, 1995; Katz et al, 1984) and it has been suggested that 
there is minimal transplacental passage of indomethacin in this trimester (Klein et al, 
1981). In the second trimester, in humans, indomethacin crosses the placenta and 
reaches the fetus in concentrations close to those f und in the mother (Moise et al, 
1990). Some studies suggest there is a similar pattern in rats, such that indomethacin 
does not cross the placenta in pharmacologically significant quantities until close to 
parturition (Klein et al 1981). However, the vast number of publications which report 
adverse side effects in fetal rats when exposed to even low doses of indomethacin 
suggests otherwise. As prostaglandins play important oles in many different systems, it 
is inevitable that blocking PG action using indomethacin can cause various 
complications within the fetus. These include gastroin estinal complications, including 
perforation and bowel necrosis (Cassady et al, 1989; Krasna et al, 1992) and disorders of 
cerebral blood flow, such as cystic brain lesions ad intracranial haemorrhage (Baerts et 
al, 1990; Norton et al 1993). In addition to the effects in utero, indomethacin can cause 
gastrointestinal ulceration in adults as well as acute renal failure (Schlondorff et al 
1993). Thus it seems the effect of indomethacin depends on the species being treated, 
the dose being administered and the timing in gestation/development.  
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Although the ability of indomethacin to block PG synthesis by inhibiting COX enzymes 
is well documented, it is important to note that indomethacin may also have other 
mechanisms of action, which are independent of COX inhibition (Hawcroft et al, 2001). 
For example, indomethacin can directly activate the transcription factor peroxisome 
proliferator activated receptor γ (PPARγ) (Lehman et al, 1997). Furthermore, Zhang et al 
(1999) have shown that some of the antiproliferative and antineoplastic effects of 
NSAIDs are independent of the inhibition of either COX1 or COX2. 
 
It should be mentioned that some of the chemicals discussed above are used regularly 
within the laboratory to elucidate the mechanisms of androgen perturbation. In addition, 
AR antagonists are often used to elucidate AR molecular mechanisms and flutamide is 
one such chemical.  
 
1.6.1.4.2 Flutamide 
Flutamide is a non-steroidal AR antagonist which competes with testosterone and DHT 
(Sufrin and Coffey, 1976). Flutamide blocks the interactions between the N-terminus 
and C-terminus of AR thus preventing transcriptional activation. Once absorbed orally, 
flutamide is converted in the liver to the biologically active metabolite, 2-
hydroxyflutamide (Xu and Li, 1998) and has a half life of only 6 hours in humans; there 
is no evidence that flutamide or its metabolite accumulate in any tissues. Flutamide does 
not affect the testicular production of testosteron r its conversion to DHT (Peets et al, 
1974). However, in order to be a competitive antagonist of these androgens, flutamide 
must be administered 500-1000 fold higher than circulating testosterone levels in order 
to induce antagonism (Simard et al 1986). Even at such high doses, complete 
antagonism is not always achieved against the competing testosterone and DHT, 
although DHT-dependent tissues are more susceptible to complete antagonism, whereas 
within the testis (where testosterone levels are extremely high) the opposite is the case.  
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1.6.2 Androgen receptor knockout models 
Other than the use of chemicals, knockouts of the AR in mice have also been an 
invaluable tool for the study of androgen action. This has been done using Cre-lox 
technology which will not be reviewed here but can be found elsewhere (Sauer et al, 
1987; Sauer et al, 1988; Orban et al, 1992). The first of the AR knockout (ARKO) 
models employed this technology to knockout AR in all cell types. The male phenotype 
was reported to be female, i.e. the genetic males were phenotypically female in outward 
appearance. ARKO males were reported to have decreased anogenital distance, micro-
phallus with hypospadias and the vas deferens, epididymis, seminal vesicles, and 
prostate were absent. In addition, the testes were far smaller than in wild type males and 
were cryptorchid and serum testosterone was low. ARKO males also displayed a 
decreased bodyweight (Yeh et al, 2002). When published, these studies only reported 
early findings of the effect of ARKO in females but stated that female fertility was not 
affected. However more recent studies have shown that ARKO females have intra-
ovarian defects and are subfertile (Walters et al, 2009).  
 
AR has also been knocked out of particular cell types and the effects reported. In 2004, 
AR was knocked out of SCs in the testis (SCARKO). In contrast to the cryptorchid and 
small testis reported in ARKO mice, the SCARKO model was found to have normal 
development of the male reproductive tract and normal descent of the testes. The testis 
weight was reduced however in comparison to respective ontrols, and it was found that 
the number of spermatocytes and spermatids were greatly reduced or absent and all 
animals were infertile. This study concluded that AR is required within the SC for 
androgen maintenance of complete spermatogenesis (De Gendt et al, 2004).  
 
Attempts to knockout AR from LCs have been reported an  these animals were infertile, 
and spermatogenesis was arrested at the spermatid st ge (Tsai et al, 2006; Xu et al, 
2007). These animals also had reduced levels of testost rone and increased levels of LH 
and FSH demonstrating the effects on the HPG axis. However, it has been shown that 
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AR knockout in this model may not be specific to LCs and some AR may have been 
knocked out of SCs also and so to date, no LC specific AR knockout model has been 
reported (De Gendt and Verhoeven, 2011).  
 
There have been two notable attempts to knockout AR in PTM cells (PTM-ARKO). The 
first of these reported decreased testis size and oligoz ospermia, but fertility was stated 
to be normal (Zhang et al. 2006). A more recent PTM–ARKO model reported grossly 
normal reproductive tract development, but the males w re azoospermic and infertile. 
These animals had normal levels of testosterone, LH and FSH but had impaired SC 
function (Welsh et al, 2009). The latter study also showed that the former knockout 
(Zhang et al, 2006) had not in fact knocked out AR in PTM cells, but rather only in the 
smooth muscle of arterioles.  
 
1.6.3 Excess exposure to androgens 
In addition to deficiencies in androgen action during the fetal period having a variety of 
affects, excess androgen exposure can also be detrimen al, particularly in females. In 
humans this is the most common endocrine disorder in woman of reproductive age. 
Androgens are produced by the ovaries and adrenal glands and excess production can 
lead to a range of virilisation phenotypes including a masculinised urogenital tract and 
external genitalia, hirsutism, acne, menstrual irregularity and fertility problems (Abott et 
al, 2005). Excess androgens in females can be due to congenital adrenal hyperplasia 
(CAH) (Barnes et al, 1994; Kalaitzogou and New, 1993) or polycystic ovarian syndrome 
(PCOS) (Abott et al 2005; Dumesic et al, 2005).  
 
CAH is an autosomal recessive disorder which occurs in most cases when there is a 
mutation in 21-hydroxylase (also called CYP21), onef the 5 enzymes required by the 
adrenal glands to synthesize cortisol (White and Speiser, 2000). This enzyme is one of 
the cytochrome p450 enzymes. Deficiency in CYP21 results in the adrenal cortex 
compensating by over-producing other cortisol precursors which leads to the excess 
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synthesis of androgens (White and Speiser, 2000). CAH females usually have normal 
internal reproductive tracts, but may display ambiguous genitalia. In addition as these 
females have high circulating androgens but not local y produced testosterone, WD 
derivatives are not present (reviewed in Merke and Bornstien, 2005). Other symptoms 
include abnormal menstruation, deepening of voice and hirsutism. Males can also be 
affected by CAH and these individuals may undergo puberty as early as 2-3 years of age 
(reviewed by Merke and Bornstien, 2005).  
 
PCOS is an autosomal dominant condition in which the ovaries (and sometimes adrenal 
glands) over-produce androgens mediated by hyperinsulaemia and LH pulses 
(Rosenfield, 1999). As well as the expected virilisation, females with PCOS also display 
abnormal menstruation and reproductive abnormalities. In addition, many of these 
patients are found to have other disorders such as insulin resistance, central obesity, 
dyslipidemia, hypertension, glucose intolerance and type 2 diabetes (reviewed by 
Dunaif, 1997). The aetiology of PCOS remains unknow but one study has suggested 
that excess androgen exposure in utero can cause the f male offspring to develop PCOS 
in adulthood (Xita and Tsatsoulis, 2006). Furthermore a microarray study reported 
PCOS theca cells to have abnormal expression of CYP17 (involved in steroidogenesis) 
and also in GATA-6, known to be involved in embryonic development and Wnt 
signalling (Wood et al, 2003). 
 
Several studies have investigated excess androgen exposure using laboratory rodents not 
only to understand disorders such as CAH and PCOS but also to address increasing 
concern about androgenic chemicals in the environment. Exposing rats to excess 
androgens, in the form of testosterone has been the most common experimental 
approach and this has been shown to lead to various degrees of virilisation of the female 
fetus. The effects reported in this approach depend very much on the dose of 
testosterone administered, the timing of administration and the strain of rats used. For 
example a study which used three different doses of testosterone in Sprague Dawley rats 
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found that although dams had a lower bodyweight and increase in embryonic 
lethality, the reproductive tract of the female offspring was normal (Fritz et al, 1984). It 
is interesting to note that this study exposed rats from e13.5- e16.5. Most studies report 
females to be susceptible to masculinisation by excess testosterone exposure from e15.5 
onwards. For example, studies published by Rhees et al in 1997 exposed female rats to 
testosterone from e16.5 onwards and reported females to have an increased AGD, 
abnormal vaginal development and opening. Interestingly, LH surges were not affected 
(Rhees et al, 1997). In general, when exposed in utero to testosterone, the female 
offspring display male-like genitalia (Welsh et al,2008; Wolf et al, 2002), increased 
AGD (Kawashima et al, 1978; McCoy and Shirley, 1992; Rhees et al, 1997) delayed 
puberty, early constant estrus (McCoy and Shirley, 1992; Slob et al, 1983) and increased 
infanticide in rats (Rosenberg and Sherman, 1974). The WD can be stabilised in females 
exposed to testosterone and its derivatives have also been found in postnatal female rats. 
Some studies have found prostates in females after excess testosterone exposure but the 
same studies have not found the WD to be stabilised. In contrast, some studies have not 
only reported the stabilising of WD but have also pr vided evidence for its coiling 
(differentiation) (Welsh et al, 2009). The latter study reported that WD derivatives 
persisted into adulthood despite the lack of exogenus androgens postnatally. 
Furthermore, WD of control females which regress were reported to have apoptotic 
activity in contrast to the WD stabilised in testosterone exposed females which have cell 
proliferative activity. Of particular significance is the timing of WD stabilisation 
reported. Welsh et al (2009) concluded that degeneration of the WD in males in which 
androgen action was ablated experimentally happened lat r than in control females and 
that a male female time difference in programming of the WD may exist.  
An extensive study was published in 2001 by Wolf et al who exposed rat fetuses to 
various doses of testosterone propionate from e14.5-e19.5. The exposure to TP in utero 
had no effect on the male pups at any dose, at the ages examined. At a dose of 0.5mg/kg 
TP, exposed females displayed increased AGD at weaning, reduced number of nipples, 
cleft phallus, small vaginal orifice, and the presence of prostatic tissue. At a higher dose 
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of 10mg/kg, virilisation of the females was more prominent, with no vaginal opening at 
all and animals also had bulbourethral glands as well as seminal vesicles. Some females 
also displayed a greatly distended, fluid filled uter s or hydrometrocolpos (Wolf et al, 
2002). These studies also reported that TP treated dams were late with parturition, had 
abnormally small litter sizes as well as lower birth weights of pups. This is a well 
documented effect of TP in rats and some studies have resorted to caesarean section and 
use of foster mothers to overcome problems with dystocia (Welsh et al, 2008, 2010). In 
contrast injecting testosterone directly into the amniotic sac had a less severe effect 
(Swanson and Bosch, 1965). This is one of the reasons why the studies conducted in this 
thesis to investigate androgens, used DHT rather than estosterone. Further reasons for 
using DHT are discussed in chapter 3.  
 
There have been reports that female rats display a homologue of the male prostate and 
this is termed the Skenes paraurethral gland. Some scientists have reported that Wistar 
rats (the strain used for the studies in this thesis) do not have this gland due to absence of 
sufficient testosterone during embryonic and neonatal periods, whereas others have 
reported that some Wistar females can have an underdev loped but functional prostate 
(Biancardi et al, 2010). In our control Wistar female rats, no prostates have ever been 
reported previously and were not found in the control studies reported in this thesis.  
 
1.7. Androgen biochemical associates 
So far, this review has discussed androgens and AR. In transcription, this ligand-receptor 
complex does not work alone. AR has been shown to work ith various transcription 
factors. Over the past 15 years, it has become established that correct AR transcriptional 
activity also depends on various factors which do not posses DNA binding affinity. 
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1.7.1 Co-regulators 
Co-regulators can be generally defined as proteins which interact with nuclear receptors 
to either enhance (co-activators) or repress (co-repressors) transcription. Co-regulators 
are not generally considered to possess specific DNA binding affinity and do not 
significantly alter basal transcription rate (McKenna et al, 1999). Almost 300 nuclear 
receptor co-regulators have been identified since the isolation of the first co-activator in 
1995. In 1969, Britten and Davidson published a theory of ’master genes’, a type of 
‘master RNAs’ suggested to directly regulate transcription, but data could not be found 
to support this. Then, the vast studies focusing on RNA pol II and regulation of mRNA 
transcription discovered a new group of proteins. These proteins, co-regulators, were 
proven to be vital in transcription in addition to RNA pol II and general transcription 
factors (Lavery et al, 2006; Lee and Young, 2000; McEwan et al, 1997). The emergence 
of new co-regulators and our understanding of co-regulator function is growing 
progressively. It is now accepted that co-regulators are involved in virtually all of the 
reactions needed for control of gene expression. Many publications now term the genes 
which encode the co-regulator proteins, the true master genes of eukaryotes, proving 
Britten and Davidson were not completely incorrect.  
 
Co-regulators that interact directly with nuclear receptors exist in large steady state 
complexes with multiple secondary co-regulator partners. Each component may have 
multiple enzymatic capabilities, for example acetyltransferase, ATPase activities, 
methyltransferase. In addition, co-regulator proteins are affected by phosphorylation, 
methylation and other modification statuses. Most c-regulators are expressed in a wide 
variety of cell types and can interact with more than one nuclear receptor and there may 
also be redundancy between or within different classes of co-regulators (Heinlein and 
Chang, 2002; Heemer and Tindall, 2007). Furthermore, multiple cofactors may regulate 
nuclear receptor function at any one time. This fundamentally complicates interpretation 
as the demonstration of co-expression of a co-regulator with a particular nuclear receptor 
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does not necessarily mean it is modulating the activity of that particular receptor at that 
time.  
 
There are many ways in which this large group of proteins can and have been 
categorized. In this review, co-regulators will be classified and briefly discussed based 
on functional properties, followed by discussion of key (for this thesis) co-regulators.  
 
1.7.1.1 Components of the chromatin remodelling complex 
Gene transcription occurs on a chromatin template, in which DNA is wound around a 
core of four basic histone proteins (H2A, H2B, H3 and H4), which form nucleosomes. 
Regions of DNA between adjacent nucleosomes are link d by histone H1 (Wolffe, 2001; 
Hayes and Hansen, 2001). DNA-histone interactions limit the accessibility of the 
nucleosomal DNA to transcription factors, thus forming an obstacle to transcription. 
Chromatin remodelling complexes alter and unwrap the histone-DNA contacts in an 
ATP dependent manner (catalysed by ATP), leading to re-organisation of the 
nucleosomal structure, thus making the chromatin statu  more permissive to 
transcription (Trotter and Archer 2008).  
 
There are several AR co-regulators identified as components of the chromatin 
remodelling complex. Androgen receptor interacting protein 4 (ARIP4) was one of the 
first proteins which illustrated chromatin remodelling with AR. ARIP4 interacts with the 
zinc finger region and stimulates AR dependent transactivation, shown in co-transfection 
studies (Rouleau et al, 2002). After this initial discovery, an array of chromatin 
remodelling complexes which work with AR have emerged, for example SRG3 (Hong et 
al, 2005) and SRCAP (Monroy et al, 2003). Perhaps the most established (in the 
literature) chromatin remodelling complex is the SW1/SNF family which contains the 
ATP-ase Brahma related gene (BRG1), shown to be a potent AR regulator. 
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1.7 .1.1.1 BRG1 
SW1/SNF compromise a family of large, multi-subunit complexes containing 8 or more 
proteins present in a cell which contain one of twocore ATP-ases; BRG1or hBRM as 
well as numerous BAFs (BRG1 associated factors) (Trotter and Archer 2008). Human 
SW1/SNF complexes usually contain core subunits of BRG1 (or hBRM), BAF170, 
BAF155 and BAF47, BAF60, BAF57 and BAF53 as well as actin (Wang et al, 1996). 
These complexes regulate transcription factors by re-organising the chromatin structure 
through one of two processes, either by facilitating nucleosome condensation, which 
induces repression of transcription or by nucleosome dispersion which assists in 
activation of transcription. BRG1 has been identified to interact with many different 




BRG1 and hBRM share a high degree of sequence identity (74%) and in vitro, display 
similar biochemical activities (Khavari et al 1993; Randazzo et al 1994), however, in 
vivo are believed to have different roles in proliferation and differentiation (Kadam and 
Figure1.8 Summary of proteins which BRG1 co-regulates in either transcriptional activation 
or transcriptional repression. Diagram adapted from Trotter and Archer, 2008. 
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Emerson, 2003; Reyes et al, 1998). Although the exact mechanisms employed in the 
different roles are yet to be elucidated, knock out models have provided insight into the 
importance of these ATP-ase units. BRG1 deficient mice die at the pre-implantation 
stage suggesting it is vital for early development. BRG1 heterozygous mice are thought 
to be more susceptible to tumour development (Glaros et al, 2008). Conversely, hBRM 
null mice are found to be viable and fertile, although they do express BRG1 at higher 
levels than controls in particular tissues and display aberrant cell cycle regulation (Reyes 
et al, 1998). The BRG1 gene is composed of multiple domains which include an ATP-
ase domain, a C-terminal bromodomain, AT-hook motif and an N-terminal region which 
houses three further domains; QLQ, HSA and BRK domains (Khavari et al 1993).  
 
The large SW1/SNF multimeric assemblies are recruited to specific gene targets through 
association with DNA-binding transcription factors, co-regulators or by general 
transcriptional machinery. Furthermore, various different interactions are thought to be 
involved in recruiting and stabilising the BRG1 unit to the hormone responsive elements 
in promoters (Trotter and Archer, 2008). Several SW1/SNF components including 
BRG1, BAF250, BAF60 and BAF57 have been shown to mediat  interactions of nuclear 
receptors including glucocorticoid, oestrogen and arogen receptors (Link et al, 2005). 
Although the role of SW1/SNF is better established in oestrogen and glucocorticoid 
receptors, progress is being made to understand if this complex is important for 
androgen receptors. BRG1 has been shown to be involved in both co-activation and co-
repression of AR (Trotter and Archer, 2008).  
 
Probasin and prostate specific antigen (PSA) are two proteins which are predominantly 
expressed in the prostate. The gene for each of these as a strong promoter sequence for 
the target of AR. Cell culture experiments have recently shown the AR target promoter 
sequences of probasin and PSA require SW1/SNF for complete activation. In the 
absence of SW1/SNF, PSA failed to activate entirely and only a low level of activation 
was observed for probasin, illustrating that probasin can be at least partially activated 
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independent of chromatin remodelling. Both gene AR promoters were fully activated 
when hBRM was re-introduced into the cell culture. The re-introduction of BRG1 
however only weakly activated probasin and did not manage to activate PSA promoter 
by the androgen receptor. This data suggested hBRM was the preferred core ATP-ase of 
SW1/SNF for AR activity (Marshall et al, 2003).  
 
Studies conducted by Dai et al (2008) found BRG1 to be involved in AR antagonism in 
prostate cancer cells. Ablating androgen action usig antagonists is an important method 
of treatment for prostate cancer; however the mechanisms by which the antagonists 
work are poorly understood. This study illustrated hat prohibitin, which is a tumour 
suppressor, is essential in androgen antagonism. BRG1 but not hBRM was demonstrated 
to be required for the repressive action of prohibitin on AR responsive promoters. The 
antagonist bound to AR is thought to induce recruitment of prohibitin, and BRG1 to 
endogenous AR responsive promoters to mediate transcriptional repression. At the PSA 
promoter, this happened by PSA disassociating from p300 (a histone modifier co-
regulator) allowing BRG1 to remodel the chromatin. The p300 co-regulator is closely 
associated with CBP (CREB binding protein) and thisco-regulator is discussed in detail 
below. However, it should be noted that CBP interacts with BRG1 and this interaction 
has been demonstrated to be vital at least in the transcriptional activation of the 
oestrogen receptor (Direnzo et al, 2000; Naidu et al, 2009). Studies have shown, in 
response to oestrogen, ER recruits BRG1, and targets BRG1 to the promoters of 
oestrogen responsive genes, in a manner that occurs simultaneously to histone 
acetylation, controlled by CBP (Direnzo et al, 2000). BRG1 mediated co-activation of 
ER signalling is regulated by the state of histone ac tylation of the cell, controlled by 
CBP. Given the importance of both these co-regulators, and the various roles they play 
and their well documented roles in ER and GR activation, it is surprising that this 
mechanism has not yet been furthered explored with the AR.  
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Some studies have found higher levels of BRG1 in malign nt prostate cancer tissue and 
this was associated with larger volume of tumour mass (Sun et al 2007), and yet the loss 
of BRG1 (targeted knockout) actually potentiates lung cancer. (Glaros et al, 2008). It is 
hypothesised that different genes have different requi ments for two ATP-ases with 
some relying on hBRM and others on BRG1 for androgen regulation. 
 
1.7.1.2 Histone Modifiers 
More localised control over transcriptional events i  the chromatin can be achieved by 
modifications of histone residues. Histone residues can be modified in a number of ways 
including acetylation, methylation, phosphorylation, ubiquitination, ADP-ribosylation 
and glycosylation. Overall, most of these modifications change the net charge of the 
nucleosome, inducing either a loosening or a tightening of the DNA histone interactions 
(Heemers and Tindall, 2007). Several co-regulator pr teins function in this pathway in 
either co-activation of AR, by recruiting histone acetylase, or co-repressing AR activity 
by de-acteylation, rendering the chromatin environme t transcriptionally repressed.  
 
1.7.1.2.1 CREB binding proteins (CBP) 
The CREB binding protein (CBP) was initially identified as a co-activator for CREB, 
the cAMP response element binding protein (Chirivia et al, 1993). These studies used 
protein interaction assays and determined that CBP can bind to CREB when CREB is 
phosphorylated by protein kinase A. Similar protein assays, using an adenoviral 
transforming protein E1A, discovered p300, a homologue of CBP as both co-regulators 
share a highly conserved sequence (Stein et al, 1990; Eckner et al, 1994). Since then, 
CBP and p300 have been reported to bind to a number of different proteins involved in 
transcriptional regulation. Their intrinsic histone acetyltransferase activity works to relax 
the chromatin and assist in transcription (Fronsdal et al, 1998) and some of the 
interactions that CPB/p300 are involved in are outlined in Fig 1.9. CBP and p300 have 
similar structures. Both genes contain a nuclear receptor interaction domain, the CREB 
interaction domain, the cysteine/histidine regions, the interferon response binding 
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domain, the histone acetyletransferase domain and a bromodomain, which binds 
acetylated lysines. A PHD finger motif has also been identified but its function is 







CBP and p300 have been reported to assist in transcription using three main methods, 
condensing or relaxing the chromatin, recruiting basal transcription machinery or acting 
as adaptor molecules. Despite their similarities, however, it should be noted that CBP 
and p300 are not functionally interchangeable (Vo and Goodman, 2001). This can be 
observed from the different phenotypes which occur as a result of specific knockouts. 
For example, heterozygous inactivation of CBP in mice leads to haematological defects 
and a predisposition to cancer which is not displayed by mice with p300 deficiencies 
(Kung et al, 2000). A similar scenario is observed in humans in whom insufficiency of 
CBP leads to Rubinstein-Taybi Syndrome (RTS), a disease characterized by mental 
retardation, craniofacial abnormalities, broad toes and thumbs as well as an increased 
Figure 1.9 Domain structure of CBP/p300 gene indicating three zinc fingers (Zn), a 
bromodomain (Bromo), a CREB binding domain (KIX), a HAT domain and glutamine-rich 
domain (Q). Association with transcriptional activators is shown above the domains with 
which they interact and transcriptional repressors are indicated below. Diagram from Vo 
and Goodman, 2001.  
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incidence of malignancy (Blobel, 2000). An identical mutation in one p300 allele 
however does not produce the same haemotological or cancer pre-disposition effects 
(Goodman and Smolik, 2000). Homozygous mutations in either CBP or p300 however 
result in embryonic lethality and furthermore, CBP/p300 double hetrozygotes are 
invariably lethal which suggests that their function may overlap to some extent (Vo and 
Goodman, 2001).  
 
The complexity of CBP and p300 protein interactions ha  led to them being described as 
molecular integrators rather than co-regulators. This is exemplified by the vast number 
of publications outlining the various different factors that CBP/p300 have been shown to 
interact with and their various modes of action. Historically, the adenovirus, E1a has 
played a large role in understanding CBP/p300. E1a is  multifunctional pleiotrophic 
protein that mediates biological effects through transcriptional activity of target genes. It 
affects proliferation and cellular differentiation to produce an oncogenic phenotype 
(Shiama et al, 1997). The N-terminal of E1a can bind to and block CBP/p300 which 
causes the cell to enter the S phase of the cell cycle. Two methods have been proposed 
for how CBP/p300 action might be blocked. The first of these proposes that E1a can 
bind to the CBP/p300 region which interacts with RNA polymerase II and TFIIB, thus 
preventing these essential (for transcription) factors from interacting with the co-
activators (Felzien et al, 1999). In addition, E1A binding to the third zinc finger domain 
of CBP/p300 has been reported, blocking the histone ac tyl activity essential for 
CBP/p300 mode of action (Chakravarti et al, 1999; Perissi et al, 1999). Other than E1a, 
CBP/p300 has been shown to interact with many other viral oncoproteins, including 
human T-cell leukemia virus (HTLV-1), V-myb and human papilomavirus E6 
(Goodman and Smolik, 2000). In addition to oncoproteins and CREB, CBP/p300 also 
works with other transcription factors such as c-myb, Sap1a, Elk1 and NFKb (Aarnisalo 
et al,1998) and many of the members of the nuclear receptor family.  
CBP/p300 has been reported to interact with the oestrogen receptor, glucocorticoid 
receptor, retinoic acid receptor, thyroid hormone receptor and the androgen receptor 
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(Aarnisalo et al, 1998). Using cell culture techniques, it has been shown that the N-
terminus of CBP/p300 works with both the N-terminal domain and DNA binding 
domain of AR. Furthermore, it has been suggested that the limiting amount of CBP in 
the cell might mediate transcriptional interference with AP-1. AP-1 is Activator Protein -
1, a transcription factor which is involved in regulation of genes involved in 
differentiation, proliferation and apoptosis.  
As briefly mentioned in section 1.7.1.1.1, it has been shown that CBP and BRG1 work 
together with oestrogen and glucocorticoid receptors (Direnzo et al, 2000; Naidu et al, 
2009). Given the various different pathways each of these co-regulators is involved with, 
and the importance of their expression during fetal life, it is surprising that their role 
with androgens during the fetal period has not gained more attention. To my knowledge, 
no such studies have been published in the literature.   
 
17.1.3 Components of the ubiquitination/ proteasome pathway 
Ubiquitination is a post translational modification f cellular proteins in which ubiquitin 
(a 76 amino acid polypeptide) is attached to lysines in target proteins. Ubiquitination 
allows proper progression through rounds of transcription and the appropriate assembly 
of the necessary proteins. Ubiquitination involves the activation of an E1 enzyme, which 
transfers ubiquitin to a conjugated E2 enzyme and this recruits E3 ligase, which transfers 
the ubiquitin to the intended target protein (Heemers and Tindall, 2007).  
 
AR co-regulators which employ ubiquitination in orde  to regulate AR activity include 
E6-AP (Khan et al, 2006), Mdm2 (Gaughan et al, 2005), PIRH2 (Logan et al, 2006), 
SNURF/RN4 (Poukka et al, 2000) and Chip (Rees et al, 2006). Each of these co-
regulators employs the ubiquitination pathway, but all work via a different mechanism. 
For example, E6-AP is recruited to the promoter region of target genes upon androgen 
binding to its receptor and interacts with the N-terminal to enhance transactivation 
(Khan et al, 2006). E6-AP may also be involved in regulating the level of AR protein. 
This is demonstrated in E6-AP null mice, which display increased AR levels, and 
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similarly, cell culture experiments in which E6-AP is over expressed causes a decrease 
in AR protein expression.  
 
Proteins such as Mdm2 interact with the AR N-terminal domain and the DNA binding 
domain and this interaction is dependent on E3 ligase ctivity. Furthermore the Mdm2-
AR complex actually recruits another AR co-regulator, HDAC1 and in response to 
androgen, both AR and HDAC1 become ubiqutinated. Mdm2 and HDAC1 work at 
target gene promoter sites to attenuate activity. Furthermore, this activity is attenuated 
by the histone acetyl transferase activity of another AR co-regulator, Tip60 (Gaughan et 
al, 2005). This is a fine demonstration of the interplay between various AR-co-regulators 
and the vast number of interactions which may be taking place, to direct the correct 
action of androgens through AR.  
 
17.1.4 Components of sumoylation 
SUMO, the small ubiqutin modifier protein is similar to ubiquitination in its 
employment of E1 activating enzyme, E2 conjugating enzymes and an E3 ligase 
enzyme, but differs due to the SUMO homologs, SUMO 1, 2, and 3. SUMO 1 has been 
shown to decrease AR activity (Poukka et al, 2000) whereas SUMO 2 and 3 enhance 
transcription (Zheng et al, 2006).  
 
1.7 .1.5 Chaperones and co chaperones 
In the absence of the ligand, AR is stabilised within t e cytoplasm by being bound to 
molecular chaperones. Although ligand binding disassociates the AR from the majority 
of the heat shock proteins (reviewed in section 1.4.1), some chaperones remain attached 
to the AR. These act as co-regulators for downstream vents such as translocation, 
transcription and even AR degradation. For example Hsp40 has been shown to be 
necessary for androgen binding to AR and defects of Hsp40 leads to problems in the 
formation of the AR–Hsp70 complex which causes AR folding defects (Fan et al, 2005). 
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In contrast, loss of Hsp70 in a mouse knock out model showed enhanced AR gene 
transcription which led to defects in spermatogenesis (Terada et al, 2005).   
 
1.7.1.6 Cytoskeletal proteins 
Conventionally, actin is thought of as a cytoplasmic organiser and a major component of 
the cell cytoskeleton. More recently, actin has been shown to be a player in 
transcriptional events also, including playing roles in chromatin remodelling (Ting et al, 
2002). SUPERVILLIN is an actin binding protein whic interacts with both the N-
terminal domain and DNA-binding domain of AR and this association is enhanced by 
androgens but furthermore cooperates with other AR co-regulators such as ARA55 and 
ARA70 (Ting et al, 2004). Three different isoforms of actin cooperate with 
SUPERVILLIN to stimulate AR transactivation. Another xample of an actin binding 
protein is GELOSOLIN which has been reported to interact with AR during nuclear 
translocation to enhance ligand dependent AR activity (Nishimura et al, 2003).  
 
1.7.1.7 Endocytosis 
Proteins which are involved in cell endocytosis canplay multiple roles and are reported 
to interact with AR to influence AR mediated transcription. One example of this is 
huntingtin-interacting protein, HIP1 which associates with AR to reduce the rate of AR 
protein degradation. HIP1 is recruited to AREs upon androgen stimulation and it has 
been shown that over-expression of HIP1 enhances AR transcription whereas 
transcription is repressed when HIP1 is knocked down (Mills et al, 2005). G-associated 
kinase (GAK) is another example of a protein involved in endocytosis which has been 
shown to interact with the N-terminal domain of AR to enhance AF1 activity, in a ligand 
dependent manner (Ray et al, 2006).  
 
1.7.1.8 Cell cycle regulators 
There seem to be few components of the cell machinery which are not involved with 
androgen and AR action. Proteins which are involved in cell cycle regulation are also 
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involved in AR modulation. One such protein is CYCLIN E, which has been shown to 
bind directly to the N-terminal domain of AR to enhance AF1 transactivation function 
(Heemers and Tindall, 2007). Another example of a cell cycle regulator involved with 
AR transcription is CDC25B, which interacts directly with AR to enhance transcription, 
and the action of this complex is enhanced by interaction with CBP (Ma et al, 2001). 
Other cell cycle regulators inhibit AR activity. An example of this is CYCLIN D1 which 
can bind directly to the AF-1 region of AR, independ t of the ligand, recruit HDACs 
and inhibit the N and C-terminal domains of AR. This activity has been shown to be 
independent of the role that Cyclin D1 plays in cell ycle regulation (Reuten et al, 2001; 
Petre-Draviam et al, 2003). The retinoblastoma protein (RB) is a protein which functions 
as a tumour suppressor and controls progression thrug  cell cycles. RB can bind to AR 
to enhance transcriptional activity and it does thi by co-operating with another AR co-
regulator, ARA70 (Yeh et al, 1998).  
 
1.7.1.9 Regulators of apoptosis 
Proteins involved in the execution of apoptosis canalso act as AR co-regulators. An 
example of this is seen with the pro-apoptotic caspase-8, which represses AR dependent 
gene expression by disrupting N and C terminal interaction of AR. This inhibits 
androgen induced nuclear localisation (Qi et al, 2007) which leads to transcriptional 
repression. An example of co-activation by apoptotic factors is displayed by Par-4, a 
pro-apoptotic protein which interacts with the AR DNA binding domain and is recruited 
to the promoter of AR driven genes. Here it enhances th  association of AR with DNA 
and increases AR dependent transcription (Gao et al, 2006).  
 
1.7.1.10 RWdd1 
A newly discovered co-regulator is Rwdd1 which in the rat has also been called small 
androgen receptor interacting protein. Rwdd1 is an abbreviation of RWD containing 1; 
RWD is a domain named after three major RWD containing proteins, RING-Finger 
containing proteins, WD domain containing proteins a d DEAD like helicases. This co-
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regulator was originally identified in the thymus only 3 years ago (Kang et al 2008a) and 
its functions are yet to be fully understood. There is evidence suggesting that AR is 
related to thymus involution as testosterone inhibits thymocyte development and 
castrated animals display thymus enlargement. Moreover androgen deprivation can lead 
to T- cell augmentation. In an epithelial cell line it has been shown that Rwdd1 can 
enhance transactivation of AR. In localisation studies, in the thymus at least, Rwdd1 and 
AR may both be cytoplasmic and upon ligand binding, RWDD1 remains cytoplasmic 
whereas the AR complex becomes nuclear. FRET studie suggest there is no direct 
interaction between RWDD1 and AR in this organ (Kang et al 2008b).  
 
1.7.2  Methylation 
In mammals, DNA methylation is a vital cellular process (Fraga, 2009). DNA 
methylation is the covalent addition of methyl group to the 5’position of cytosines. This 
usually occurs on a cyotisne which is followed by a guanine and termed CpG 
dinucleotides (reviewed by Garcia-Carpizo et al, 2011). CpG dinucleotides occur in a 
low frequency in vertebrates but stretches of DNA with high CCG content with high 
frequency of CpG dinucleotides relative to the bulk genome have been identified and 
these are termed CpG islands (Gardiner-Garden et al, 1987). Most CpG dinucleotides 
are methylated but those located in CpG islands, found mainly in promoter regions of 
genes, are not usually methylated (Garcia-Carpizo et al, 2011). DNA methylation is 
responsible for genomic imprinting, X chromosome inactivation in females and for 
securing monoallelic gene expression by repressing expression of maternal or paternal 
genes. DNA methylation is catalysed by DNA methyltransferase (DNMT) enzymes and 
knockout mice lacking these enzymes die at the morula stage (Shock et al, 2011, 
Woroniecki et al, 2011). Generally, DNA methylation leads to the repression of gene 
expression whereby methylated genes are either not transcribed or transcribed at a 
reduced rate (reviewed by Garcia-Carpizo et al, 2011).   
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A full review of the role of gene methylation in the embryo and in postnatal life is 
outwith the scope of this review and can be found elsewhere (Walsh, 2006, chapter 5). 
Methylation and the enzymes involved have become an important focus of epigenetic 
research and the literature concerning methylation and AR is increasing. Very recently, 
histone methyltransferase (HMT) and histone demethyltransferase (HDM) have been 
shown to be involved in AR gene regulation. In particular, an HMT enzyme termed 
SET9 interacts with AR and associates with the PSA promoter in a ligand dependent 
manner. SET9 adds a methyl group onto a lysine residu  within the hinge region of PSA 
and this modification is necessary for AR activity in prostate cancer cells. Thus, SET9 
plays an important role in cancer progression and implicates another mode of AR 
regulation (Gaughan et al 2010). Another study done in prostate cancer cells has shown 
lysine specific demethylase 1 (LSD1 also known as BHC110) co-localises with AR in 
vitro and in vivo to stimulate AR expression. LSD1 can demethylate to control specific 
gene expression (Metzger et al 2005).  
 
1.7.2.1 DNA methyltransferase like -3 (DNMT3L) 
Four DNMT enzymes involved in catalysing DNA methylation have been characterised 
in the literature. DMNT3A and DNMT3B are de novo methyltransferases which 
function to establish DNA methylation patterns early in development and DNMT31 
maintains methylation patterns during replication (Aapola et al, 2002). The fourth 
DNMT enzymes, is DNMT3L (DNMT3-like) and this member shares similarity in 
protein structure to DNMT3A, DNMT3B and DNMT31 and in addition, it has been 
shown that DNMT3L is required specifically for the establishment of maternal genomic 
imprints and is vital for de novo methylation (Aapola et al, 2002). However, DNMT3L 
lacks the catalytic motif required for methyltransferase and is believed to function as a 
regulator of methylation at imprinted loci rather than a cytosine methylatransferase 
enzyme (Aapola et al, 2002; Garcia-Carpizo et al, 2011). Although the mechanisms by 
which DNMT3L regulates methylation are not completely understood, it has been 
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shown that DNMT3L can mediate transcriptional repression through interaction by 
associating with histone deactylase activity (Aapol et al, 2002; Deplus et al, 2002).  
 
Targeted disruption of DNMT3L expression in mice led to severe hypogonadism and 
Sertoli cell only phenotype with azoospermia. Heterozygous progeny of the DNMT3L 
deficient homozygous females failed to develop past 9 days of gestation due to 
embryonic defects resulting in biallelic expression of genes which are normally only 
expressed from one the of paternal origin (Bourc’his et al, 2001). Further studies have 
characterised the testis of DNMT3L knock out mice to understating the cause of the 
impaired spermatogenesis (Webster et al, 2005)  and found GC in these mice were 
arrested and died around the early meiotic stage (Hata et al, 2006). Microarray 
expression profiling of the testis of DNMT3L knockout mice found a down regulation of 
gonad specific and or sex-chromosome linked genes (Hata et al, 2006).  
 
1.7.2.2 Brother of the regulator of imprinted sites (BORIS) 
 CTCF is a conserved and ubiquitous 11 zinc finger protein which is involved in various 
aspects of gene regulation and forms methylation sensitive insulators that regulate X 
chromosome inactivation and expression of imprinted g nes (Loukinov et al, 2002). 
More recently a paralogue for this gene was identifi d, BORIS, which has the same 
exons encoding the 11 zinc finger domain as the CTCF gene (Klenova et al, 2002). 
However BORIS expression has only been found in the testis and is predominantly 
expressed during embryonic male germ cell development; however, it is also expressed 
in tumours and consequently has been classified as a cancer-germline or cancer-testis 
gene (Nguyen et al, 2008; D’Arcy et al, 2008). Using cancer cell lines, it has been 
shown that disruption of DNA methylation induces BORIS expression. In addition the 
promoter site of BORIS has DNA hypomethylation and histone 3 modification patterns 
(Woloszynska-Read et al, 2007). Furthermore, the BORIS promoter is repressed by CpG 
methylation in a dose dependent manner which suggests a role for DNA methylation in 
BORIS transcriptional regulation.  
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1.7.3 Prostaglandins 
Prostaglandins, the products of the arachidonic acid pathway, were originally isolated in 
1935 from the seminal fluid of the prostate (Goldblatt 1933, Von Euler 1936). 
Prostaglandins are lipid compounds which are derived from essential fatty acids. They 
have been shown to be autocrine and paracrine mediators involved in a wide variety of 
physiological effects in various tissues and organs around the body. These physiological 
effects include activation of the inflammatory response (Williams and Peck, 1977), 
platelet movement, calcium regulation (Horribin et al, 1978) and regulation of hormonal 
secretions of the hypothalamic-pituitary-testicular xis (Vermes et al, 1979). The 
arachidonic acid pathway is summarised in Fig 1.10. In brief, an intermediate is created 
from phospholipase–A2, which is either catalysed down the cycloxygenase pathway to 
produce prostaglandins and thromboxanes or catalysed down the lipooxygenase pathway 
to form leukotrienes. The cyclooxygenase (COX) enzymes are crucial in the formation 
of prostaglandins. In order to inhibit the inflammatory process and consequent pain, 














Figure 1.10 Summary of the production of prostaglandins from phospholipids and the 
involvments of COX1 and COX2.   
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COX1 is present in most tissues to maintain regular f nction whereas COX2 is mainly 
expressed in tissues upon their inflammation (Kuboto et al 2011). Perhaps surprisingly, 
therefore, COX2 is the predominant isoform expressed in the fetal male reproductive 
tract (Kirschenbaum et al, 2000). Using immunohistochemistry, it has been shown that 
COX1 levels are minimal in the male reproductive trac , with no expression detected in 
fetal life. COX2 has been found in the fetal and adult seminal vesicles, and also in the 
ejaculatory ducts (vas deferens), with expression varying and correlating with levels of 
testosterone (Kirschenbaum et al, 2000). A role for prostaglandins in regulating 
testosterone production is well documented (Sawada et al 1998, Romanelli et al 1995, 
Wang et al 2003), and will not be reviewed in full detail here. In brief, it should be noted 
that arachdonic acid is involved in the regulation of testosterone production in adult 
Leydig cells (Romanelli et al 1995). Furthermore, some reports suggest COX2 is 
involved in the regulation of steroidogenic acute regulatory gene transcription and 
hormone biosynthesis (Wang et al, 2003). Moreover, mice deficient in COX1 remain 
fertile whereas deficiencies in COX2 lead to infertility (Kirschenbaum et al, 2000). 
 
A series of studies published in the late 1980’s suggested that the arachidonic acid 
pathway was involved in the masculinising action of testosterone, particularly the 
embryonic external genitalia in mice. The initial studies blocked masculinisation using 
oestradiol 17-β or cyproterone acetate and animals displayed typical evidence of 
impaired androgen action, such as reduced anogenital dist nce and hypospadias. This 
effect was reversed by the administration of arachidonic acid and, furthermore, this 
reversal was blocked by administering COX inhibitors such as aspirin and indomethacin 
(Gupta and Goldman 1986). The mice in this study were exposed to treatments between 
e11-e14 and Gupta termed this time as ‘a critical period for affecting anogenital 
distance’. Later studies by the same group investigated two key prostaglandins, PGE2 
and 6-keto-PGF1. These studies reported male and female fetuses to have similar levels 
of these PGs before ‘the period of sexual differentiation’, which in this study is defined 
as e13-e17. During the period of sexual differentiation, these prostaglandins were found 
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to increase in the male genital tract but not in the female. Furthermore, when female 
fetuses were exposed to testosterone, their levels of these PGs were reported to increase, 
and in males exposed to an anti-androgen, the investigated PG levels decreased (Gupta, 
1989). This study suggests three concepts which are important to this thesis; the first of 
these is that the period of masculinisation in mice is from e13-e17. This correlates with 
what we now call the masculinisation programming window (MPW), a time frame found 
in rats when correct androgen action is critical in the development of the male 
reproductive tract. In rats this time frame is suggested to be e15.5-e18.5 (Welsh et al, 
2008). The MPW was discussed in detail in section 1.1.6. The second important concept 
is that prostaglandins are important for male sexual differentiation. Finally, blocking PG 
synthesis using indomethacin can affect virilisation. In the last study published by this 
group in this field, an in vitro organ culture was u ed to determine the role that PGE2 
played in differentiation of the testosterone dependent Wolffian duct (WD). This study 
found that blocking PG synthesis using an anti-PGE2 antibody, even in the presence of 
testosterone, blocked differentiation of the WD in a dose dependent manner. 
Furthermore, the differentiation of a WD in females a  a result of exposure to 
testosterone in utero, was inhibited by exposure to indomethacin (Gupta and 
Bentlejewski, 1992). Thus a very convincing set of studies, demonstrating a critical time 
period for masculinisation, but also the importance of arachidonic acid and 
prostaglandins in producing the correct male (and female) phenotype. Investigations by 
other groups have also suggested PGs are important in the male reproductive tract.  
 
1.8 Non genomic effects of androgens 
The discussions so far in this review have centred around the genomic actions of 
androgens. However, there is growing evidence indicating that androgens are capable of 
triggering cellular processes through non-genomic, rapidly occurring mechanisms 
(Kousteni et al, 2001; Nazareth and Weigel, 1996; Peterziel et al, 1999). These actions 
usually occur within seconds or minutes and are oftn dependent on plasma membrane 
associated signalling pathways that lead to the activation of cytoplasmic second 
Chapter 1                          Literature Review 
 
Page | 70 
messengers. The two most studied non genomic androgen pathways involve kinase 
associated intracellular signalling and modulation of intracellular calcium levels. The 
molecular mechanisms and, more importantly, physiological relevance of the non 
genomic effects remains largely unknown but recently more studies are being 
undertaken to gain insight into this.  
 
The emerging literature suggests that non-genomic androgen action may be important in 
the fetal male reproductive tract. A rapid increase in intracellular calcium was observed 
when primary rat Sertoli cells, human androgen dependent (LNCaP) and androgen 
independent (PC3) human prostate cancer cells were exposed to testosterone, DHT or 
R881 (an AR agonist). In another study, testosterone was able to induce a rapid increase 
in concentration of the transcriptional factor CREB in rat primary Sertoli cell culture via 
MAPK pathways (Cheng et al, 2007). However, it is important to note that both rat 
Sertoli cells and LNCaP cells contain a population of plasma membrane associated AR 
which transiently increase in expression in response to testosterone stimulation. 
Therefore it is yet to be elucidated whether the non genomic actions of androgens are in 
fact taking place via the classical AR genomic mechanism, through membrane bound 
AR or perhaps by another membrane associated signalling pathway.  
 
MAP kinases are proteins which transduce signals coming from cell membrane receptors 
after binding of growth factors such as epidermal growth factor (EGF) or insulin like 
growth factor 1(IGF-1). Yeh et al (1999) illustrated MAP kinases can phosphorylate and 
activate the AR, with the respective phosphorylation site being in the N terminal 
domain. Further studies have shown that not only can MAP kinases activate AR in the 
absence of androgens, but in the presence of androgens, AR can activate MAP kinases.  
A different route of ligand independent AR activation is through cross talk with PKA 
pathways. Studies have shown that PKA can interact with the N-terminal domain of AR, 
and in addition activators of AR such as forskolin can induce AR activation and PSA 
secretion in the absence of androgens (Nazareth and Weigal, 1996).  
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1.9. The indifferent reproductive tract 
The reproductive tract consists of the gonads, the internal genital system and the external 
genitalia. The development and differentiation of the gonads is primarily driven by 
genetics whereas differentiation of the internal and external genitalia is under the 
influence of hormones produced by the gonads and the appropriate receptors. During 
gastrulation, the embryo becomes tri-laminar with three germ layers; the ectoderm, the 
mesoderm and the endoderm (Carlson, 2004). Through a series of complex morphogenic 
movements, the tri-laminer embryo is converted into a tubular embryo containing a 
foregut, midgut and hindgut (Moore and Persuad, 2003). The hindgut terminates 
caudally in an expansion called the cloaca.  
 
The mesoderm is the source of much of the urogenital system, and within this layer, 
three structures form; the pronephros, the mesonephros and the metanephros. The 
pronephros is the first to form and is a rudimentary, nonfunctional structure which gives 
rise to the pronephric duct. The pronephros regresses and is succeeded by the 
mesonephros; however, the pronephric ducts persist alongside the mesonephros and are 
called the mesonephric ducts, also termed the Wolffian ducts. The cranial end of the WD 
is connected to the gonads via the mesonephric tubules, which later in males form the 
efferent ducts. Later, and laterally to the WD, invaginations of the coelomic epithelium 
gives rise to paramesonephric ducts, also called th Müllerian duct. The MDs are 
positioned on the lateral side of the cranial WD but cross to the medial side at the caudal 
end. The WD gives rise to the internal reproductive ract of the male whereas the MD 
gives rise to the internal reproductive tract in the female and this is discussed in section 
1.9.1.  
 
The hindgut terminates caudally in an expansion called the cloaca which reaches a 
cloacal membrane on the ventral surface of the embryo (Yamada et al, 2003). The 
cloacal membrane and the oropharyngeal membrane are the only two sites of the embryo 
which are bi-layered with the absence of the mesoderm layer. The bi-layered cloacal 
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membrane retracts into the perineum due to the cranial and medial migration of 
mesodermal cells. These migrating mesodermal cells spread around the cloacal 
membrane and pile up to give rise to three swellings (Sajjid, 2010; Yamada et al, 2003). 
One swelling is the genital tubercle (GT) which appears in the midline between the 
cloacal membrane and the umbilicus. The GT, which will later form the phallus, at this 
stage is the same size in both males and females (Yamada et al, 2003). Distally, on either 
side of the cloacal membrane, two pairs of swellings appear, termed the urogenital folds 
and the urogenital swellings. A wedge of mesenchymal cells then forms the urorectal 
septum which migrates caudally to divide the cloaca into a ventral portion called the 
urogenital sinus (UGS) and a dorsal part called the anorectal canal (Baskin. 2004) The 
differentiation of the UGS is discussed further in section 1.9.2. The urorectal septum 
fuses with the cloacal membrane eventually causing a division between the urinary and 
genital systems (Yamada et al, 2003; Sajjid, 2010).  
 
1.9.1 Development of the internal genitalia 
The initially identical urogenital tract in both sexes consists of two duct systems, the 
WD and the MD. In males, the WD gives rise to the epididymis, vas deferens and 
seminal vesicles, and the MD regresses. In the females the MD is programmed to form 
the fallopian tubes, uterus, cervix and upper third of the vagina and the WD regresses 
(Jirasek, 1971; Hashimoto, 2003; Rey and Picard, 1998; Sajjid, 2010).  
 
In males the MD regresses under the direction of AMH, which is secreted by the Sertoli 
cells, and binds to its receptor AMHR2 (Donahoe et al, 1977). This induces a signalling 
cascade that results in the production and secretion of matrix metalloptoteinase 2 
(MMP2). MMP2 induces apoptosis in the epithelial cels of the MD (Roberts et al, 
2002). Failure of this to occur in males leads to persistent MD syndrome (PMDS) 
(Thomson et al, 1994; Rey et al, 2011). Once the MD has regressed, testosterone from 
the LCs stabilise and differentiate the WD into the epididymis, vas deferens, and seminal 
vesicles and much like other male specific organs, thi  differentiation, is dependent upon 
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epithelial mesenchymal interactions (Xavier and Allard, 2003; Welsh et al, 2009). 
Testosterone can reach the WD in one of two ways, via the blood circulation, which is 
an endocrine interaction or via testicular fluid. 
 
In rats, studies have illustrated that AR is expressed from e14.5 onwards specifically in 
mesenchymal cells of the WD whereas, AR does not switch on in the epithelial cells 
until e18.5 (Cooke et al, 1991) when the WD begins to elongate and convolute to 
produce a highly coiled epididymal structure. It is believed the effects of androgens on 
the epithelium are indirect and likely occur via the production of paracrine factors from 
the mesenchyme. Conversely, the paracrine factors pr duced by the mesenchyme and 
which differentiate the epithelium, stimulate production of growth factors and other 
signals which are essential for the growth of the mesenchyme; these include epidermal 
growth factor (EGF) (Gupta, 1999; reviewed by Archambeault et al, 2009), growth 
hormone (GH) (Nguyen et al, 1996), insulin-like growth factor 1 (Igf1) (Baker et al, 
1996), transforming growth factor beta 2 (Tgfβ2) and fibroblast growth factor (Fgf) 
(Thomson and Cunha, 1999). Moreover, Hox genes, which are well established for their 
role as critical regulators of cell differentiation, positional arrangement, and patterning 
during the development of various organs, display regional specificity within the WD 
(reviewed in Hannema and Hughes, 2007). The precise role Hox genes play in WD 
development however is yet to be established.  
 
In females the lack of testosterone causes the WD to regress and the lack of AMH 
allows the MD to persist (Jirsova and Vererova, 1993; Sajjid, 2010). Excess androgens 
in females in utero causes the WD to stabilise as discussed in section 1.3.3. It should be 
noted that the MD derivatives can develop even in the absence of the ovary contrasting 
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1.9.2 Differentiation of the UGS 
The UGS forms in both males and females when the cloaca is subdivided by the 
urorectal septum. The UGS is divided into three sections, the upper, pelvic and phallic 
regions (Meeks and Schaeffer, 2011; Wilson, 1978). Like most structures of the 
reproductive tract, sexual dimorphism of the UGS is dependent on the presence or 
absence of androgen action. In males, the upper part of the UGS forms the future urinary 
bladder, the phallic part gives rise to the spongy part of the urethra and the urethral 
vestibules and the pelvic portion is where the prostate originates from (Carlson, chapter 
16).  
 
AR is expressed in the UGS mesenchyme and upon DHT binding, these cells induce 
differentiation of the epithelial cells though local paracrine effects of growth factors 
(Meeks and Schaeffer, 2011). This causes the outgrow h f solid buds from the UGS 
epithelium into the UGS mesenchyme. This epithelial-mesenchymal interaction results 
in cell differentiation and prostate branching morphogenesis (Chung and Cunha, 1983). 
Studies have shown that activation of AR by DHT in the mesenchymal cells results in 
the activation of at least the following pathways; Notch, FGF, TGF, Wnt and Shh 
(reviewed by Meeks and Schaeffer, 2010). Shh signall ng causes the prostatic ducts to 
bud off the epithelium of the UGS and the extent of budding is controlled by the 
inhibitory action of BMP-4 (Pu et al, 2004). Furthermore, HOXA13 and HOXD13 are 
also involved in the positioning of the tissue and differentiation of prostatic buds 
(Podlasek et al, 1997; Warot et al, 1997).  
 
It is interesting to note that the genes which control formation of the prostate are also 
involved in formation of the genital tubercle in the male. How the same set of control 
genes leads to the formation of two completely distinct structures is not yet understood. 
It is possible that interacting partners may be expr ssed differentially, or different 
thresholds or combination of expression may be the det rmining factors. In addition, 
other molecules such as CD44 and follistatin, not known to play a role in GT 
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development, have been identified in prostate development (Cancilla et al, 2001; 
Gakunga et al, 1997; Wang et al, 1999). Later, condensation of the mesenchyme, urethra 
and WD give rise to the adult male prostate, the function of which is to produce an 
alkaline fluid that contributes to seminal plasma to support sperm and ejaculation.  
In females, the cranial and caudal portion of the pelvic area of the UGS gives rise to the 
urethra and vaginal vestibule respectively.  
 
1.9.3 Differentiation of the male external genitalia 
After the initial bipotential phase, between weeks 9-12 of human pregnancy, the 
genitalia becomes sex specific. In males, the GT elongates and a groove appears in the 
ventral aspects called the urethral groove. Initially, the groove and urethral folds only 
extend part of the way along the shaft of the elongati  phallus and terminate in a solid 
plate of epithelial cells, termed the urethral plate, which extends into the glans penis 
(Carlson, 2004). The urethral plate then canalizes causing the urethral groove to extend 
distally into the glans (Yamada et al, 2003). The ur thral folds grow towards each other 
and fuse in the midline, eventually causing the urethral groove to form a tubular penile 
urethra. Hypospadias occurs when the urethral folds fail to fuse, leading to an abnormal 
location of the urethral opening. The site at which the fusion fails, dictates where the 
hypospadias occurs on the penis and this can occur anywhere from the perineal region 





Figure 1.11 Diagrammatic representation of development of the urethral plate, urtheral 
groove, ostium, anus and scrotum. Figure from Yamada et al, 2003 
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The urethral groove and the urethral plate are thoug t to be lined by and derived from 
the endoderm (based on histological examinations) ad some believe that the urothelium 
lining all of the urethra is endodermal in origin (Seifert et al, 2008; Yamada et al, 2003). 
The urothelium is a unique epithelium found only in the ureter, bladder and urethra with 
only the ureter urothelium being mesodermal in origin as it is derived from the 
embryonic WD. However, because the epithelium of the urethral folds is precisely at the 
interface of the ectoderm and endoderm, controversy xists amongst the experts and 
some believe the penile urethra could be ectodermal in origin (Larson, 2001). The 
ectodermal in-growth theory postulates that the glandular urethra is formed by an in-





Despite the controversy about whether the urothelium is of ectodermal or endodermal 
orgin, it is widely agreed that the ectoderm will gve rise to the penile skin (Yamada et 
al, 2003) and most substances of the penis are actually derived from the mesodermal 
cells which segregate into corporal bodies, connectiv  issue and dermis. Dense 
mesenchymal condensations give rise to corporal tissue within the shaft of the 
developing penis, and these differentiate further to give rise to the connective tissue 
Figure 1.12 Diagrammatic representation of the two theories of how the penile urethra forms, 
with the ectodermal intrusion theory on the left and the endodermal transformation theory on 
the right. Figure from Wang and Baskin, 2008.  
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capsules termed the tunica albuginea (Baskin, 2004). Around the tubular urethra, the 
mesenchyme differentiates into smooth muscle of the mucosa and submucosa of the 
urethra. In humans, this is surrounded by erectile tissue of the corpus spongiosum, also 
termed the corpus urethrae. In some species, includi g rats and mice, the GT 
mesenchyme will also form an os penis composed of bone and cartilage (Rasmussen et 
al 1986) and the growth of the os is stimulated by androgens and signals from the 
epithelium (Murakami 1986). In both humans, rodents and indeed most species in which 
penile growth has been studied, there is dorsal-ventral patterning, illustrated by the 
corpus cavernosa being located dorsally and the urtheral plate, groove and urethra being 
located ventrally. This is also true for the os penis which develops between the corpus 
cavernosum (dorsal) and the urethra (ventral). The molecular mechanisms determining 
this pattering, also seen in the outgrowth of other limb appendages, are poorly 
understood, but it is widely hypothesized that mesenchymal-epithelial interactions play a 
critical role. It is thought that signals from the epithelium can determine both proximal-
distal and dorsal-ventral polarity.  
 
Although the initial ambisexual stage of GT outgrowth, described in section 1.9 is 
hormone independent, development of the male penis is heavily reliant on androgen 
action. Within the developing GT, testosterone is metabolised by 5α-reductase to the 
more potent androgen, DHT. AR receptors are found in all cells of the GT but are 
particularly dense in expression in the mesenchymal cells, and it is also in these cells 
where 5α-reductase type 2 is also localised, specifically around the urethra and urethral 
seam. Although the exact molecular mechanisms and downstream genes of AR 
activation in the GT at specific stages, still remain to be elucidated, an extensive number 
of studies have shown that the action of DHT and AR is fundamental for correct 
development.  
 
Although the exact downstream triggers of AR are yet to be defined, certain genes have 
been shown to be vital in GT development and much of this information has been 
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obtained from mice knock-out models. The first of these to merit consideration is the 
fibroblast growth factor family which has 23 family members which exert their effects 
through four different Fgf surface receptors. Initially, in the cloaca, both Fgf8 and Fgf10 
are expressed, and this later separates to Fgf8 being expressed in the distal urethral 
epithelium and Fgf10 in the surrounding mesenchyme (Haraguchi et al, 2000). Fgf10 
acts as a paracrine factor that signals through Fgf receptor 2IIIb, which is expressed in 
the urethral plate and urethral epithelium. Fgf10 null mice produce a malformed GT, 
with failed fold fusion and in fact severe hypospadias, suggesting that Fgf10 has a 
critical role in GT development (Cohn et al, 1995; Min et al 1998). Another transcription 
factor which appears to be critical in GT development, and indeed in limb, tooth, foregut 
and prostate development, is sonic hedgehog (SHH) (Seifert et al, 2010).  This 
glycoprotein is expressed in the cloaca, the urogenital sinus and later also in the urethral 
plate epithelium. SHH is vital for proximo-distal growth and in culture has been shown 
to control the growth of the GT through genes such as Patched 1 (Ptch1) (Lin et al, 
2009), bone morphogenetic protein4 (Bmp4), Hoxd-13 and Fgf10. Although Shh is not 
required for initial outgrowth, it is necessary forsustained outgrowth and formation of a 
tubercle (Cohn, 2011). Shh mutant embryos form the initial genital swellings but these 
buds arrest immediately after initiation and fail to give rise to a tubercle. This can be 
partially rescued by over-expression of β-catenin. Given the importance of this gene, 
additional studies have removed Shh signalling at different stages and found the extent 
of genital tubercle outgrowth is determined by the duration of Shh signalling, with 
earlier ablation resulting in more severe truncation. Shh is also required for development 
of the closed urethral tube and for correct position ng of the urethral opening with 
deletions resulting in hypospadias as described above. Furthermore these studies have 
established that Shh primarily targets the centre distal urethral epithelium through Wnt 
and fgf8 signalling but also regulates Hoxa13 and Hoxd13 expression independent of 
distal urethral signalling.   
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Hox genes are also well established in their role in GT development and although four 
are known to be expressed in the GT, Hoxa13, Hoxd13, Hoxd11 and Hoxd12, it is 
thought that Hoxa13 and Hoxd13 play a more important role (Warot et al, 1997). Both 
of these are expressed in the mesenchyme of the GT and mice null for both of these 
genes fail to develop a GT or a cloaca. Mutations in Hoxa13 can induce a partially or 
completely divided uterus, septum vaginalis, and hypospadias (Morgan et al, 2003).  
 
The expression and up-regulation of TGF-β receptor III and TGFβ1 selectively in the 
urethral epithelial plate suggests that TGFβ signalling is another important factor and 
regulator of urethral tube development. In the absence of TGFβ receptor III, palatal 
fusion is inhibited. The exclusive expression in the urethral epithelium is also true for 
Frizzled 1, the receptor for Wnt ligands, suggesting here are several signalling pathways 
required in urethral tube formation (Li et al, 2006).  
 
A p53 homolog, p63 is also an important transcription factor in the epidermis and 
urothelium and null mice and mutations in humans lead to a micropenis phenotype 
(Yamada et al, 2003). Although the key genes involved in penile development have been 
discussed, it should be considered that there are mny other genes, the exact molecular 
roles of which remain to be elucidated, but for which defects result in hypospadias. Such 
genes include Mamld1, Dicentric, Mid1, Rxfp2 and Atf3 (Matzuk and Lamb, 2008). 
 
1.9.4 Differentiation of the female external genitalia 
Development of the female external genitalia is essentially the default, promoted by the 
absence of androgens and possibly the presence of ostrogens. The distal end of the 
combined paramesonephric ducts contact the posterior wall of the urogenital sinus to 
form a pair of endodermal swellings called the sinovaginal bulbs (Sajjid, 2010). These 
structures are originally solid and later, when the lumen forms, develop into the lower 
two thirds of the vagina. The lumen of the vagina remains separated from the remaining 
urogenital sinus by a thin membrane, the hymen, whereas the urogenital sinus caudal to 
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the vaginal opening becomes the vestibule. Thus the vagina is made in part from the 
paramesonephric ducts and the sinovaginal bulb of the urogenital sinus. In the absence 
of testosterone, the urogenital folds and swellings do not fuse and form the labia minora 
and labia majora respectively. The genital tubercle develops into the clitoris and 
canalization of the vaginal plate results in the lower part of the vagina. The phallic 
portion of the urogenital sinus forms a vestibule in which the urethral meatus, the 
vaginal orifice and the ostium of the opening of the vestibular glands can be found. The 
anogenital distance does not increase, the rims of the urethral groove do not fuse and the 
labioscrotal swellings give rise to the labia major. The dorsal commisure forms at their 















Masculinisation of the male fetus requires the testis to produce androgens and for these 
hormones to elicit a response through its receptor and an array of important associates. 
Furthermore, extensive studies summarised in this review have proven that the timing of 
androgen action is fundamental. Correct androgen action is required during the MPW in 
order for correct programming of the male reproductive tract. Deficits in androgen 
Figure 1.13 Diagrammatical representation summarising the development of the male and female 
external genitalia. Figure from Yamada et al, 2003  
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action, caused by genetics or the environment can cuse TDS disorders and 
malformations induced at this time cannot be corrected by postanatal androgens. Thus 
androgen action during the MPW is key in correct male development and identification 
of the mechanisms of androgen action during this time frame is required to further our 
understanding of the origins of TDS.  
 
It is during the MPW that the Wolffian duct is stabilised, and the genital tubercle, 
prostate and anogenital distance are all programmed and yet what makes androgen 
action during this time period different to any other time period is a complete mystery. 
Androgen action begins once the Leydig cells produce testosterone, and remains active 
throughout the fetal period and for some time postnatally, with a surge at puberty and 
activity thereafter. However, the essential programming which takes place during the 
MPW cannot be induced during any other time period, as far as is known. More 
importantly, any deficit in correct androgen action during this time cannot be corrected 
later.  
 
The possibility exists that it is not the events occurring within the window which may be 
unique, but rather what is ‘opening and closing the window’, or regulating the window. 
The events occurring before the MPW have had very little investigation and yet it would 
make sense that some sort of ‘pre-set up’ would be required for the androgen 
programming to take place. This simply could just be the availability of androgen as the 
production of testosterone almost coincides with the start of the MPW. If this is true, 
could providing androgens to the fetus, prior to the MPW initiate the MPW any earlier? 
There is the possibility that this may be restricted by AR expression. This is the focus of 
chapter 3.  
  
As discussed in this literature review, the role of c -regulators in the activation or 
repression of androgen action is emerging to be critical. There are many co-regulators 
known to be essential in AR action, such as BRG1 and CBP, and yet their role in the 
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male reproductive tract, in the disorder of hypospadias or indeed in the MPW are 
completely un-characterised. The aim of chapter 4 was to provide some initial 
information to address this deficit.  
 
The earliest studies, to my knowledge, which identify a ‘critical time period’ are those 
which found that arachidonic acid and the role of prostaglandins is involved in the 
masculinisation process, as reviewed in section 1.7.3. These studies had the MPW pin-
pointed in the mouse and also found the phenotypes on  would expect when androgen 
action is deficient just within the MPW, such as hypospadias, cryptorchidism and 
reduced AGD. Furthermore these studies suggested that prostaglandins are critical 
during the MPW. However, convincing as these studies are, they have never been 
repeated, not done in another animal model, or taken ny further. The final aim of this 
thesis was to determine if prostaglandins are vital in the MPW and or even involved 
prior to this time frame. These results are presented in chapter 5, where the effects of 
blocking PGs before and during the window were examined in fetal life and at 3 
postnatal time points. These time points of examinatio  were also conducted in chapter 3 
as any effects in fetal life either before or during the MPW, may not present until later in 
life.  
 
Although many genes and downstream targets of androgen action have been identified, 
little has been noted to be unique in the presence or absence during the MPW, to 
elucidate why this time frame differs for androgen action. Repeated studies in rodents 
have shown that hypospadias occurs when androgen action is blocked during the MPW 
and not thereafter. The final results chapter of this esis sought to identify candidate 
genes which may be androgen regulated in the GT during the MPW both to gain insight 
into genes involved in hypospadias but also to ident fy downstream targets which may 
be unique to the MPW. 
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The main aims of this thesis are: 
 
To investigate the regulation of the MPW, specifically if the availability of androgens 
and AR are ‘opening factors’ and if the exposure to androgens before the MPW can 
initiate masculinisation earlier 
 
To characterize expression patterns for co-regulators during and after the MPW, in the 
GT as well as in the developing testis. The co-regulators are known to be important in 
androgen action but their role and potential importance in the developing male 
reproductive tract is yet to be determined. 
 
To investigate if prostaglandins are critical for masculinisation before and during the 
MPW.  
 
To identify androgen regulated candidate genes in the MPW involved in urethral 
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2. General Materials and Methods 
2.1 Animal Work 
All animal work was completed in accordance with the UK Home Office Animal 
Experimentation (Scientific Procedures) Act 1986 under project licence 60-3259. The 
animals used were Wister rats originally purchased from Harlan UK and then bred to 
generate stock within our own animal facility. A majority of licensed procedures were 
performed by Mark Fisken and William Mungal who also provided day to day animal 
husbandry. I performed some licensed procedures under my personal license 60-11992. 
 
2.1.1 Welfare Conditions 
Animals were housed in a room with a fixed 12 hours per day light cycle, from 7am-
7pm. The room temperature was kept between 20-25°C and an average humidity of 
55%. Fresh tap water and food (soya free) were available ad libitum. The rats were kept 
in clear sided, solid bottom cages and typically females would be housed in groups of 
six and stud males housed individually. For mating, a male and female were placed 
temporarily in a cage with a mesh grid bottom that allowed the copulatory plug to fall to 
the tray below.  
 
2.1.2 Timed-mating 
Time mating was used to determine the date of conception and gestational stage of 
pregnant rats. One male and one female were placed tog ther in a grid bottomed cage, 
by Mark Fisken or William Mungal at the end of the working day (approximately 4pm) 
in order to allow mating to take place overnight. The following morning the tray beneath 
the cage was examined for a copulatory plug. If found, mating was presumed to have 
occurred and the date was recorded and designated as mbryonic day e(0.5). The male 
would then be removed and the female housed separatly. Females rats have an oestrus 
cycle of four to five days, so copulation could take up to five days to occur. To minimise 
the risk of non-pregnancy, whenever possible, sexually mature, proven fertile males and 
females were used, usually around 3 months of age but at least 10 weeks old. 
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2.2 In vivo treatments 
The chemicals administered to pregnant female rats for tudies in vivo were flutamide, 
testosterone proprionate (TP), dihydotestostoetrone (DHT), diethylstilboestrol (DES) or 
indomethacin and for each, the respective vehicle was administered to other females as a 
control. Flutamide was administered by oral gavage using a 10-12cm long 15-16G blunt 
ended steel gavage cannula, (Medicut, Sherwood Medical Industries Ltd, UK) attached 
to a disposable plastic 1ml syringe. DHT, TP and indomethacin were administered daily 
and DES every second day, by subcutaneous injection using a 25G, 0.5 x16mm needle 
(BD Microlance) attached to a plastic 1 ml syringe. Each pregnant female was weighed 
prior to dosing in order to administer correct volume of chemical for bodyweight. 
Treatments were administered between 0900 and 1100 hrs and animals were checked 
thereafter regularly for signs of toxicity or discomfort.  
 
2.2.1 Flutamide 
Flutamide is a synthetic anti-androgenic agent thatcompetitively blocks the action of 
testosterone and DHT by binding to the androgen receptor (AR). To investigate 
androgen specific mechanisms which are critical during the masculinisation 
programming window (MPW, e15.5-e18.5) flutamide was administered to block these 
mechanisms, during this time window. For all studies n this thesis, flutamide was 
administered, at 100mg/kg per day during the MPW. Previous studies had shown this 
dose induces severe hypospadias in all exposed males (MacLeod et al, 2010). Due to 
insolubility in corn oil directly, flutamide was dissolved in 2.5% dimethyl sulphoxide 
(DMSO; Sigma) diluted in corn oil, then administered at 1ml/kg bodyweight using oral 
gavage. Flutamide was freshly prepared for each study, kept at room temperature 
between doses and disposed of appropriately at the end of each study. Control dams 
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2.2.2 Testosterone Propionate (TP) 
TP is an androgenic steroid and is used to manipulate circulating testosterone levels. To 
investigate the effect these androgens may have on both the developing male and female 
during the MPW, and to investigate mechanisms activted by androgens, TP was 
administered to the pregnant dams from e15.5 to e18.5 at 20 mg/kg per day. This dose 
was chosen based on studies in the literature (Welsh t al, 2008). TP is insoluble in 
water and therefore was dissolved in corn oil (20mg per ml corn oil) at the beginning of 
each study and administered at 1ml/kg bodyweight by subcutaneous injection, using a 
disposable plastic 1ml syringe, fitted with a 25G needle. Any remaining TP was 
disposed of appropriately at the end of each study. For control animals, female dams 
were administered only corn oil daily from e15.5-e18.5. TP has the ability to be 
aromatized into oestradiol, and so the effects seen in exposed pups could have been 
mediated by oestrogen effects. In order to ensure any effects seen were due to androgen 
action, TP treatment was only used for initial preliminary studies and for a majority of 
the project, DHT was used, which cannot be aromatized.  
 
2.2.3 Dihydrotestosterone (DHT)  
DHT, a more potent (~10 fold) androgen than testoster ne, cannot be aromatised to 
oestradiol, therefore any effects seen following trea ment would be through the androgen 
receptor. DHT was administered to pregnant dams in one of two gestational windows. 
Either daily between e11.5-e14.5 (the early window ((EW)) or daily during the MPW 
(e15.5 to e18.5). DHT was initially administered at 1mg/kg but when no effect was seen 
in the females (see chapter 3) this dose was increased to 10mg/kg. DHT was dissolved in 
corn oil at the beginning of each study and administered by subcutaneous injection using 
a disposable plastic 1ml syringe, fitted with a 25G needle, at 1ml/kg bodyweight. For 
control animals, female dams were administered onlycorn oil daily from either e11.5-
e14.5 or e15.5-e18.5. Any remaining DHT was disposed of appropriately at the end of 
each study. 
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2.2.4 Diethylstilboestrol (DES)  
DES is a synthetic nonsteroidal oestrogen and was used for studies in this thesis, to 
compare treatment effects with TP to assist in determining if effects seen were due to TP 
conversion to oestradiol and its binding to oestrogen receptors. The side effects of in 
utero exposure to DES are well documented (Herbst et al 1971) and previous studies 
have shown that an optimum dose of 100µg/kg should be administered on alternate days 
in order to avoid adverse effects on the dams (McKinnell et al, 2001; Williams et al, 
2001). DES was administered to the pregnant dams on e15.5 and e17.5 (which would 
ensure DES was available throughout the MPW) at 100µg/kg. DES was dissolved in 
corn oil (100µg per ml corn oil) at the beginning of each study and administered at 
1ml/kg bodyweight by subcutaneous injection, using a disposable plastic 1ml syringe, 
fitted with a 25G needle. For control animals, female dams were administered corn oil 
on the appropriate days. Any remaining DES was disposed of appropriately at the end of 
each study.  
 
2.2.5 Indomethacin 
Previous studies suggested blocking prostaglandins during the MPW, using 
indomethacin, may affect male reproductive tract development (Gupta and Goldman, 
1986; Gupta, 1989; Gupta and Bentlekewski, 1992). Previous studies have used various 
doses (from 0.5mg/kg – 10mg/kg) in mice and rats (section 1.6.1.4.1) and an initial dose 
for studies in this thesis was chosen at 2mg/kg, administered by gavage, in order to see 
an effect in pups, with minimal side effects on thedam. However, even at this dose, 
dams were having difficulty with parturition, some giving birth late but most not giving 
birth at all. In addition, the oral route of administration was causing heavy gastric 
bleeding in the dams and so the decision was taken to administer indomethacin by 
subcutaneous injection, which was also the route used by Gupta (1989). Therefore a 
lower dose of 1mg/kg was chosen and administered to the pregnant dams from e15.5 to 
e18.5, by subcutaneous injection. The indomethacin was dissolved in corn oil (1mg per 
ml corn oil) at the beginning of each study and administered at 1ml/kg bodyweight by 
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subcutaneous injection, using a disposable plastic 1ml syringe, fitted with a 25G needle. 
For control animals, female dams were administered only corn oil daily from e15.5-
e18.5. Any remaining indomethacin was disposed of appropriately at the end of each 
study.  
 
2.3 Necropsy procedure and gross dissection 
Pregnant dams were killed by inhalation of carbon dioxi e followed by cervical 
dislocation under schedule 1 of the Animal (Scientific Procedures) Act 1986. Once 
deceased, the pregnant dam was placed on her back and the abdomen opened. The uterus 
was removed, each amniotic sac cut open and the umbilical cord severed. Once removed 
from the dam, foetuses were placed in ice-cold 0.01M phosphate buffered saline (PBS, 
Sigma). If late gestation (i.e. e19.5 and older) the foetuses were decapitated and then 
placed in the ice cold PBS.  
 
Once placed in the chilled PBS, the foetuses were transported to the dissection area, on 
ice, to avoid degeneration. Pups taken at e21.5 were iped cleaned and bodyweight and 
anogenital distance (AGD) were recorded prior to each pup being decapitated.  
 
2.3.1 Fetal bodyweight and AGD 
Bodyweight of e21.5 pups was evaluated using an electronic analytical balance (Handy 
H110, Sartorius). Anogenital distance (AGD) was measured as the distance between the 
midpoint of the anus and the base of the genital tubercle. This was measured on e21.5 
pups using electronic digital callipers with a resoluti n of 0.02mm (Faithfull Tools, 
Kent). Under normal circumstances, the AGD of male r ts should be 1.5-2 times greater 
than females from e21.5 onwards. If reduced AGD is seen in males, it suggests a deficit 
in androgen action and masculinisation during the MPW (MacLeod et al, 2010; Welsh et 
al, 2008).  
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2.3.2 Fine dissection 
Fine dissection was carried out in a designated dissection area. Individual foetuses were 
placed on their backs and onto a bed of paper towels, dampened with PBS in an 
appropriately sized petri dish. The foetuses were th n placed under a binocular 
dissecting microscope (Leica, MZ6) with a transilluminated stage. External lighting was 
provided by external cold lights (Leica CLS 150x) which are designed to cause minimal 
heat damage to the tissue they illuminate. The genital tubercle (GT) was dissected from 
the base from each foetus using fine tweezers. 
 
If the tissue was being fixed in Bouin’s, the tip was lightly marked using green tissue 
biomarker (Biostain Ready Reagents Ltd, Merseyside, UK), to facilitate embedding of 
the tissue in a consistent ‘tip down’ orientation. After GT removal, the abdomen was 
opened with a horizontal incision slightly below the umbilical cord. The intestines were 
pushed up and out of the abdominal cavity to access the gonads and urogenital tract. 
Gonads and attached ducts were removed and placed in a petri dish containing chilled 
PBS for microdissection. Gonads were separated fromducts using the bevelled edge of 
27G needles (Monoject, sterile needles, 0.4mm x 12mm) attached to disposable plastic 
1ml syringes.  
 
2.3.3 Postnatal tissue collection 
Postnatal animals were culled on either PND8, 25, 75 or 90. These animals were killed 
by inhalation of carbon dioxide followed by cervical dislocation under schedule 1 of the 
Animal (Scientific Procedures) Act 1986. The penis or clitoris were dissected, the length 
measured using electronic digital callipers with a resolution of 0.02mm (Faithfull Tools, 
Kent). The tissue was weighed prior to being either snap frozen or fixed in Bouin’s 
fixative. Following phallus removal, the testis, prostate and seminal vesicles were 
removed from the males and the ovaries and occasionlly, the uterus, was removed from 
females. Each tissue was individually weighed and either fixed in Bouin’s fixative or 
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snap frozen. Where abnormalities were seen in the reproductive tract, these were 
photographed using a Nikon D70S digital camera. 
 
2.3.4 Tissue fixation 
Once GT, gonads and ducts had been microdissected, they were either fixed as outlined 
below or snap frozen on dry ice in 1.5ml Nunc tubes, appropriately labelled and 
archived at -80°C. Alternatively, depending on tissue requirements, tissue was fixed by 
immersion in Bouin’s solution (BIOS), a formaldehyde based fixative containing glacial 
acetic acid, formalin, and picric acid, which forms cross links between proteins and 
aldehydes producing a stable structure. The tissue was submerged in appropriate 
volumes of Bouin’s fixative in an airtight container before being transferred to 70% 
ethanol. Fetal tissue was left for fixing in Bouin’s fixative for 1 hour before transfer to 
ethanol, and postnatal tissue was left for 4 hours. Po tnatal testes were cut in half after 2 
hours and placed back in the Bouin’s fixative for the remaining 2 hours to allow the 
fixative to penetrate the entire tissue.  
 
2.4 Fixed tissue processing 
Following transfer to 70% ethanol, the tissue was processed by the histology support 
services. Briefly, the tissue was processed through a series of graded alcohols using an 
18 hour automated cycle on a Leica TP-1050 (Leica UK Limited, UK) tissue processor, 
then embedded in molten paraffin wax by hand. These blocks were left to cool and 
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2.5 Investigation of protein expression 
2.5.1 Immunohistochemistry 
Protein expression was detected within specific cell(s) in tissue sections, fixed in 
Bouin’s, using specific antibodies. In brief, this involved the following steps (Fig. 2.1) 
which are described in greater detail below: 
• Tissue sections were cut at 5µm, and mounted on slides  
• Tissue was dewaxed and re-hydrated 
• Depending on the primary antibody being used, targe antigen was retrieved 
• Non specific antigens were blocked 
• Tissue was incubated with the primary antibody 
• Tissue was incubated with the secondary antibody  
• The secondary antibody (and hence primary antibody) was detected using an 
amplification system 
• Antibody visualized using a colour reaction (DAB) 









 Figure 2.1 Schematic diagram representing the principles of determining protein expression 
within a cell using immunohistochemistry. The primary antibody binds to the antigens of the 
protein of interest within the cell. A secondary antibody conjugates to species specific regions of 
the primary antibody.  The secondary antibody is conjugated to biotin and the entire enzymatic 
reaction binds to chromagen causing a colour change and allowing visibility of the protein of 
interest in specific cell types.  
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In order to allow reproducibility of results and provide data for accurate comparison of 
immunostaining between treatment groups, sections from control and treated animals 
were processed in parallel on at least two occasions: sections from at least three animals 
in each treatment group were run on each occasion. Appropriate negative controls were 
included, whereby the primary antibody was replaced by blocking serum alone, or when 
available, blocking peptide, to ensure that any staining observed was specific.  
 
2.5.1.1 Sectioning 
Fixed tissue embedded in paraffin blocks was chilled on ice in order to harden the wax 
and allow for easier cutting. 5µm thick sections were cut using a hand-operated 
microtome (RM 2135, Leica) and floated onto 30% industrial methylated spirit (IMS, 
Fischer Scientific), followed by water heated to 45-50°C, to allow for any creases to 
smooth out. Each individual section was then mounted onto pre-labelled (slide labeller, 
Leica IPS) charged glass slides (Superfrost Menzel GmbH & Co.) and placed in metal 
racks. Slides were dried overnight at 50°C.  
 
2.5.1.2 Dewaxing and rehydration 
Wax was removed from slides by submerging them in xylene for 5 minutes x2. Slides 
were then rehydrated by placing them for 20 seconds i  each of the following alcohols; 
absolute alcohol x2, 95% alcohol, 80% alcohol and 70% alcohol.  
 
2.5.1.3 Antigen retrieval 
Bouins is a formaldehyde based fixative and can cause the formation of protein cross-
links that may mask antigenic sites within a tissue. Antigen retrieval will break these 
cross-links which then allows the detection of the antigen. This is not always required 
for all antigens, but was required for all immunohistochemistry done in this thesis. 
Antigen retrieval required placing slides in a Tefal Clipso pressure cooker (Tefal) 
containing 2L of boiling buffer consisting of 0.01M citrate buffer (pH6). Once the lid 
was sealed, pressure was set at the highest setting and full pressure achieved, indicated 
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by onset of continuous steam release and the slides then left for 10 minutes. The 
pressure was then released and the cooker removed from heat. The slides were left for a 
further twenty minutes in the buffer, then removed and cooled in water and transferred 
to Tris-buffered saline (TBS) for 5 minutes x2.  
 
2.5.1.4 Blocking 
Slides were incubated in 3% hydrogen peroxide (BDH) in methanol for 30 minutes to 
block any endogenous peroxidase activity which could have caused non specific 
background staining. After this, slides were washed in tap water and then in TBS for 5 
minutes x2. Excess TBS was wiped from around each tissue section. Slides were 
blocked in normal serum (Diagnostic Scotland) diluted 1:5 in TBS and 5% bovine serum 
albumin (BSA, Sigma) to block non specific binding sites. The serum used depended on 
the species the secondary antibody was raised in.  
 
2.5.1.5 Primary antibodies 
Titre runs were carried out for each primary antibody to establish the optimal working 
concentration. The antibody was diluted to the requir d concentration in the appropriate 
normal serum/TBS/BSA, placed on each tissue section on each slide and incubated at 






Table 2.1 Primary antibodies used and their optimum working concentrations 
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2.5.1.6 Secondary antibodies 
After overnight incubation with the primary antibody, slides were washed for 5 minutes 
in TBS x2 and incubated with biotinylated secondary ntibody. The secondary antibody 
was chosen to be specific against the species in whch t e primary antibody was raised 
in, and to be raised in the same species as the normal blocking serum used. The 
biotinalyted secondary antibody was diluted 1:200 in normal blocking serum and placed 





2.5.1.7 Signal amplification and chromagen detection 
After incubation with the secondary antibody, slides were washed in TBS for 5 minutes 
x2. The secondary antibody signal was amplified using steptavidin-horseradish 
peroxidise (Strep-HRP) (Vector Laboratories, Peterborough, UK) diluted 1:500 in TBS 
(ABC-HRP; DAKO, Ely, UK).  Slides were then incubated with Strep-HRP for 30 
minutes at room temperature.   
 
Following Strep-HRP amplification, antibody localistion was visualised using 3,3’-
diaminobenzidine (liquid DAB+; DAKO). DAB chromagen was diluted in the specific 
buffer, as per the manufacturers’ instructions of 1drop per 1ml. Sections were incubated 
with DAB until staining developed to the required intensity (microscopically monitored) 
and this varied depending on the antibody and targe tissue. The reaction was stopped by 
immersing the sections in TBS.   
 
Table 2.2 Secondary antibodies used and their optimum concentration 
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2.5.1.8 Counterstaining 
Slides were counterstained with haematoxylin for 4 minutes, ensuring the saturation of 
all binding sites. Slides were then rinsed in tap water and briefly immersed in 1% acid 
alcohol to remove any non-specific background staining, then rinsed again in tap water. 
Slides were briefly immersed in Scott’s tap water (approximately 20 seconds) to allow 
an alkaline environment which caused the haemotaxylin staining of the nuclei to turn 
blue. Scott’s tap water was washed off the slides by placing them in tap water.  
 
2.5.1.9 Dehydration and mounting 
Slides were dehydrated through increasing concentrations of alcohol, briefly in 70% 
alcohol, 80%, 90% and finally in absolute alcohol x2. Slides were then cleared in xylene 
for 5 minutes x2. The slides were covered using glass coverslips (VWR International) 
and pertex, a solvent based glue (Cellpath, Hemel, H mpstead UK). Slides were left to 
dry at room temperature before being archived or imaged.  
 
2.5.1.10 Imaging 
Slides were examined using a Provis microscope (Olympus Optical., London, UK) and 
photographed using an attached digital DCS330 camer (Eastman Kodak, Rochester, 
NY). Captured images were compiled using Adobe Photoshop and Adobe Illustrator.  
 
2.5.2 Fluorescent Immunohistochemistry 
Fluorescent immunohistochemistry is a method for detection of more than one antigen 
simultaneously using different coloured flourophores. It allows better visualisation of 
some antigens and also allows co-localisation of antige s to be visualised. Similar to the 
DAB immunohistochemistry, protein expression was detect d on sections of Bouins 
fixed tissue using specific antibodies. In brief, this involved the following steps: 
• Tissue was dewaxed and re-hydrated 
• The target antigen was retrieved 
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• Non specific antigens were blocked 
• Tissue was incubated with the primary antibody 
• Tissue was incubated with the secondary antibody 
• Secondary antibody detected using fluorescent tyramide amplification system 
• The above three steps were repeated where more than one protein was being 
detected (a different colour of fluorescence was used for each protein) 
• Non stained tissue was counterstained with Dapi 
• Slides mounted using Permaflour 
2.5.2.1 Primary antibodies 
Tissue was dewaxed, rehydrated, citrate retrieved (where necessary) and non specific 
antigens blocked exactly as described in section 2.5. Titre runs were carried out for each 
primary antibody to establish the optimal working con entration, and diluted to these 
concentrations in the appropriate serum. Slides were incubated with the primary 
antibody overnight at 4°C, and as with all immunohistochemistry, at least three slides 
for each experimental group were added to confirm staining and appropriate positive and 







Table 2.3 Primary antibodies used for immunofluorescence and their optimum concentrations  
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2.5.2.2 Secondary antibodies 
The secondary antibody (table 2.4) used was peroxidase labelled and diluted 1:200 in the 
appropriate serum and incubated on slides for one hour before being detected by the 





2.5.2.3 Detection system 
The fluorescent detection system used was the Tyramide Signal Amplification (TSA) 
system (PerkinElmer, MA, USA). Tyramide (red, green or blue) was diluted 1:50 and 
incubated on slides for ten minutes before they were washed in PBS. Slides were 
covered where possible in tin foil thereafter to avid light exposure and bleaching.  
 
2.5.2.4 Counterstaining and mounting 
Dapi (Molecular Probes, Invitrogen, Paisley, UK) was used as a nuclear counterstain for 
immunoflourscent runs. Dapi was diluted 1:1000 in PBS and placed on slides for ten 
minutes. Slides were then mounted using PermaFlour aqueous mounting medium 
(Thermoscientific) and left in the dark at 4°C overnight to set prior to being imaged. 
 
2.5.2.5 Confocal microscopy 
Immunofluorescence slides were imaged using a Zeiss LSM710 Confocal Microscope 
(Carl Zeiss Ltd, Hertfordshire, UK) and Zen software (Carl Zeiss Ltd)  
 
2.5.2.6 Double immunofluorescence  
If more than one antigen was being detected in the sections, after the initial tyramide 
detection, slides would be washed in PBS for 5 minutes x2 and blocked in normal serum 
Table 2.4: Secondary antibodies used for fluorescence immunohistochemistry 
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for 30 minutes. The primary antibody for the second a tigen being detected was added 
to the tissue and left overnight at 4°C in a humidity chamber. As outlined above, slides 
would then be washed in TBS for 5 minutes x2, the appropriate secondary, peroxidase 
labelled antibody would be added to the slides for 30 minutes. The second antigen of 
interest would be detected using a different coloured tyramide. Slides were 
counterstained, mounted and imaged as outlined above (section 2.5.2.4-5)  
 
2.5.3 Western blots 
Western blotting is a technique which allows the separation of proteins according to 
their molecular size. This is done using protein electromobility on a gel with specifically 
sized pores.  Western blot was attempted in this the is to identify the androgen receptor 
protein, in rat fetal tissue, prior to the MPW.  
In brief, the technique involved the following: 
 
• Tissue was lysed to release protein 
• Protein samples were prepared with appropriate running buffers 
• Protein samples were loaded on to a gel and separatd using electrophoresis 
• The separated proteins were transferred from the gel onto a membrane 
• Primary and secondary antibodies were incubated with the membrane 
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2.5.3.1 Protein extraction 
The tissue was broken open using lysis buffer, allowing the cells to release their 
proteins. The whole cell protein was harvested from frozen tissue using RIPA lysis 
buffer and in order to minimise degradation, tissue was kept frozen on dry ice until the 
protease inhibitor was added to the lysis buffer and then lysis buffer added to the tissue. 
In order to break the non-covalent bonds within the proteins and give the protein a 
negative charge to facilitate their separation in the acrylamide gels, SDS was added to 
the sample. Samples were then homogenised in 75µl RIPA buffer using a cordless 
handheld homogeniser (Sigma Z36,997-1) to disrupt the tissue and release the protein. 
The homogenate was incubated on ice for 1 hour prioto centrifugation at 2500rpm for 
10 min. The protein enriched supernatant was collected in a fresh 1.5ml eppendorf and 
stored at -80°C until required.  
Figure 2.2 Schematic diagram summarising the processes involved in protein detection by Western 
blotting 
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2.5.3.1 Preparing samples 
Ideally, 15µg of protein in a total volume of 20µl would be used in each sample but this 
was restricted by the sample availability, concentration and finite volume of the wells in 
the gels. The appropriate volume of sample was added to 5µl of NuPage, 4x LDS 
Sample buffer (Invitrogen) and 2µl NuPage 10x reducing agent (Invitrogen) and made 
up to 20µl in de-ionised water, to allow for complete reduction of proteins. The protein 
was denatured by heating these samples to 70°C for 10 minutes followed by brief 
centrifugation prior to being loaded onto the gel.  
 
2.5.3.2 Gel electrophoresis 
Proteins were carefully loaded into the gel (12% acryl mide 1mmNuPage Novex bis-tris 
gels (Invitrogen)). These gels have a lower pH than st dard SDS Page gels and allow 
for denaturing gel electrophoresis. NuPage SDS MOPS buffer (Invitrogen) was used as 
the running buffer with Nupage Antioxidant (Invitrogen) added to a cathode buffer 
chamber. This inhibits the reduced proteins from re-oxidising. A size marker, SeeBlue 
Plus2 (Invitrogen) was run alongside the gel, which contained ten proteins. The proteins 
were separated by running the gels at 200 volts for app oximately 40 minutes.  
 
2.5.3.3 Western transfer of proteins 
Once the proteins were separated by gel electrophoresis, specific proteins were 
investigated. Proteins were transferred onto an immobilin-FL PVDF membrane 
(Millipore, Herts, UK) for fluorescent detection using a Hoefer TE22 transfer chamber. 
The protein gel plates were prised apart and the gel was carefully removed and placed in 
a petri dish with running buffer. A ‘sandwich; was made with the gel membrane set in 
between layers of blotting paper, sponges and then bou d in a blotting cassette. The gel 
membrane, layers of blotting paper and sponges wereequilibrated in NuPage transfer 
buffer (Invitrogen). The cassette was placed in the transfer chamber and transferred 
overnight at 20volts. 
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2.5.3.4 Primary antibody 
Following transfer of the protein onto the membrane, the membrane was blocked in 
dried skimmed milk powder (20%w/v) in TBS +0.05% Tween-20 (Sigma) and then 
incubated overnight at 4ºC with primary antibody. The same primary antibodies were 
used as for immunohistochemistry but were diluted 10x more than for 
immunohistochemistry. An anti-ß-tubulin antibody (Sigma) was used as a 
standardization control. Membranes were washed in TBS+0.05% Tween and incubated 
at room temperature with an appropriate secondary antibody diluted TBS+0.05% Tween 
for one hour. The membrane was then washed in TBS alone before being visualised.  
 
2.5.3.5 Imaging 
The membranes were visualised and analysed using the Odyssey Infrared Imaging 
System (Li-cor Biosciences). Blots were scanned andviewed using the odyssey 
Software (Li-cor Biosciences).  
 
2.6 Investigations of Gene Expression 
To investigate gene expression in specific tissues, standard PCR and QRT-PCR were 
used. For both these techniques, RNA must be extracted from the tissue (which had been 
frozen at -80°C after dissection) and cDNA synthesis d from the RNA, to be used for 
both PCR techniques. 
 
2.6.1 RNA extraction 
RNA was extracted from frozen tissue using the RNeasy mini extraction kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instruc ions. Briefly, the frozen tissue 
was homogenised in 2ml tubes with lysis buffer consisting of RLT buffer containing β-
mercaptoethanol, using a hand homogeniser (Kontes Pellet Pestle) on ice. After 
homogenization, 350µl 70% ethanol was added to each s mple and transferred into 
RNeasy mini columns and centrifuged for 15 seconds at 10,000rpm. The flow through 
was re-loaded into the column to maximise yield befor  being centrifuged again for 15 
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seconds at 10,000rpm. The flow through was then discarded and 350µl of RW1 buffer 
was added and samples centrifuged for 15 seconds at 10,000rpm. On column DNase 
digestion was performed by incubating with DNase (10µl DNase 1 stock and 70µl RDD 
buffer) for 15 minutes at room temperature. Following this incubation, 350µl of RW1 
buffer was added and the column was centrifuged for 15 seconds at 10,000 rpm. The 
column was then transferred to a new collection tube and 500µl RPE buffer was added 
and the column centrifuged for 15 seconds at 10,000rpm. The flow through was 
discarded and 500µl 80% ethanol was added and centrifuged for 2 minutes at 10,000 
rpm. The column was then transferred to a fresh colle tion tube and centrifuged at full 
speed (14,000 rpm) for 2 minutes in order to dry the membrane. The RNA was then 
eluted by adding 14µl RNase-free water directly onto the membrane and then 
centrifuging for 1 minute at 10,000 rpm to collect the RNA. RNA concentrations were 
measured using the Nanodrop spectrophotometer and stored at -80°C before use.  
 
2.6.2 RNA quantification  
The purity and concentration of RNA samples was analysed using the Nanodrop-1000 
spectrophotometer (Nanodrop Technologies, Delaware, USA). The nanodrop only 
requires 1.5µl sample which is pipetted directly onto the measurement pedestal. The 
amount of 260nM UV light absorbed by the sample is measured and the Beer Lambert 
law is used to relate this to the concentration of the light absorbing molecule, ie the 
RNA.  
The nanodrop also measures the absorption of light at 280nM, the wavelength absorbed 
by impurities such as protein, salt and solvents. Given the ratio of 260nM:280nM, the 
purity of the RNA sample can be ascertained, ideally the 260nM:280nM ratio should be 
2, although values in the range of 1.9-2.1 are acceptable. 
 
2.6.3 Preparation of cDNA for PCR- reverse transcription 
The Invitrogen ROX Vilo kit was used to make cDNA from isolated tissue RNA. The 
following master mix was made: 
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The reagents were added together in 0.2ml sterile thin walled PCR tube and cycled in a 
thermo-cycler on the following programme:  
25 °C for 10 minutes 
42 °C for 60 minutes 
85 °C for 5 minutes.  
cDNA was then stored at -20°C until required for use.  
 
2.6.4 PCR  
PCR is a technique which employs thermal cycling to separate a DNA strand and allow 
short, specifically designed, complementing DNA sequence primers, to bind to a 
particular sequence of interest. A heat stable DNA polymerase enzymatically constructs 
a new DNA strand. Repeated heating to a denaturing temperature and cooling to an 
annealing temperature, allows for this process to make millions of copies of the DNA 
sequence for particular genes and subsequent proteins of interest. In order to confirm 
that detectable, multiple copies of the correct sequence have been formed, the PCR 
product can be run on an agarose gel where applying voltage allows the DNA bands to 
be separated and visualised using UV light.  
A master mixture was made using the following:  
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Each tube was briefly vortexted before being placed in the thermal cycler under the 
following programme: 
95°C  5 minutes 
95°C   15 seconds 
65°C   30 seconds 
72°C   1 minute 
72°C  10 minutes 
4°C   10 minutes 
Each sample was then loaded onto a 0.7% agarose gel. In brief, this was made by 
dissolving 1.4g of agarose in 200ml 1x TAE buffer and placing in a microwave for 
approximately 2 minutes before adding 20µl SYBR safe DNA gel stain. The solution 
was poured into a gel tank, in which a comb was inserted with appropriate well numbers. 
Once solidified, at room temperature, the gel was submerged in a solution of 1x TAE, in 
a tank connected to a power supply. 10µl of each PCR sample was loaded into 
individual wells and a voltage was applied of 70V for approximately 30 minutes, to 
allow for the negatively charged nucleic acids to mve through the agrose gel. The 
separated DNA bands were viewed under UV light using Geneflash Syngene bioimaging 
UV light box (Syngene, Cambridge, UK) and photographed.  
 
 
Gene Forward Primer 5'→3' Reverse Primer 3'→5'
AR AAG CAG GTA GCT CTG GGA CA CGT TTC TGC TGG CAC ATA GA  
 
2.6.5 Quantitative RT-PCR (QRT-PCR) 
Quantitative RT-PCR is based on the principles of standard PCR described in section 
2.6.4, however as well as amplifying the target DNA, QRT-PCR also simultaneously 
quantifies the target DNA. As with standard PCR, forward and reverse primers were 
designed for the target DNA sequence. In addition, n RT-PCR, a probe from the 
Universal ProbeLibrary (Roche) was assigned to each reaction which bound to a specific 
Repeat for 35 cycles 
Table 2.5: Sequences of genes investigated by standard PCR 
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location in between the forward and reverse primers. At the 5’ end of the probe was a 
reporter dye, 6-carboxyfluorescein (FAM) and at the3’ end was a quencher dye, 6-
carboxy-tetramethyl-rhodamine (TAMRA). The quencher would suppress the reporter 
dye while the probe is intact, but when the target sequence is present, the probe will 
anneal to the cDNA between the forward and reverse p imers. Taq polymerases then 
cleave the probe so that the reporter dye (FAM) is no longer quenched and can emit a 
fluorescence signal. This occurs at every cycle and consequently the fluorescent activity 
increases as PCR product is formed and this signal is measured quantitatively by the 
sequence detection system.  
 
2.6.5.1 Primer Design 
Primers were designed for each gene of interest using the free Universal ProbeLibrary 
assay design centre at http://www.roche-applied-science.com/sis/rtpcr/upl/exhome/html. 
For each gene of interest this library allowed design of the primer sequences and 
provided the number of the probe compatible with the Universal ProbeLibrary (Roche). 
The primers were then purchased from MWG Biotech, London, UK, which were then 
diluted to 20µM with nuclease free water. Table 2.6 summarises the primer sequences 
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Gene Forward Primer 5'→3' Reverse Primer 3'→5' UPL Probe Number:
AR CCT GGG CTT TTC CTT CTT TC CAG CGG ATT CAA AAT GTG C 13
Asporin
AAG AAA ACC TCT CTT CTG 
ACA AGG GCA CAC AGC CAA AAG CAG TA 56
BORIS
GAA GAA AAA GAA AGA TGC 
GGT CT GAG ATC CGG CTC AGC ATT T 82
BRG1 ACG GTG TCC CAG CTA GAT TC
GCA TCC GCA TGA ACA TAC 
TTC 20
CBP/P300 GGC AAA GAG GAC CAG ACG AAT CGG TGG GAA TTG ATG TC 22
COX1
GCT CTT CAA GGA TGG GAA 
ACT
TTC TAC GGA AGG TGG GTA 
CAA 42
COX2 CTA CAC CAG GGC CCT TCC
TCC AGA ACT TCT TTT GAA TCA 
AGG 5
DNMT3L GAG GGT GTG GAG CAA CAT TC GCT CTT CCT TAG GGG TCA GG 41
FKBP5 CTC AAA CCC CAA TGA AGG AG GCA GTC AAA CAC CCT CC A 66
ROBO1
GCA GAG AGG CCT ACA CAG 
ATG
CAC TGG GCG ATT TTA TAG 
CAG 10
RWDD1 ACA ACG CAA CGA GTT GGA G GCT GGG TGG GTT TTC TGA TA 109
SLIT2 GCC ATT CAG GAC TTC ACC TG CGA AGG ACA ACG GGA GAG 108
SNURF AAC AGC ACG TCC CAG AGA GT AGA ATG CCG TGG GTA CA GT 85
SRY TCA GCC TCA TCG AAG GGT TA GCA ACT TCA CGC TGC AAA G 82
Transgelin AGT GTG GCC CTG ATG TGG
TCA CCA ACT TGC TCA GAA 
TCA 5
VAV3 CCA TGG AGA AGT CGA ACC TG
TTC ACA TAT TGT GCC AAG TCC 
T 21
 
2.6.5.2 Q-RT-PCR reaction 
Sample to be analysed using the Taqman system were run in triplicate in a 96 well 
MicroAmp optical reaction plate (Applied Biosystems). For each sample, a tube 
containing the following was prepared, totalling 45µl.  
 
Table 2.6 Sequences and probe numbers of primers designed for QRT-PCR 
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Reaction 1X (15 µl)
Taqman mastermix 7.5
18s (Applied Biosystem) 0.225
Forward primer (20µM) 0.15
Reverse Primer (20µM) 0.15
Universal Probe (Roche) 0.15
cDNA 1
dH2O 5.325  
 
Each Taqman reaction mixture was vortexed and then divided into three wells, with 
13.5µl in each. When each sample was loaded, the entire plate was sealed with a 
MicroAmp optical adhesive cover (Applied Biosystems) and then loaded onto the 
ABI7900 sequence detection system.  
 
2.6.5.3 Analysis of results - comparative Ct method 
The Taqman RT-PCR system provided the results as an amplification plot, which 
showed the amount of reporter dye/fluorescence generated during amplification, which 
is proportional to the amount of PCR product formed. The FAM Ct value is the cycle 
number at which the fluorescence rises above the threshold level, representing when the 
amount of amplified DNA becomes significantly above the background level. The 
threshold was determined at a point during the exponential increase of the PCR product. 
The FAM Ct value was dependent on the original amount of target mRNA in the 
reaction mixture, such that a difference in Ct value by one compared to a reference 
sample equated to a two-fold difference in RNA in the initial reaction mixture. 18s 
ribosomal RNA was used as an internal control, to adjust for mRNA variation between 
samples.  
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By analysing the differences in FAM Ct value compared to a reference control (usually 
adult rat testis), relative changes in RNA expression of the target gene were calculated 
using the comparative Ct method. This required the calculation of the ∆Ct value, which 
was the difference between the FAM Ct and the 18s Ct value for each of the three 15µl 
reaction wells for each sample. From these triplicates, the mean ∆Ct for that sample was 
calculated. Using the mean ∆Ct, the ∆∆Ct was then calculated, which was the difference 
between the mean ∆Ct of each sample compared to the mean ∆Ct of the reference 
sample. In most cases, the reference sample was adult r t testis total RNA, collected and 
processed in house.  
The amount of amplified target was calculated as 2-∆∆Ct, which was based on the 
mathematical equation for the exponential amplification of the PCR reaction Xn=X0 x 
(1+Ex)n, where Xn is the number of target molecules at the threshold at cycle n, X0 is 













Figure 2.3 A typical QRT-PCR amplification plot. 1- plateau phase, 2 linear phase, 3 exponential 
phase, 4 background.  
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amplification and n is the number cycles. If the efficiencies of the target and internal 
control reactions are equal, the 2-∆∆Ct value provided a measure of relative 
quantification, showing the fold increase or decrease in mRNA expression in samples in 
relation to the reference sample, which always has a 2-∆∆Ct value of one. 
 
2.7 Optical Projection Tomography (OPT) 
OPT is a 3D optical microscopy technique developed by the MRC Human Genetics 
Unit. In brief, it is a machine in which up to 1cm3 of tissue is mounted and rotated. 
Whilst being rotated, light from a lamp is converted into an even illumination by a 
diffuser. The light then passes through the tissue specimen and is focused by the optics 
of the microscope onto a CCD imaging chip. The light rays do not follow straight paths 
through the specimen but the intensity recorded at each position on the camera chip 
approximates a projection through the focused part of the specimen. 400 images are 
taken per tissue specimen and reconstructed using a ‘back project algorithm’ which 
















Figure 2.4 Schematic diagram showing the principles of OPT. CIC represents camera 
imaging chip 
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2.7.1 Tissue preparation for OPT 
As none of the tissues used were freshly dissected, but had been embedded in paraffin 
wax (2.1), tissue samples were dewaxed using the following: 
Solution Time in solution















2.7.2 Embedding & mounting tissue for OPT scanning 
Tissue to be scanned requires to be mounted in 1% agarose. This was made by adding 
1.5mg of agarose to 150ml of de-ionised water and heating in a microwave for 
approximately 2 minutes to homogenise the solution. The temperature was monitored 
until the agarose solution was 60°C. The solution was filtered through Whatman filter 
paper and the temperature further monitored until the solution was at 32°C, when it was 
poured into a petri dish placed on a cold plate at 4°C. The tissue was transferred from 
PBS, using tweezers, into the agrose and using forceps was suspended in the centre of 
the dish until the agarose had completely set around the specimen. The agarose around 
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the specimen was trimmed using a microtome blade and mounted, using superglue, 
upside down on to a specifically designed magnetic mount and allowed to set for 5-10 
minutes. The mounted specimen was placed in a solution of methanol which was 
changed at least three times over the course of 2 days. One day prior to the sample being 
used in the OPT machine, the mounted tissue was tran ferred to BABB solution, which 
is 2 parts Benzyl Benzoate and 1 part benzyl alcohol. This solution clears the tissue 
specimen, making it transparent prior to scanning. The specimen was left in BABB 
overnight before being scanned.  
 
 
Figure 2.5 Process of embedding and mounting tissue for scanning. A: tissue in agarose being 
cut with blade. B: Tissue after being cut. C: correct positioning of tissue. D: Tissue mounted onto 
magnetic mount ready for BABB solution and then OPT imaging.  
 
2.7.3 Scanning 
The Bioptonics microscopy OPT Scanner 3001 was used to take 400 images of each 
sample, under both white light and UV light, under standard settings outlined in the user 
guide. The images were put together using the NRecon software, using standard settings.  
 
2.8 Statistical analyses 
All statistical analyses in this thesis were carried out using GraphPad Prism (version 5, 
GraphPad software Inc., SanDiego, CA). When appropriate, values are expressed as 
means ±SEM, and differences between means were analysed, for two groups, using an 
unpaired two tailed t-test. Three or more groups were analysed by either using a one way 
analysis of variance (ANOVA) followed by the Bonferroni post-hoc test (for 3 or more 
groups) or a two way analysis of variance ( 2-way ANOVA). Fisher’s exact test was 
A B C D 
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used to calculate the values in the contingency table reported in chapter 3. If necessary 
(unequal variances, skewed distributions) values were logarithmically transformed prior 
to statistical analysis. Asterisks were used to indicate level of significance based on the 
following criteria: *P<0.05, **P<0.01 and ***P< 0.001. 
 
2.9 Commonly used solutions 
Bouin’s Solution: purchased from Triangle Biomedical Scienes Ltd, Lancashire, UK. 
Citrate Buffer : 42.02g citric acid monohydrate was added to 1.9L distilled water. Made 
up to 2lL and pH 6 using NaOH and used at 0.01M by diluting 1:10 in distilled water. 
Eosin: 1% (w/v) eosin (15g) was diluted in 1200ml of distilled water. 1% (w/v) eosin 
(5g) was diluted in 500 ml methylated spirit. Both solutions were mixed together and 
filtered. 1ml formaldehyde was added to prevent bacerial growth.  
Harris’s haematoxylin 2.5g of haematoxylin was added to 25ml absolute alcohol and 
50g aluminium potassium sulphate was added to 500ml disti led water. Both solutions 
were combined and boiled and 1.25g mercuric oxide added slowly. The solution was 
cooled on ice before being filtered. 4ml (per 100ml of haematoxylin) of glacial acetic 
acid was then added.  
PBS: 1 tablet of PBS concentrate (Medicago, Sweden) in 1L of distilled water.  
Scott’s Tap Water: 10g potassium chloride and 100g magnesium sulphate were 
dissolved in 5L of tap water. 
TBS: 60.6 Tris (Sigma) was added to 87.6 NaCl (Sigma) to 300 ml Hydrocholric acid 
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3.1 Introduction 
Masculinisation of males is set up by androgen exposure during the masculinisation 
programming window (MPW). Deficiency in androgen exposure in this window results 
in reduced size of all reproductive organs, increased risk of reproductive disorders and 
reduced anogenital distance (AGD) (Foster and Harris, 2005; MacLeod et al, 2010, 
Welsh et al, 2008). As outlined in section 1.1.6, it is unknown what determines the onset 
and closing of the MPW, and for example whether androgen exposure itself and/or the 
availability of androgen receptors is important in this regard. Moreover, as the level of 
androgen exposure within the MPW is all important for determining normal male 
reproductive development, a further question posed i  what happens if there is additional 
(exogenous) androgen exposure and, for example, what happens if this exposure occurs 
before the MPW as opposed to during it? The primary objectives of the studies in the 
present chapter were to address these questions. Therefore, studies were undertaken to 
establish if androgen receptor mRNA and protein are expressed prior to the MPW or 
whether their ontogeny coincided with opening of the MPW. Following this, more 
detailed studies were undertaken to evaluate if masculinisation could be advanced or 
enhanced by treating pregnant rats with either 1 or 0 mg/kg/day dihydrotestosterone 
(DHT) prior to (early window, EW; e11.5-e14.5) or during the MPW (e15.5-e18.5), and 
then evaluating male (and female) offspring in fetal life (e18.5, e21.5), early puberty 
(day 25) or adulthood (~day 75).  
 
Although there are some relevant studies in the literature (reviewed in Wolf et al, 2002; 
Welsh et al, 2008), these have not examined androgen administration prior to the MPW 
and have used testosterone formulations for treatment. For example, studies by 
Kawashima et al (1978) exposed rats to methyltestoster ne, late in gestation, from 
e17.5-e20.5 and found that female offspring were masculinised in adulthood, 
demonstrating the some testosterone exposure can have some virilising effects even late 
in gestation. Furthermore, some studies exposed rats to testosterone on individual days 
of gestation to determine how the effect on female offspring correlated with exact day of 
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exposure. Even the earliest day of treatment for this study was e16.5 (Rhees et al, 1997). 
This study reported that exposure to testosterone on either e16.6, e17.5 or e18.5 caused a 
significant increase in female offspring AGD and treatments on any day between e16.5-
e20.5 caused delays in vaginal opening. Other studies have found that female fetal 
exposure to testosterone can also cause (in addition to increased AGD) reduced number 
of areolas and nipples, cleft phallus and presence of prostate tissue (Wolf et al, 2002). 
This study used testosterone propionate from e14.5-e19.5 in rats, and in male offspring 
no effects of the testosterone exposure were found ther than a reduction in glans penis 
weight. Indeed in the studies which really defined the MPW by Welsh et al (2008), 
testosterone was used as the choice of androgen exposure, and this exposure began at 
e15.5. Female offspring were reported to have developed prostates and seminal vesicles 
when exposed between e15.5-e19.5 but no masculinisation was reported when females 
were exposed between e19.5-e21.5 other than an increase in phallus length. No effects 
were reported in the male offspring after exposure to testosterone (Welsh et al, 2008). 
Thus there are no studies published that outline the effect of androgen exposure in the 
rat, in the fetal period, earlier than the MPW.  
 
Testosterone can be readily converted by the aromatase enzyme to oestradiol, and 
aromatase is strongly expressed in the placenta during p egnancy. Moreover, if rats are 
exposed to oestradiol or other potent oestrogens during pregnancy they can also induce 
dystocia, fetal loss and growth restriction, much like testosterone treatment does. One 
major problem that emerged from the studies described that used testosterone treatment 
during pregnancy was complications with giving birth, essentially delayed birthing 
(dystocia). From descriptions in the various studies, this manifest as increased loss of 
pregnancies due to death in utero or cannibalisation, reduced litter size and growth 
restriction of the pups that were born (Fritz et al, 1984; McCoy and Shirley, 1992; 
Rosenberg and Sherman, 1974). For example, in the studie  by Welsh et al (2008, 2010) 
using Wistar rats, these effects were so severe that the authors had to caesarian derive 
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pups from testosterone propionate (TP)-exposed dams and cross-foster them to other 
dams in order that offspring could be studied postnatally.  
 
As fetal growth restriction and reduced litter size are changes that are potentially 
confounding in any study investigating aspects of fetal development, it was considered 
important to avoid these if it was possible. Therefo , in the present studies 
dihydrotestosterone (DHT), rather than testosterone propionate, was used for treatment, 
in the expectation that because it cannot be aromatised o oestradiol it would not cause 
the same adverse pregnancy effects as testosterone administration. Additionally, DHT is 
a more potent androgen than testosterone (~10-fold), because it binds to the androgen 
receptor with higher affinity and more tightly (i.e. it dissociates less readily form the 
receptor) than does testosterone (Grino et al, 1990; Toth and Zakar, 1982). DHT was 
also used to ensure that any effect induced could be clarified as an androgen response 
rather than an oestrogen (from conversion of testoster ne to oestradiol) response.  
 
3.2 Materials and Methods 
3.2.1 Animals and treatments 
Briefly, pregnant rats were treated with DHT, or con il during the MPW (e15.5-e18.5) 
or during the period immediately preceding the MPW (e11.5-e14.5), hereafter referred 
to as ‘early window’ (EW) (section 2.2). Treatments were administered daily by 
subcutaneous injection and in each time window. Initially 1mg/kg DHT was 
administered to pregnant dams but when no effect was seen in the females, this dose was 
increased to 10mg/kg.  
 
Control and DHT-treated dams were either killed befor  term (e18.5, e21.5) or allowed 
to give birth, and resulting offspring then killed on either postnatal day (PND) 25 (= 
early puberty) or 75 (= adults). For fetal studies, pregnant dams were killed by inhalation 
of CO2 followed by cervical dislocation, fetuses were removed, and placed in ice-cold 
PBS. E21.5 fetuses were weighed and AGD measured using digital callipers and the 
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fetuses then decapitated (see section 2.3). The genital tubercle, gonads and ducts were 
removed by microdissection from both e18.5 and e21.5 fetuses and imaged using a Leica 
MZ6 camera attached to a dissecting microscope fittd with cold lights. In studies 
designed to determine if AR was present in tissues prior to the MPW, control fetuses 
were recovered from pregnant dams at e11.5, e12.5, e13.5 and e14.5. The genital/lower 
abdominal area was dissected from each pup and either stored at -80°C for RNA 
extraction and PCR investigation or fixed in Bouin’s fixative for 1 h before being 
transferred to 70% ethanol before being processed into paraffin wax blocks using 
standard procedures and an automatic tissue processor.  
 
Postnatal animals were killed by inhalation of CO2 followed by cervical dislocation. 
Bodyweight and AGD were measured before dissection of the phallus, gonads and 
ventral prostate (if present), which were weighed. The length of the phallus was 
measured by digital callipers. Tissue was fixed in Bouin’s fixative for 4 hours before 
being transferred to 70% ethanol and embedded in paraffin wax as above.  
 
 3.2.2 RNA extraction and RT- PCR for androgen receptor (AR)  
Briefly RNA was isolated from the genital area (perin um + genital tubercle) of control 
male and female pups at e11.5, e12.5, e13.5 and e14.5, and converted into cDNA (see 
section 2.6). The primers used for detection of AR exons 1 and 3 (forward 
AAGCAGGTAGCTCTGGGACA; reverse CGTTTCTGCTGGCACATAGA); revealed 
bands of 765 and 613 bp.  
 
3.2.3 Immunohistochemistry for the androgen receptor (AR) 
Briefly, immunohistochemical staining (section 2.5) for the AR was performed on 
sections of tissue from the lower abdomen/genital region of control animals at e11.5, 
e12.5, e13.5, e14.5 and e15.5. Table 3.1 outlines details of the AR antibody used. 
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Table 3.1 Details of AR antibody used in Chapter 3 
Primary Antibody Source Retrieval Species Dilution
Androgen Receptor Abcam, Cambridge Citrate Rabbit 1:500  
 
3.3 Results 
3.3.1 Effects of DHT exposure on the dams, gestational length and litter size  
Treatment with either dose of DHT in either time window had no detectable effect on 
health of dams, gestational length or on fetus number (e18.5, e21.5) or litter size at birth. 
There was no significant difference in the weight of the dams on the last day of 
treatment with DHT in comparison to vehicle (Fig.3.1). Using a one way ANOVA 
followed by a bonferroni test, no significant differences were noted for number of pups 
per litter in each treatment groups and no dams were found to suffer from dystocia. 
 








Figure 3.1 Effect of treatment with vehicle (V control) or dihydrotestosterone (DHT) at 1 or 
10mg/kg/day before (EW: early window; e11.5-e14.5) or during the masculinisation programming 
window (MPW; e15.5-e18.5) on maternal bodyweight on the last day of treatment (A) and number 
of pups per litter (B). N=8 for each treatment group.  
 
Maternal treatment period with vehicle or DHT                Maternal treatment period with vehicle or DHT 
 
A B 
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RT-PCR of tissue extracts from the lower genital area showed detectable AR mRNA 
expression from e11.5 – e14.5 (Fig.3.2A), which is the period immediately preceding the 
MPW. As reproductive tissues are not well developed at most of these ages, assessment 
of whether AR protein was expressed immunohistochemically is problematical, but 
tissue from the region of the developing mesonephros clearly expressed the AR protein 
at e13.5 (Fig. 3.2B), suggesting that at least in some tissues the AR protein may be 
expressed prior to the MPW. A pragmatic conclusion fr m these studies was that further 
similar investigations were unlikely to be any more d finitive, and that the tentative 
conclusion was that AR expression was unlikely to be the determining factor for opening 
of the MPW. Moreover, if AR was expressed prior to the MPW in relevant reproductive 
Figure 3.2 Evidence for expression of the androgen receptor before the masculinisation 
programming window (MPW), based on RT-PCR (arrow) on tissue extracts from the lower 
abdominal/genital area (A) and immunoexpression (B) in a tissue section from the mesonephric 
area of an e13.5 fetus (B). In A, each well corresponds to tissue from a different fetus and a 
product size of 765 bp.  In B, a section from the mesonephric area at the onset of the MPW (e15.5) 
is shown for comparison. 
 
E13.5 E15.5 
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tissues or progenitor tissues, then exposure to exogenous androgen (DHT) at this time 
would establish if these AR were functionally coupled in ways that would allow 
‘premature masculinisation’. Therefore, the logical next step was to investigate the 
effects of DHT exposure during these periods or during the MPW itself. 
 
3.3.3 Effect of DHT exposure in utero on AGD in males and females 
AGD measurement from e21.5 onwards provides an accur te read-out of androgen 
exposure within the MPW (Welsh et al, 2008; MacLeod et al, 2010). The effect of 
maternal treatment with 1 or 10mg/kg DHT before and during the MPW, on AGD in 
male and female offspring is shown in Fig. 3.3. As expected, AGD was significantly 
longer in control males at all ages than in females. In males, DHT exposure at either 
dose in either time window (i.e. before or during the MPW), had no significant effect on 
AGD. In females, AGD was significantly increased, compared with controls, at e21.5 
after exposure to either 1 or 10mg DHT during the MPW, but this difference was not 
maintained postnatally (Fig. 3.3). In contrast, exposure of females to DHT at either dose 
during the EW (i.e. prior to the MPW) did not alter AGD at any age (Fig. 3.3). These 
results showed that androgen exposure prior to the MPW was without effect on AGD in 





Chapter 3           Effect of DHT before & during the MPW 
 













Figure 3.3 Effect of treatment with vehicle (VEH; control) or dihydrotestosterone (DHT) at 1 
or 10mg/kg/day before (EW: early window; e11.5-e14.5) or during the masculinisation 
programming window (MPW; e15.5-e18.5) on anogenital distance (AGD) in male and female 
offspring in fetal life (top), early puberty (middle) and in adulthood (bottom). Values are the 
mean ± SEM for 4-24 animals per group from 3-6 different litters. *P<0.05, **P<0.01, 
***P<0.001, in comparison with respective male control value. aP<0.001, in comparison with 





Maternal treatment period with vehicle or DHT 
Female Male 
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3.3.4 Effect of DHT exposure in utero on development of the Wolffian duct  
Coiling of the Wolffian duct normally first appears at e19.5 in the male rat with full 
coiling developed by e21.5 (Welsh et al, 2007). Coiling is never observed at e18.5 in 
normal males, as confirmed in controls in the present studies (Fig. 3.4). Exposure to 
either 1 or 10mg DHT treatments prior to (EW) or during the MPW did not induce 
premature Wolffian duct coiling at e18.5 in males, nor did it exagerrate normal coiling 
evident at e21.5 (Fig. 3.4). In normal female rats the Wolffian duct has largely regressed 
by e18.5 (Welsh et al, 2009), but exposure to the 10mg dose of DHT during either the 
EW or the MPW resulted in stabilization of the Wolffian duct in 58% and 81% of 
females, respectively, at e21.5 (Fig. 3.4 and Table 3.2). In contrast, no retention of 
Wolffian ducts was observed in females exposed in either time window to the 1mg dose 
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Figure 3.4 Effect of treatment with vehicle (Control) or dihydrotestosterone (DHT) at 1 or 
10mg/kg/day before (EW: early window; e11.5-e14.5) or during the masculinisation programming 
window (MPW; e15.5-e18.5) on Wolffian duct development (arrows) in males (top two rows) and 
females (bottom row). Note that at e18.5 the Wolffian duct is a simple straight tube in males, 
whereas by e21.5 it has developed conspicuous coiling; DHT exposure in EW or MPW does not 
induce precocious coiling at e18.5 or affect it detectably at e21.5 (similar results for 1 mg DHT 
dose, not shown). In females, exposure to 10mg DHT, but not to 1mg (not shown), in the MPW and 
to a lesser extent in the EW (Table 3.2) induces stabilisation of the Wolffian duct so that it is evident 

















                Control                            DHT 10mg EW        DHT 10mgMPW 
      Control               DHT 10mg MPW 
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               Female 
Figure 3.5 Effect of treatment with vehicle (VEH; Control) or dihydrotestosterone (DHT) at 1 or 
10mg/kg/day before (EW: early window; e11.5-e14.5) or during the masculinisation programming 
window (MPW; e15.5-e18.5) on ventral prostate (VP) weight in early puberty (top) and in adulthood 
(bottom). Values are the mean ± SEM for 4-24 animals at each age from 3-6 different litters. 
***p<0.001, in comparison with respective male control value. Note that in females, exposure to 1mg 
DHT in either EW or MPW did not result in VP formation and not all females exposed to 10mg DHT 





Maternal treatment period with vehicle or DHT 
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In utero exposure of males to either dose of DHT in either time window did not 
significantly alter VP weight at either PND25 or in adulthood (Fig. 3.5). In females, 
exposure to the 10mg DHT dose during the MPW induce a VP in all females when 
evaluated at PND25 or in adulthood, although the glands were always notably smaller 
than those found in normal males of the same age (Table 3.2; Fig. 3.5). A proportion of 
females exposed to 10mg DHT prior to the MPW (EW) also had some prostatic tissue 
but this was more variable than in females exposed during the MPW (e.g. only one lobe 
of a VP present). Females exposed to the 1mg dose of DHT in either time window did 
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Table 3.2. Effects of in utero DHT exposure on reproductive development in females 















e21.5 0/20 0/20 14/10*** 0/13 13/3*** 
Ventral prostate 
Present/absent 
PND25 0/18 0/15 3/3** 0/4 5/0*** 
Ventral prostate 
Present/absent 
Adult 0/20 0/10 10/4*** 0/4 4/4** 
Nipples  
Present/absent 
PND25 18/0 20/0 0/6*** 4/0 0/5*** 
Nipples  
Present/absent 
Adult 20/0 10/0 0/14*** 4/0 0/8*** 
Vaginal opening 
Present/absent 
Adult 20/0 10/0 0/14*** 4/0 0/8*** 
Uterine 
abnormalities 
PND25 0/18 0/15 4/2** 0/4 0/5 
Uterine 
abnormalities 










1Females exposed to vehicle treatment in either the EW or MPW 
*P<0.05, **P<0.01, ***P<0.001, in comparison with incidence in respective control group 
(Fisher’s exact test) 
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3.3.6 Effect of DHT exposure in utero on development of the phallus 
In utero exposure of males to either dose of DHT in either time window did not 














Figure 3.6 Effect of treatment with vehicle (VEH; Control) or dihydrotestosterone (DHT) at 1 or 
10mg/kg/day before (EW: early window; e11.5-e14.5) or during the masculinisation 
programming window (MPW; e15.5-e18.5) on phallus length in early puberty (top) and in 
adulthood (bottom) in males and females. Note the different scales for male and female results. 
Values are the mean ± SEM for 4-24 animals at each age from 3-6 different litters. Results were 







    MPW EW MPW EW 
Maternal treatment period with vehicle or DHT                        Maternal treatment period with vehicle or DHT 
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However, surveyed as a whole, it appeared that mean p nis length was slightly but 
consistently smaller in DHT-exposed males compared with controls (P=0.016 at PND25 
and P=0.062 in adults by analysis of variance including data for either dose and either 
time window of exposure). Surprisingly, in females, there was little obvious impact of 
fetal DHT exposure on phallus length, except for a small significant increase in the 10 
mg DHT EW group in adulthood (Fig. 3.6). However, this comparison is probably not 
accurate because the phallus is structurally indisti ct in control females, thus making it 
difficult to dissect and accurately measure its length. In contrast, in most females at 
either PND25 or in adulthood that had been exposed in utero to 10mg DHT prior to the 
MPW, the phallus had a clear tubular structure as occurs in males, although much 
smaller in diameter; this change was not observed in most females exposed to 10mg 
DHT during the MPW. 
 
3.3.7 Effect of DHT exposure in utero on development of the testis and ovaries 
In utero exposure of males to either dose of DHT in either time window did not 
significantly alter gross morphology of the testis (not shown) or its weight at either 
e21.5, PND25 or in adulthood (Fig. 3.7). Ovarian weight in females exposed to DHT in 
utero tended to be smaller than in controls, but this only reached statistical significance 
for animals exposed to the 10mg DHT dose during the EW (Fig. 3.8). 
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Figure 3.7 Effect of treatment with vehicle (VEH; Control) or dihydrotestosterone (DHT) at 1 or 
10mg/kg/day before (EW: early window; e11.5-e14.5) or during the masculinisation 
programming window (MPW; e15.5-e18.5) on testis weight in fetal life (top), early puberty 
(middle) and in adulthood (bottom). Results were analysed using a one way ANOVA Values 
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3.3.8 Effect of DHT exposure in utero on development of other reproductvie tissues 
in females  
Females exposed to 10 mg DHT in either time window lacked nipples at Pnd25 and in 
adulthood, whereas exposure to 1mg DHT had no effect (Table 3.2). Similarly, a vaginal 
opening was absent in all females exposed to 10mg DHT in either time window but was 
present in all females exposed to 1 mg DHT (Table 3.2). Fluid distension of the uterus 
(hydrometrocolpus) was evident in a proportion of DHT-exposed females that lacked a 
vaginal opening (Table 3.2), and in some affected indiv duals this accumulation was 
extensive, resulting in gross abdominal distension (Fig. 3.8); one animal had its uterus 
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Figure 3.8 Effect of treatment with vehicle (VEH; Control) or dihydrotestosterone (DHT) at 1 or 
10mg/kg/day before (EW: early window; e11.5-e14.5) or during the masculinisation programming 
window (MPW; e15.5-e18.5) on ovarian weight in early puberty (A, top) and in adulthood (A, bottom). 
Values are the mean ± SEM for 4-12 animals at each age from 3-5 different litters (N=2 litters for 1mg 
DHT MPW group). Results were analysed using a one way ANOVA *P<0.05, in comparison with 
respective control value. Panel B shows an example of gross distension of the uterus (asterisks), 
termed hydrometrocolpos, in a female rat exposed to 10mg DHT in the MPW (for incidence data see 
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3.4 Discussion 
The primary aim of the present studies was to establi h if experimental exposure of the 
male rat fetus to a potent, non-aromatisable androgen (DHT), either during or prior to 
the MPW, was able to advance or enhance any aspect of male reproductive 
development. The results show unequivocally that DHT exposure of fetal males to a 
dose (10mg/kg/day) of DHT that is able to ‘masculinise’ females when they are exposed 
either prior to or during the MPW, has no detectable effect on male reproductive 
development. In particular, the results show that DHT exposure prior to the normal 
MPW cannot advance (timing of Wolffian duct differentiation) or enhance (testis, penis 
and VP size, AGD) male reproductive development. Furthermore, exposure of males to 
‘extra’ androgen during the MPW, in the form of DHT, was similarly without any 
‘enhancing’ effect. The results also indicate that sensitivity of the female reproductive 
tract to androgens may start earlier than the MPW. 
 
The use of DHT for the present studies could be considered as non-physiological 
because the physiological androgen that circulates in fetal males is testosterone, whilst 
DHT is generally produced locally within androgen target tissues via the 5α-reductase 
enzyme (Imperato-McGinley & Zhu, 2002). However, previous studies that have used 
testosterone formulations for treatment of rats in pregnancy have all reported adverse 
pregnancy side-effects such as dystocia, fetal loss/growth restriction (Wolf et al, 2002; 
Welsh et al, 2008), which may result in confounding effects. In earlier studies by our 
own group using testosterone, they had to resort to caesarian delivery of pups and their 
cross-fostering to nursing mums to enable survival of pups for study of their postnatal 
development (Welsh et al, 2008, 2010). As oestrogen tr atment of pregnant rats can 
result in similar pregnancy problems (Zimmerman et al, 1991), a logical conclusion is 
that the adverse pregnancy effects of maternal testosterone treatment result from its 
aromatisation. The present results support this interpretation by showing that 
administration of the non-aromatisable androgen, DHT, was without any adverse effect 
on pregnancy or timing of delivery. As oestrogens can exert important effects on male 
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reproductive development in rodents (Delbes et al, 2006; Goyal et al, 2007; Prins et al, 
2007), the present studies also avoided any potential confounding from such effects. 
Therefore, the studies can be considered as providing a reasonably definitive assessment 
of the role and importance of androgens before and during the MPW in male 
reproductive development. The only caveat is that if some aspects of male reproductive 
programming during the MPW result from testosterone metabolism to oestradiol, then 
such effects will have been missed. However, as earlier findings involving the 
administration of testosterone during (and after) the MPW to rats did not report any 
‘enhancing’ effects in male offspring (Wolf et al, 2002; Welsh et al, 2008, 2010), such 
effects seem unlikely. 
 
A major goal of the present studies was to establish if programming of male 
reproductive development could be advanced by exposure to DHT prior to the MPW. 
The initial AR studies indicated that AR mRNA is expressed prior to the MPW and, at 
least in some tissues (meosnephros) the AR protein may be present prior to the MPW, as 
reported previously by others (Bentvelsen et al, 1995). Irrespective of this, DHT 
exposure prior to the MPW did not exert any detectable effect in males, and of most 
interest it did not advance coiling of the Wolffian duct, a change that occurs after 
completion of the MPW but which has been shown to be programmed within the MPW 
(Welsh et al, 2007). As reproductive organ size in DHT-exposed males was comparable 
to controls at all ages investigated, it is also concluded that reproductive development in 
males cannot be enhanced by DHT exposure prior to oduring the MPW. This fits with 
previous conclusions from studies involving exogenous testosterone exposure during 
periods that included the MPW (but not earlier) (Wolf et al, 2002; Welsh et al, 2008, 
2010); it also agrees with studies in rhesus monkeys involving fetal androgen exposure 
(Herman et al, 2000). This generates two further conclusions. First, that exposure to 
endogenous androgens during the normal MPW is sufficient to maximally program 
reproductive organ size. Second, that it is not the availability of androgens that ‘opens’ 
the MPW, an important conclusion as it suggests that other factors involved in AR 
Chapter 3           Effect of DHT before & during the MPW 
 
Page | 133 
activation/signaling (e.g. co-regulators) may be important in delimiting androgen action 
within the MPW. These are the subject of investigation in chapter 4. 
 
The most unexpected results from the present study were those in DHT-exposed female 
offspring. Although the ‘masculinisation’ changes that we report in females (stabilized 
Wolffian duct, VP induction, uterine abnormalities/hydrometrocolpos, lack of nipples, 
absent vaginal opening) have all been reported previously in female rats exposed to 
exogenous androgens during fetal life (reviewed and reported in Wolf et al, 2002; Welsh 
et al, 2008), the present studies are the first to have assessed the effect of androgen 
exposure only prior to the MPW. Whilst such exposure was without detectable effect in 
males, exposure of female offspring to 10mg/kg DHT prior to the MPW was only 
marginally different than exposure during the MPW in masculinising female offspring; 
in some respects, such as effects on the phallus, DHT exposure prior to the MPW may 
even have been more effective than during the MPW. These findings could simply mean 
that there has been ‘spill-over’ of DHT exposure from the early window of treatment 
(e11.5-e14.5) into the start of the MPW (e15.5-e18.5), a possibility that we cannot 
exclude as the DHT preparation used is relatively long-acting and was administered in 
oil so as to prolong absorption and exposure. On the o er hand, exposure of females to 
10mg/kg DHT prior to the MPW was without significant effect on AGD at e21.5, 
whereas some effect due to ‘spill-over’ would have be n expected, as exposure to even 
1mg/kg DHT during the MPW increased AGD at e21.5. This raises the possibility that 
androgen sensitivity of females may not be restricted o the MPW, as concluded 
previously (Welsh et al, 2008), but may be initiated somewhat earlier than this. If so, this 
suggests that androgen sensitivity of females is somewhat different to that of males. This 
would not be without precedent, as sensitivity of Wolffian duct degeneration to lack of 
androgens is different (occurs earlier) in females than in males, at least in rats and mice 
(Welsh et al, 2009). For other female-specific disorders, such as lack of nipples, lack of 
a vaginal opening and induction of hydrometrocolpos, there is not a literature on age-
specific windows for induction, so it is feasible tha  the window of susceptibility is 
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wider than is the MPW in males. One unexpected, and unexplained, finding from the 
present studies was that the increase at e21.5 in female AGD induced by DHT-exposure 
during the MPW was no longer evident at PND25 and i adulthood. The present 
findings and those of others indicate that once AGD has been programmed by androgens 
in the MPW it is more or less a lifelong change. Other than the use of DHT, there is no 
other difference between the present and other studies that would readily explain this 
odd finding.  
 
In conclusion, the studies reported in this chapter d monstrate that it is not the 
availability of androgens which initiates the MPW, and exposure of the male fetus to 
exogenous ‘additional’ androgens prior to or during the MPW does not advance or 
enhance masculinisation of the fetus, including ultima e reproductive organ size. 
Furthermore, the female reproductive tract was susceptible to virilisation by exogenous 
androgen exposure prior to, as well as during, the MPW, which to the best of my 
knowledge had not been reported before. 
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4.1 Introduction  
The previous chapter demonstrated that the availability of androgens or AR were 
unlikely to be the factors regulating the MPW. There are various other possible 
pathways via which specific aspects of androgen action might be regulated within the 
MPW. Some of these possibilities include AR co-regulators, reviewed in section 1.7.1 
and known to be vital in androgen action, and gene methylation which could silence or 
un-silence genes involved in the regulation of the MPW. There is a surprising lack of 
data characterizing AR co-regulators, methylation enzymes and general androgen 
biochemical associates in the fetal male reproductive tract and, considering the aims of 
this thesis, this warranted investigation. 
 
AR co-regulators play an important role in androgen action and this is reviewed in detail 
in the literature review of this thesis. Over 300 nuclear receptor co-regulators have been 
identified. A large number of these have been characte ized in relation to oestrogen or 
glucocorticoid receptors but less co-regulators have been identified to be AR specific or 
indeed regulated by AR and the overall picture is sketchy. It is well established that 
many co-regulators are fundamentally necessary in embryonic development and 
inactivating mutations of these can be embryonic lethal or cause disorders. However, 
characterization of key androgen co-regulators in the male reproductive tract, and 
furthermore their possible role in the MPW, has not been investigated. This was 
therefore an objective of this chapter.  
 
To initially identify co-regulators which work with AR, GeneGo was employed. 
GeneGo is bioinformatics software which produces gene xpression pathways. Kristine 
Belling a bio-informatics PhD student was very kind and carried out the studies using 
GeneGo to determine AR pathways. The co-regulators in these pathways were compared 
against a microarray study designed in our group and u dertaken by a Finnish 
commercial enterprise using Affymetrix microarrays. The microarray was designed to 
identify potential androgen regulated genes, switched on in the GT during the MPW, by 
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comparing the genes expressed at e17.5 in rat control male GT (normal androgen 
action), control female GT (normal lack of androgen action in females), flutamide 
exposed male GT (blocked androgen action) and testost rone exposed female GT 
(excess androgen action that should mimic males). Genes which overlapped between 
GeneGo and the microarray outcome were investigated in the literature and those of 
interest were further investigated by Taqman-PCR. The genes identified by comparing 
the GeneGo pathways and the outcomes of the microarray study were Brg1, Cbp, Fkbp5, 
Snurf, Transgelin and Vav3. Of these, Brg1 and Cbp had interesting patterns of 
expression during the MPW (see appendix 3 3). 
 
Another co-regulator was studied in this chapter which was not found via the Genego 
pathway or the microarray. This was Rwdd1, a novel co-regulator which had been found 
to be androgen regulated in the adult thymus but again, for which there is currently no 
published data within the male reproductive tract (Kang et al 2008a, Kang et al 2008b).  
 
Aside from androgen co-regulators, it was also important to consider other mechanisms 
of regulation and one key mechanism known to be vital in embryonic development is 
methylation (section 1.7.2). Methylation can cause silencing of normally active genes, or 
activate (demethylation) normally silent genes but ultimately leads to stable changes in 
gene expression (reviewed by Garcia-Carpizo et al, 2011). The AR gene encompasses an 
approximately 15-kb CpG island at the transcription start site and exon 1 (Jarrard et al, 
1998) and most studies that have investigated AR methylation have focused on prostate 
cancer (Kinoshita et al, 2000; Sasaki et al, 2002; Takahashi et al, 2002). However, more 
recently, some studies have been published regarding the role of methylation in male 
fetal development. One study found that rat fetal exposure to vinclozin (anti-androgen) 
or to methyxychlor (an oestrogen) affected methylation patterns in the offspring 
resulting in decreased spermatogenic capacity and increased chances of infertility and 
the altered DNA methylation in the germ line was passed on for up to the four 
generations studied thereafter (Anway et al, 2005). However, these studies are somewhat 
Chapter 4   Androgen Receptor & methylation co-regulators 
 
Page | 137 
suspect as they have not so far proved to be repeatabl  (Inawaka et al, 2009). 
Furthermore, some studies have investigated DNMT3L, a regulator of methylation 
(section 1.7.2.1) and mouse knockout models have severe hypogonadism and 
azoospermia (Bourc’his et al, 2001). Another protein believed to be involved in 
methylation is BORIS (section 1.7.2.2) The expression of BORIS protein has only been 
found in the testis and it has been shown that disruption of DNA methylation can 
increase expression of BORIS and thus some scientists consider BORIS a marker for 
methylation in the testis. Taking into account that anti-androgens might affect 
methylation patterns in the fetus and that both DNMT3L, a methylation regulator and 
BORIS a methylation marker are important in the testis and also because another PhD 
project found both of these proteins to have changing expression in the male 
reproductive tract (M.S Jobbling submitted 2009), DNMT3L and BORIS were of key 
interest in the regulation of the MPW.   
 
Table 4.1 shows the list of possible androgen biochemical associates which were 
targeted and investigated initially using Taqman-PCR. Of these, Fkbp5, Snurf, 
transgelin and Vav3 did not show any obvious pattern of change in expression across the 
MPW, so were not selected for further study. (This is also summarised in appendix 3). In 
contrast, Brg1, Cbp, Rwdd1, Dnmt3l and Boris displayed interesting mRNA expression 
changes in relation to the MPW (at least in the GT) and were therefore investigated 
further. The aim of the studies in this chapter was to investigate genes which might be 
differentially expressed before, during, or after the MPW, and to at least provide 
preliminary evidence as to their possible implication in specifying the MPW or in 
modulating androgen action specifically within the MPW. The protein of the 3 co-
regulators and 2 methylation regulators chosen for investigation, were also studied in 
testis. AR expression in the testis is well characterized at different time points, for 
example, in the SC AR is switched on between PND4-10 and more strongly thereafter. 
Consequently the testis provides a dynamic system in wh ch to dissect the potential role 
and importance of the androgen biochemical associates.   
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4.2 Materials and Methods: 
Two types of studies were done in this chapter, the first of these analyzed expression 
patterns across the MPW. The genes which had interesting expression patterns were then 
investigated in relation to androgen or oestrogen ma ipulation.  
4.2.1 Animals and Treatments: 
Briefly, pregnant rats were treated with flutamide, DBP or DES or appropriate vehicle 
during the MPW, (section 2.2). The genital tubercle, gonads and ducts were dissected 
from the resulting rat fetuses at e16.5, e17.5, e19.5 or e21.5, from both male and female 
pups. The penis and testis were dissected from PND25 and adult males. The tissue was 
fixed in Bouin’s fixative and processed for immunohistochemical analysis or frozen at -
80°C for RNA analysis 
4.2.2 RNA analysis: 
The mRNA level of co-regulators of interest was investigated using Taqman (section 
2.6). Briefly, RNA was isolated from frozen tissue and converted into cDNA and 
quantitative RT-PCR performed. Time course experiments investigated the expression 
before, during, and after the MPW. The effect of trea ments on co-regulator expression 
was investigated in the fetal life. The genes investigated and primers used are listed in 
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4.2.3 Fluorescence immunohistochemical analysis 
Fluorescence immunohistochemistry (section 2.5.2) was used to determine the co-
localisation of AR with specific co-regulator proteins in the male reproductive tract, 
from control and treated animals. Briefly, staining was performed on sections of fetal 
and postnatal tissues. The various tissues examined in this chapter are summarized in 
Table 4.2. A minimum of 3 animals from 3 litters were investigated at each age and in 
each treatment group. The antibodies used are listed in Table 2.3. 
 
Tissue Collection Ages
Treatments  groups 
investigated (all treatments 
in MPW)
Genital Tubercle e16.5, e17.5, e19.5, e21.5 Control, Flutamide
Penis PND25, PND90 Control, Flutamide
Testis
e21.5, PND4, PND10, 
PND25
Control, Flutamide, DES, 
DHT, Indomethacin, DBP
Wolffian Duct e17.5, e19.5, e21.5 
Control, Flutamide, DES, 
DHT, Indomethacin  
 
Table 4.2 Details of tissues examined in chapter 4 
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4.3 Results 
4.3.1 BRG1 expression in the male reproductive tract 
BRG1 is a co-regulator involved in chromatin re-modelling and known to work with 
oestrogen receptor, glucocorticoid receptor and androgen receptor (reviewed in section 
1.7.1.1.1). BRG1 expression has not been characterized in the male reproductive tract. 
To determine if Brg1 was expressed in the developing genital tract at the mRNA level, 







Brg1 mRNA expression decreased in the genital region and GT during the MPW, as 
highlighted in Fig. 4.1 (A, B). In the male genital tubercle, there was a significant 
decrease in expression of Brg1 at e17.5 in comparison to e14.5, prior to the MPW. When 
Figure 4.1 Quantitative analysis of Brg1 mRNA levels in the lower abdomen/genital area 
(A), male GT (B), testis (C) and Wolffian duct (D) of control male rats. Using a one way 
ANOVA * P<0.01 in comparison with respective e14.5 value. Values are means ±SEM 
for 6 animals/group from a minimum of 3 litters. Pink shading depicts sampling ages 
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Brg1 mRNA was investigated in the testis and WD no significant differences in 
expression were found at any age, although, in both tissues expression appeared to 
increase after the MPW. BRG1 protein expression was investigated (using 




In the control male GT, nuclear BRG1 expression was present in most cells of the 
developing GT at e17.5, e19.5 and e21.5 and at PND25 in the penis. BRG1 was also 
expressed in cells where AR was absent. Taqman-PCR results suggested that BRG1 
Figure 4.2 Representative photomicrographs of BRG1 expression (red) and AR expression (green) in 
control male GT at e17.5 (A), e21.5 (B) and PND25(C) T= the tip of the GT, O=Os penis; the uretheral 
area is indicated by an arrow and the corpus cavernosum by asterisks. Each scale bar (bottom left) 
represents 200µm. Panel D represents a negative control with no BRG1 antibody present. Note the 
more pronounced co-expression (yellow) of these two proteins at PND25 in comparison to earlier time 
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mRNA expression was lower in the GT during the MPW and increased thereafter. This 
did not appear to be reflected at the protein level as the e21.5 GT appeared to show the 
most intense BRG1 expression but this was not quantified. At PND25 in the penis, both 
AR and BRG1 mRNA expression had decreased, but in contrast to the fetal samples, 
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Figure 4.3 Representative photomicrographs of BRG1 expression (red) and AR expression (green) in 
testes from control rats at e21.5(A), PND4 (B), PND10 (C) and PND25(D). Co-localisation (yellow) is 
mainly apparent in Sertoli cells (indicated by the arrows), beginning at day 4 in some Sertoli cells and 
becoming ‘stage-dependent’ by PND10-25. Asterisks show BRG1 immunopositive germ cells. Scale 












Chapter 4   Androgen Receptor & methylation co-regulators 
 
Page | 144 
The expression of BRG1 in the testis has not been reported previously. Using 
immunohistochemistry, nuclear BRG1 was found to be present in the testis at e21.5, 
PND4, PND10 and PND25 (Fig 4.3). At e21.5, BRG1 was expressed in the SC within 
the seminiferous tubules, perhaps weakly in some germ c lls and also in some, but not 
all, cells within the interstitium. At PND4, BRG1 positive cells in the interstitium were 
infrequent but SC continued to express BRG1, as did some germ cells. Interestingly, as 
AR expression switched on at PND4 within some SC, co-lo alisation with BRG1 first 
became evident. This co-localization became far more pronounced at PND10, but also 
became highly variable between seminiferous tubules and this trend became even more 
marked at PND25. It is possible that this variation reflects ‘stage-dependency’, but this 
remains to be investigated. At PND10 and PND25 expression of BRG1 in GCs, 
especially in spermatocytes, also became much more obvious, although as GCs are AR 
negative, no co-localisation was seen.  
A B 
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4.3.1.1 Effects of fetal exposures during the MPW on BRG1 expression 
Immunohistochemistry was used to determine if altered androgen/oestrogen action in the 
testis by exposure to DBP, DES, or flutamide during the MPW, would affect BRG1 
expression. In the e21.5 testis, where nuclear BRG1 expression was found mainly in the 
SC as well as in occasional interstitial cells in co trols, a similar pattern of staining was 
found in testes from fetuses which had been exposed to DBP, DES, or flutamide, with 
no obvious treatment effects (Fig 4.4).  
Figure 4.4 Representative photomicrographs of BRG1 expression (red) and AR expression 
(green) in e21.5 testes from animals exposed to DBP (A), DES (B), flutamide (C) and vehicle 
(D) during the MPW. Note the virtual absence of co-localisation (yellow) and lack of any 
obvious treatment effects (A, B and C) on patterns of expression in comparison to control (D). 
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In the PND25 testis, there was prominent nuclear BRG1 expression in SC and some 
interstitial cells and a similar pattern of staining was found in testes from animals which 
had been exposed in the MPW to DBP, DES, flutamide or vehicle (Fig.4.5). As 
expected, AR was prominently expressed in SC, peritubular myoid cells and some 
interstitial cells. Co-localisation of AR and BRG1 was evident in some, but not all, SC 
and in occasional interstitial cells. There was no obvious treatment-related change in the 





Figure 4.5 Representative photomicrographs of BRG1 expression (red) and AR expression 
(green) in PND25 testes from animals exposed during the MPW to DBP (A), DES (B), flutamide 
(C) or vehicle(D). Note the prominent expression of BRG1 in germ cells (asterisks) and the co-
localisation of AR and BRG1 (yellow) in some but not all Sertoli cells (arrows). The scale bar 
represent 200µm.   
A B 
C D 
* *  
* 
* *  
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4.3.2 CBP expression in the male reproductive tract 
CBP is a co-regulator involved in histone modification and is a well established co-
regulator that modulates transcription in many different pathways (reviewed in section 
1.7.1.2.1). CBP is well known to work in collaboration with BRG1 but the expression of 
CBP in the developing male reproductive tract has not been reported in the literature. To 
determine if Cbp was expressed in the developing genital tract at the mRNA level and 











Figure 4.6 Quantitative analysis of Cbp mRNA level in the lower abdominal/genital region 
(A), GT (B), testis (C) and Wolffian duct (D) of control male rats. Using a one way ANOVA  
* P<0.01 in comparison to e14.5. Values are means ±SEM for 6 animals/group from a 
minimum of 3 litters. Pink shading depicts sampling ages within the MPW. 
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Cbp mRNA decreased in expression during the MPW in the lower abdomen of rats 
when compared with ages before and after the MPW, as highlighted in Fig.4.6 (A). In 
the male genital tubercle, there was also a significant decrease in expression of Cbp at 
e17.5 in comparison to e14.5 GT, prior to the MPW, with higher expression again after 
the MPW at e21.5, although the latter increase was not statistically significant (Fig. 
4.6B). In contrast, Cbp mRNA expression in the testis and WD did not exhibit any 
significant differences in expression in or outside of the MPW. CBP protein expression 
was investigated using immunohistochemistry in the genital tubercle (Fig. 4.7) and testis 
(Fig.4.8, 4.9 and 4.10) to see if these mRNA findings could be confirmed at the protein 
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Figure 4.7 Representative photomicrographs of CBP expression (red) and AR expression (green) in 
control male GT at e17.5 (A), female GT at e19.5 (B), male GT at e21.5 (C) and PND25 penis (D). 
T= the tip of the GT, O=OS penis, the urethral area is indicated with an arrow and corpus 
cavernosum with asterisks. Co-localisation of CBP and AR shows as yellow. Negative control for AR 
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Similar to the results found for BRG1, nuclear CBP expression was found in the GT. 
Although at e17.5 it was not possible to obtain a transverses section, only a vertical one 
and therefore it was unclear exactly which cells CBP was expressed in at this age. 
However, it can be seen that at e17.5, CBP expression was near the tip of the GT and 
much of this was not co-localised with AR expression. In the female GT at e19.5, CBP 
was found only in the urothelial cells and blood vessels and staining was specific to 
these areas; it seems likely that a similar expression pattern would be found in the e17.5 
male GT if a transverse section had been obtained. I  the male GT at e21.5, CBP was 
not expressed in the urothelial cells and at PND25, in the penis, AR was still widely 
expressed whereas CBP was much more restircted in expression, but wherever it was 
expressed, it mainly co-localised strongly with AR in the urethral epithelium and in the 
outer epidermis and prepuce (Fig.4.7).  
  
Figure 4.8 Representative photomicrographs of CBP expression (red) and AR expression 
(green) in control rat testes at e21.5 (A), PND4 (B), PND10 (C) and PND25 (D).Note that CBP is 
only co-expressed with AR in SC (arrows) from around day 10, and that this showed some 
evidence for ‘stage-dependence’. Note, in contrast that CBP co-localized with AR in the 
interstitial cells extensively at e21.5 with a progressive reduction thereafter up to PND10. Note 
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The expression of CBP in the testis has never been r ported. Using 
immunohistochemistry, nuclear CBP was found to be pr sent in the testis at e21.5, 
PND4, PND10 and PND25. At e21.5, CBP was expressed in the SC and some germ 
cells within the seminiferous tubules and also strongly within cells of the interstitum. At 
PND4, CBP expression in interstitial cells was much less pronounced than at e21.5, but 
SCs continued to express CBP strongly. CBP only co-expressed with AR in SC from 
around day 10, and this co-expression demonstrated some ‘stage-dependence’. However, 
in contrast CBP co-localized with AR in the interstitial cells extensively at e21.5 with a 
progressive reduction thereafter up to PND10. CBP was also found to be expressed in 
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Immunohistochemistry was used to determine if possible disrupted androgen action in 
the testis by exposure to either DBP, DES, flutamide or vehicle, during the MPW 
affected subsequent CBP expression. In the e21.5 testis, nuclear CBP was found in SC 
and some germ cells as well as in the interstitium in control tissue and co-localisation of 
CBP with AR was only evident in interstitial cells. A similar pattern of staining was 
Figure 4.9 Representative photomicrographs of CBP expression (red) and AR expression 
(green) in e21.5 testes from fetuses exposed to DBP (A), DES (B), flutamide (C) or vehicle (D) 
during the MPW. Note the similar pattern of expression in the different treatment groups and 
that co-localisation of CBP and AR (yellow) is restricted to some interstitial cells. Scale bar 
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At PND25 in control testes, nuclear CBP expression was found in SC, most GCs and in 
occasional interstitial cells. Clear co-localisation could be seen with AR and CBP in the 
SC but this varied between seminiferous tubules which suggested this co-localisation 
was stage dependent. A similar pattern of co-expression was found in animals exposed 
to DBP, DES, or flutamide, and thus these did not appe r to affect AR or CBP 
expression or co-localisation. (Fig.4.10).  
Figure 4.10 Representative photomicrographs of CBP expression (red) and AR expression 
(green) in PND25 testes from animals exposed to DBP (A), DES (B), flutamide (C) or vehicle 
(D) during the MPW. Note that AR and CBP co-localise in SC (yellow) but this varies 
between seminiferous tubules (‘stage dependent’) and does not appear to be treatment 
modulated. Scale bars represent 200µm.  
A B 
C D 
*  *  
*  
*  
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4.3.2.2 Co-expression of BRG1 and CBP 
It has been reported that BRG1 and CBP work in collab ration in many cell types in 
their roles to co-regulate transcription. In order to determine if both co-regulators were 
expressed in the same cell types in the male reproductive tract, double 
immunohistochemistry was used. The genital tubercle, WD and testis were examined 
and it was found that BRG1 and CBP were expressed together in every cell type in each 
of these tissues irrespective of age. One was never obviously expressed without the other 
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Fiure 4.11 Representative photomicrographs of BRG1 expression (red) and CBP expression 
(green) in male control e17.5 GT (A), e21.5 GT (B), e21.5 WD (C) e21.5 testis (D) PND 10 testis 
(E) and PND25 testis (F). Note that for the most part, BRG1 and CBP are co-expressed (yellow), 
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4.3.3 RWDD1 expression in the male reproductive tract 
There is some evidence which suggests that RWDD11 can co-regulate the AR and this 
may be important in the thymus. RWDD1 is a very newly discovered co-regulator and 
its expression patterns in the developing reproductive tract are completely unknown. 
Rwdd1 expression was first investigated in the GT using Taqman RT-PCR and then 
using immunohistochemistry, to determine i) if its expression changed in relation to the 
MPW, ii) if its expression was altered by flutamide and iii) if this co-regulator co-






In the male control GT, expression of Rwdd1 was non-significantly higher at an age 
during the MPW in comparison to ages before or after this time point (Fig 4.12).  
 
Figure 4.12 Quantitative analysis of Rwdd1 mRNA level in control male rat GT at e14.5, 
e17.5 and e21.5. No significance was found using a one way ANOVA. Values are means 
±SEM for 6 animals/group from a minimum of 3 litters. Pink shading depicts sampling age 
that lies within the MPW.   
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Immunohistochemistry was used to investigate if RWDD1 was present at the protein 
level in the GT and if it might be expressed in the same cells as AR. RWDD1 was found 
to co-localise with AR in most cell types that expressed AR in the developing GT 
whereas co-expression was more restricted in the diff rentiated PND25 penis. In the 
female GT at e19.5 there was still substantial co-expression of RWDD1 and AR, but this 
was more restricted than in the male GT at 17.5 and e21.5 (Fig 4.13). As the co-
localisation of RWDD1 and AR in the male GT and penis was rather striking, it was of 
Figure 4.13 Representative photomicrographs of RWDD1 expression (red) and AR expression 
(green) in control male GT at e17.5 (A) female GT at e19.5 (B) male GT at e21.5 (C) and PND25 
penis (D). Note the widespread co-localization of AR and Rwdd1 (yellow) in the developing GT and 
the more restricted co-localization at PND25. Arrows indicate the urethral area and o=os penis. 
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interest to determine the effect of blocking androgen action using flutamide on Rwdd1 
expression.  
 





To determine if perhaps Rwdd1 might be androgen regulated in the GT as it is suggested 
to be in the thymus, Rwdd1 mRNA expression was determined in GT from vehicle and
flutamide exposed fetuses during the MPW. A significant decrease in Rwdd1 expression 
was found in e17.5 GT from flutamide exposed males compared with controls (Fig 
4.14).  
 
Figure 4.14 Effect of flutamide exposure in the MPW on Rwdd1 mRNA level in e17.5 male GT. 
Using a unpaired, two tailed t-test *P<0.05 in comparison with respective control. Values are 
means ±SEM for 9 animals/group from a minimum of 2 litters. 
Figure 4.15 Representative photomicrographs of RWDD1 expression (red) and AR expression (green) 
in the male GT at e21.5 after exposure in the MPW to vehicle (A) or flutamide (B and C). Note that 
whilst flutamide exposure does not affect AR expression, it profoundly inhibits RWDD1 expression so 
that there is minimal co-localisation (yellow). Arrows show the urethral area whilst asterisks indicate 
the corpora cavernosa and o=os penis. Scale bar represent 200µm.  





* * * * * 
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Immunohistochemistry was used to determine if the significant difference seen in Rwdd1 
mRNA expression in GT from control and flutamide exposed fetuses (Fig 4.14) was 
reflected at the protein level. As it was not possible to obtain representative and 
comparable e17.5 GT sections to do this, e21.5 GT sections were used. RWDD1 protein 
expression was profoundly reduced in e21.5 GT obtained from fetuses that had been 
exposed to flutamide during the MPW. This was found for four different fetuses from 2 
different litters, although the degree of protein suppression was somewhat variably 
affected (Fig 4.15).  
 
RWDD1 expression in the testis 
 
Figure 4.16 Representative photomicrographs of RWDD1 expression (red) and AR expression 
(green) in control rat testes at e21.5 (B) PND10 (C) and PND25 (D). Negative control can be 
seen in panel A with no Rwdd1 antibody. Co-localization is indicated by arrows and was 
pronounced in Sertoli cells at Pnd10-25 (absent at e21.5) and in some interstitial cells at all 
ages. Scale bar represents 200µm.  
A B 
C D 
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The expression of RWDD1 in the testis has never been reported and given the 
interesting results reported in Fig 4.15, RWDD1 expr ssion was investigated in the 
testis. Nuclear RWDD1 was found to be present in the testis at e21.5, PND10 and 
PND25 (Fig. 4.16). At e21.5, RWDD1 was expressed in peritubular myoid cells and 
cells within the interstitium and in all of these clls it co-localised with AR. At PND10, 
co-localization of RWDD1 with AR was found in SC and co-localisation was also still 
evident in peritubular myoid and some interstitial ce ls, and this pattern was maintained 
and became even clearer by PND25 (Fig. 4.16). At PND10 and PND25, Rwdd1 
expression was also apparent in most germ cells, although it is unclear whether or not 
this is specific. Unfortunately further studies of RWDD1 protein expression were not 
possible because subsequent batches of the antibody obtained from the supplier no 
longer worked. This also meant that more definitive studies on the GT, and of flutamide 
effects, were not feasible at the protein level.  
 
4.3.5 BORIS expression in the male reproductive tract 
In the context of investigating regulation of the MPW, one possibility which merited 
investigation was methylation enzymes. Preliminary studies were carried out on a 
methylation regulator, DNMT3L and a methylation marker, BORIS. Both methylation 
associates were investigated initially using Taqman-PCR followed by 
immunohistochemistry.  
 
 Figure 4.17 Quantitative analysis of Boris mRNA level in the male GT at different fetal ages 
(A) and after vehicle or flutamide exposure in the MPW (B).Using a one way ANOVA * 
P<0.05 in comparison with e14.5 GT. Values are means ±SEM for 3-6 animals/group from a 
minimum of 2 litters. Pink shading indicates sampling ages that lie within the MPW. 
A B 
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Boris mRNA expression in the male control GT was found to be highest prior to the 
MPW at e14.5, was marginally lower during the MPW at e17.5 and then decreased 
significantly by e21.5 (Fig. 4.17 A). Taqman-PCR was used to determine if blocking 
androgen action in fetuses by exposure to flutamide would affect Boris expression. The 
GT of these fetuses had a lower expression of Boris in comparison to control male GT at 








Immunohistochemistry was used to determine if the (non-significant) decrease in BORIS 
mRNA expression in GT from flutamide-exposed fetuses was incidental or whether it 
was also seen at the protein level. At e21.5, in the male GT, BORIS protein expression 
did appear to be less extensively expressed and there appeared to be larger areas in 
which AR was expressed without coincident BORIS expr ssion, as found in the GT 
control. However, this is at best a tentative conclusion.  
Figure 4.18 Representative photomicrographs of BORIS expression (red) and AR 
expression (green) in control male GT at e21.5 (A) and in a GT from a flutamide exposed 
fetus (B). Note that although considerable co-localization occurs (yellow), parting some 
areas AR and BORIS expression appear not to coincide. Scale bar represent 200µm. 
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Using immunohistochemistry, BORIS was detected at e21.5 in control male testis, in the 
SC, GC, interstitial cells and PTM cells and some co-localisation with AR could be seen 
in he PTM and interstitial cells (Fig. 4.19). Nuclear BORIS expression was detected in 
Figure 4.19 Representative photomicrographs of BORIS expression (red) and AR expression 
(green) in control male testis at e21.5 (B) PND4 (C) and PND25(D). BORIS expression is absent 
or minimal at e21.5 but is expressed in the SC at PND4 but not in the interstitial cells. At PND25, 
expression of BORIS can be seen in SC, some germ cells, PTM cells and cells of the 
interstitium. Co-localisation of AR and BORIS (yellow; arrows) was evident in peritubular cells, 
some Sertoli cells and some interstitial cells. Scale bars represent 200µm. The negative control 
for BORIS antibody is shown in panel A 
C D 
B A 
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PND4 testis in the SC and in some GC and some cells of the interstitium. By PND25, 
BORIS was clearly expressed in the interstitium, also co-localised with AR in the SCs as 
well as in the PTM cells.  
 
4.3.6 DNMT3L expression in the male reproductive tract 
DNMT3L is a more recently discovered methylation enzyme and some preliminary 
studies have reported it may be involved in AR methylation and was therefore a strong 
candidate for present investigation. Dnmt3l message expression was investigated using 







Fiure 4.20 Quantitative analysis of Dnmt3l mRNA levels in male GT. No significant differences 
were found using a one way ANOVA. Values are means ±SEM for 4-6 animals/group from a 
minimum of 2 litters. Pink shading shows sampling age within the MPW. 
Figure 4.21 Quantitative analysis of Dnmt3l mRNA levels in GT from vehicle (control) and 
flutamide exposed fetuses. Using a one way ANOVA *P<0.005, ***P<0.0001 in comparison with 
respective control. GT. Values are means ±SEM for 5 animals/group from a minimum of 2 litters. 
Pink shading shows sampling age within the MPW. 
Chapter 4   Androgen Receptor & methylation co-regulators 
 
Page | 164 
Similar to Boris expression (Fig 4.17), Dnmt3l expression in the normal male GT 
decreased through fetal development with expression being highest at e14.5 and lower at 
e17.5 and e21.5, although these differences were not significant, probably because of the 
low N number. To determine if blocking androgen action in the MPW affected Dnmt3l 
expression, GT from animals exposed to flutamide during the MPW were compared 
with age matched vehicle-exposed animals. During the MPW, at e16.5 and e17.5, there 
was a statistically significant decrease in Dnmt3l mRNA expression in GT from 
flutamide exposed males in comparison to respective ontrol GT. This decrease was not 
evident after the MPW at e21.5 (Fig. 4.21). Interprtation of this flutamide effect is 
difficult, not least because the direction of effect is opposite from what might be 
deduced from the age related change in Dnmt3l expression (Fig. 4.20). In the latter 
situation, Dnmt3l expression is lower in the MPW than beforehand, so if this lowering is 
androgen-regulated, then blockade of this by flutamide should increase DNMT3L 
expression in the GT during the MPW, but the opposite was found. On balance, this 
perhaps makes it more likely that the non-significant but higher expression of DNMT3L 
at e14.5 is not accurate, and in this regard it is noteworthy that values for DNMT3L 
mRNA expression at this age were extremely variable.  
 
 Figure 4.22 Representative photomicrographs of DNMT3L expression (red) and AR 
expression (green) in male GT at e21.5 exposed during the MPW to vehicle (A) or flutamide 
(B). Scale bars represent 200µm. O=Os penis; the uretheral area is indicated by an arrow and 
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Using immunohistochemistry, DNMT3L protein expression was investigated in the male 
GT at e21.5. At e21.5, in the control male GT, DNMT3L was found  to be expressed in 
most cells types and co-localised with AR, in addition, DNMT3L was also found in the 
cells in which AR are not expressed, mainly the corpus cavernousum and blood vessels. 
Taqman-PCR results suggested that DNMT3L expression decreases in flutamide 
exposed GT in comparison to control GT but only at e16.5 and e17.5. Unfortunately it 
was not possible to determine the DNMT3L protein expr ssion at these ages, however in 
the e21.5 GT of fetuses exposed to flutamide, DNMT3L protein expression was found in 
the cells around the urethra and in the blood vessels and expression was not markedly 
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DNMT3L protein expression was investigated in the testis. DNTM3L co-localised with 
AR in peritubular myoid cells and some interstitial cells in e21.5 control testes. Some 
non-specific staining could be seen in the seminiferous tubules at this age and also at 
PND4. However in PND4 testes DNMT3L expression in peritubular myoid cells and 
interstitial cells was less prominent than at e21.5, although there was still co-localisation 
Figure 4.23 Representative photomicrographs of DNMT3L expression (red) and AR 
expression (green) in control testis at e21.5 (A, B) PND4 (C) and PND25 (D). The arrows 
indicate co-localisation of AR and DNMT3L. A shows a negative control illustrating absence 
of DNMT3L antibody. Note that DNMT3L is expressed in peritubular myoid and some 
interstitial cells at e21.5 where it co-localizes with AR. A similar picture was evident at 
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with AR. At PND25, DNMT3L co-localised with AR in the SCs, peritubular myoid and 
some interstitial cells and stage specific DNMT3L expression was also evident in some 
GCs.  
 
The protein expression patterns of BORIS and DNMT3L in the testis called for further 
investigation. It was of importance to determine if d srupting androgen action by 
flutamide, DBP or DES in the testes affected DNMT3L expression, however both of 
these antibodies ran out around the same time. Upon re- rdering, it was not possible to 
get the DNMT3L antibody originally used (rabbit polyclonal) and a chicken polyclonal 
was ordered as this was the only one available. This antibody had been used to detect 
protein by western blotting and not imuunohistochemistry and despite attempts on the 
bench and on the bond machine, the chicken polyclonal DNMT3L antibody would not 
work on the rat testis using immunohistochemistry. Although the BORIS antibody 
ordered was of the same specificity as the previous, it also did not work well.  Whilst 
writing this thesis, the rabbit monoclonal antibody for DNMT3L from Abcam has 
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The tables below summarize the cell types in the testis within which the 3 androgen co-
regulators and 2 methylation regulators were found. Highlighted cells outline when and 











Table 4.3 Summary of 3 co-regulator and 2 methylation regulator protein expression in cells types 
of the testis, found by immunohistochemistry. Co-localisation with AR highlighted in green 
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4.4 Discussion 
The studies in this chapter aimed to investigate a range of factors that might potentially 
modulate androgen action during the MPW or be modulated by androgens during the 
MPW. The starting point to narrow down the vast number of androgen biochemical 
associates reported was to use bioinformatics software; Genego. This identified gene 
expression pathways involved with AR. These pathways were compared to the results of 
the microarray study done by our group, (see section 6.1). Six androgen co-regulators 
were found to overlap between pathways identified using Genego and genes identified in 
the microarray namely; Brg1, Cbp, Fkbp5, Snurf, Transgelin and Vav3. The expression 
of each of these co-regulators was investigated using Taqman-RT-PCR in the genital 
area of fetuses from e11.5-e21.5. The mRNA expression patterns of Cbp and Brg1 were 
interesting and both were found to be decreased in expression during the MPW. 
Furthermore, it is well established that these two co-regulators can work in conjunction 
(Direnzo et al, 2000; Naidu et al, 2009). It was surprising that neither BRG1 nor CBP 
had been characterized in the male GT or in the testis before and consequently both were 
investigated using immunohistochemistry.  
 
Both BRG1 and CBP were found to be expressed in the genital tubercle. Due to 
difficulties in gaining the correct orientation of GT at e17.5 and younger ages, it was not 
possible to detect with certainty if protein levels of BRG1 and CBP were decreased 
during the MPW, in comparison to before and after the MPW as suggested by the 
Taqman RT-PCR results. However, in the e21.5 GT, it was clear that BRG1 and CBP 
were expressed but did not co-localise with AR. Both f these co-regulators were found 
to be expressed in the blood vessels, corpus cavernosum and urothelial cells. In the 
testis, both BRG1 and CBP were expressed in interstitial cells throughout development 
from e21.5 to PND25, it is interesting that BRG1 was found to be expressed in a 
population of cells of the interstitium which do not express AR and no co-localisation 
was found between AR and BRG1 in the interstitial cel s at any age. In contrast, CBP 
was found to be in cells of the interstitium which do express AR and co-localisation 
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between CBP and AR was found in the interstitial cells of the testis throughout 
development at e21.5, PND4 and PND25. The investigations of the co-expression of 
BRG1 and CBP demonstrates that CBP and BRG1 are co-localised in some cells of the 
interstitium, thus there is a population of cells in the testis which express CBP and AR 
and not BRG1 and there is separate population of interstitial cells which express CBP 
and BRG1 but not AR. Further studies could use immuohistichemistry to determine 
what these populations are, for example fetal Leydig cells or progenitor adult Leydig 
cells. Both BRG1 and CBP were found to be expressed in the SC and co-localised with 
AR when AR was switched on at by PND10. Although the co-localisation of CBP with 
AR was much clearer than BRG1 with AR. Both CBP and BRG1 were found to be 
expressed in the GCs at all ages investigated. It has been reported that both BRG1 and 
CBP knockout models are embryonic lethal, however some studies have conducted 
targeted knockouts to determine role of each of these in a particular tissue type, for 
example, BRG1 was knocked out of the lung and this potentiated lung cancer (Glaros et 
al, 2008). A targeted knockout of either CBP or BRG1 in the testis might provide some 
very interesting answers as to roles these proteins may play in the SC and GCs. Another 
useful study would be to determine the exact stages of spermatogenesis which correlates 
with CBP and BRG1 expression. Exposure to DES, DBP or flutamide during the MPW 
did not affect the expression of BRG1 or CBP et e21.5 or at PND25 but further 
experiments on flutamide exposed GT and also characterization with the female 
reproductive tract are called for to determine if BRG1 or CBP might be androgen 
regulated.  
 
In the GT and testis, RWDD1 was found to co-localise with AR. Furthermore a 
significant decrease in Rwdd1 expression was found at the mRNA and protein level in 
GT from animals which had been exposed to flutamide during the MPW and 
consequently had disrupted androgen action. Many further studies need to be conducted 
to determine if RWDD1 is androgen regulated throughout the development of the GT, 
for example looking at younger ages. Also the effect of other anti-androgenic chemicals 
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as well as oestrogens on the expression of RWDD1 should be investigated. In addition, 
RWDD1 should be characterized in the ducts, in the testis and also within the female 
reproductive tract to determine if RWDD1 is specific to the male GT and reproductive 
tract. It would also be interesting to investigate RWDD1 expression in the tissue of AR 
knock out mice. No knockout of RWDD1 has yet been rpo ted. In the testis, RWDD1 
was found to co-localise with AR in some interstitial cells as well as the PTM cells at all 
ages investigated. Of interest also was that RWDD1 could not be seen in the e21.5 SC 
but was found in the postnatal period at PND4 and PND25, co-localizing with AR, once 
it has switched on. Although some staining was seen in the GC it was non-specific.  To 
the best of my knowledge these are the first reporting’s of RWDD1 in the GT and in the 
testis and these findings show that RWDD1 is expressed, in the tissue investigated at 
least, in all cell types that express AR. Furthermore, the effect of flutamide exposure on 
RWDD1 expression in the GT calls for urgent further experiments. As mentioned above, 
these should start with full characterization in the male and female reproductive tract and 
then compare with various androgen disrupting treatm n s.  
 
It is widely accepted that methylation is vital in embryonic development (Shoeck et al, 
2011; Woroniecki et al, 2011) and some methyl transfera e enzymes are known to be 
involved in AR gene regulation (Gaughan et al, 2010; Metzger et al, 2005) (Section 
1.7.2). For example some studies have shown that hypermethylation of AR can occur in 
prostate cancer (Jarrad et al, 1998; Kinoshita et al, 2000) and a more recent study has 
shown that in hypospadias patients, the penile foreskin has decreased expression of AR 
and increased expression of DNMT3A (a key methylation enzyme) in comparison to 
control patients, suggesting that hypermethylation of the AR maybe involved in 
hypospadias (Vottero et al, 2011). Although altered methylation of specific genes could 
provide an explanation for aspects of the MPW (e.g. silencing after the MPW of genes 
that are androgen-regulated within the MPW), this fir t requires identification of genes 
that are androgen-regulated in the MPW (see chapter 6). In the absence of such 
information, the approach taken was to investigate wh ther expression of genes involved 
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in methylation regulation might either change during the MPW or be androgen-regulated 
during this period. BORIS and DNMT3L (indicators ofmethylation activity) were 
chosen for study initially, with the aim to possibly study further the expression of other 
DNMT enzymes at a later stage.  
 
CTCF is well established in the literature as an 11-zinc finger protein involved in gene 
regulation and forms methylation sensitive insulators which regulate X-chromosome 
inactivation and expression of imprinted genes (Loukinov et al, 2002). CTCF is 
expressed in the nucleus of most somatic cells. BORIS shares a similar structure to 
CTCF but has been defined in the literature as testis specific because it has been found 
in the cytoplasm of spermatocytes (Loukinov et al, 2002). BORIS expression is thought 
to be negatively regulated by DNA methylation, p53 and CTCF (Renaud et al, 2007). 
Considering BORIS expression is thought to be negatively regulated by methylation in 
the testis, and in addition BORIS expression has never been reported in the GT, this was 
investigated in this chapter. These studies found that BORIS is expressed in the GT at 
both the mRNA and protein level. Taqman-PCR results suggested that Boris expression 
decreases in the developing GT and a significant decrease was seen after the MPW at 
e21.5 in comparison to before the MPW at e14.5. Unfortunately, due to tissue 
orientation issue, it was not possible to determine if this change in expression of Boris 
was true at the protein level, however immunohistochemistry did show that the BORIS 
protein is expressed in the GT at e21.5 in the urothelial cells, the os penis, the corpus 
caversoum and the blood vessel, this expression was similar in the GT of male fetuses 
that had been exposed to flutamide during the MPW. In the testis, BORIS was found to 
be expressed in the interstitial cell, the SCs, the GCs and the PTM, although expression 
was not found in the latter at PND4. Furthermore, expr ssion of BORIS in the GC (at 
the three ages investigated) was non-specific and some literature does state that BORIS 
expression in the GC is cytoplasmic and not nuclear. BORIS is classified at a cancer 
testis antigen (CTA) because its expression is found in human neoplasma and not in 
normal tissue other than the testis (Villella et al, 2005). The studies in this chapter 
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however have found BORIS to be expressed in the GT and also in other cell types other 
than the GC in the testis, namely SC and cells in the interstitium. These studies however 
are preliminary and require strengthening by further experiments, which would firstly 
include determining BORIS expression before and during the MPW as well as after the 
MPW. Also it would be useful to use immunohistochemistry and markers of various 
cells types to characterize which population of cells in the interstitium BORIS is 
expressed in. Recently, the outcomes of a BORIS knockout mouse model were reported 
(Suzuki et al, 2010). These studies reported that BORIS knock out mice were fertile, but 
had small testis in comparison to controls and alsohad defects in spermatogenesis. This 
study investigated the changes in expression of certain genes in the testis of BORIS 
knockout models but there was no characterization of BORIS expression in the cell 
types of control testis other than GCs, and this is important to understand why a 
deficiency in BORIS expression might affect spermatogenesis.  
 
DNMT3L is a member of the DNMT family of enzymes involved in methylation. 
DNMT3L has no methyl transferase catalytic site but is thought to regulate methylation 
through histone deactylase activity. DNMT3L knock out mice have severe 
hypogonadism and are azoospermic, however this study did not report if any effect was 
seen in the penis, for example, hypospadias.  The studie  in this chapter found Dnmt3l 
mRNA was expressed in the GT before, during and after the MPW and although no 
significant difference in expression was found, the results suggest a possible decrease in 
Dnmt3l expression as the GT develops. A significant decrease in Dnmt3l expression was 
seen in the GT of fetuses exposed to flutamide at e16.5 and e17.6 (both time points fall 
in the MPW). At the protein level, DNMT3L was found to be expressed in the GT at 
e21.5 in control males and the GT of males exposed to flutamide during the MPW and 
although staining of DNMT3L looked less pronounced in the GT of flutamide exposed 
fetuses, this was not quantified. In the testis, DNMT3L was expressed in some cells in 
the interstitium and the PTM cells at e21.5 and co-lo alised with AR in these cells. 
DNMT3L was not found to be expressed in SC until PND25 and at this age, DNMT3L 
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and AR co-localised. Interestingly DNMT3L was only found to be expressed in the GCs 
in the postnatal period at PND4 and PND25, the expression of DNMT3L appears to be 
stage specific. The characterization of DNMT3L in relation to AR in the testis has not 
been previously reported and given the phenotype of the DNMT3L knockout model, this 
information is important to understand the mechanisms by which DNMT3L works in the 
testis. The DNMT3L results reported in this chapter are very preliminary and require 
further investigation; firstly within the developing control male reproductive tract and 
female reproductive tract, but also further studies are called for on the effect of flutamide 
on DNMT3L protein expression in the GT before and during the MPW.  
 
This requirement for GT tissue before and during the MPW is not just restricted to the 
further experiments called for in DNMT3L protein expression investigation, but also for 
the other 4 androgen biochemical associates investigated in this chapter. The lack of 
protein expression data in the GT before and during the MPW is the major weakness of 
the studies reported in this chapter and this issue hould be resolved to investigate the 3 
androgen co-regulators and 2 methylation regulators in correlation to the regulation of 
the MPW.  
 
In these studies, the testis provided a method to investigate the expression of the 5 
regulators in relation to well documented AR expression. Each of the 5 regulators was 
found to co-localize with AR in the SC by the time AR expression was fully switched on 
at PND25 and the importance of this co-localization requires further investigation. One 
of the major set-backs with the studies in this chapter was that when 3 working 
antibodies were replaced, namely Rwdd1, BORIS and DNMT3L, frustratingly, it was 
not possible to determine if disrupting androgen action would affect expression of these 
regulators in the testis at various ages, which is important information particularly as 
RWDD1 expression appears to be an androgen regulated in the GT and DNMT3L 
knockout mice are azoospermic.  
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In conclusion, the mRNA expression of 9 genes was investigated before, during and 
after the MPW and, each 5 of these displayed interes ing patterns of expression during 
the MPW in the GT. It could not be verified at this stage, if these patterns of expression, 
during the MPW, were reflected at the protein level. The approach taken therefore was 
to  investigate expression of these proteins in relation to AR expression, with emphasis 
on studies in situations of dynamic changes in AR expr ssion and or androgen action, 
namely in the fetal to postnatal testis transition and in the GT and testis from animals 
exposed to the AR antagonist, flutamide, in the MPW. hilst these studies have not 
clearly resolved the involvement of the AR biochemical associates in the MPW, they 
have raised a number of interesting findings and questions. For example, the differential 
co-expression of BRG1 and CBP with AR in interstitial cells versus SC in the 
developing testis suggests that different co-activators may be used by these cell types 
and or that androgen action is fundamentally different. Further studies in this area are 
likely to provide useful new insights into the role(s) and regulation of androgen action 
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5.1 Introduction 
Prostaglandins (PGs) are involved in many different systems of the developing embryo. 
There is conflicting data about the effects of blocking PGs using indomethacin, a COX 
enzyme inhibitor, in utero and this is reviewed in sections 1.3.1.4.1 and 1.4.3. The 
conflict mainly arises from differences in species used, doses administered, route of 
administration and treatment time in gestation. Nonetheless, there is substantial evidence 
that prostaglandins are important in the production of testosterone (Kubota et al, 2011; 
Sawada et al, 1998; Wang et al, 2003) and some studie  suggest that obstructing PG 
pathways using indomethacin can affect masculinisation of the male mouse embryo 
(Gupta and Goldman, 1986; Gupta, 1989; Gupta and Betlekewski, 1992). This suggests 
that correct androgen action may be related to corre t PG action. However these studies, 
which were conducted in the late 1980’s, have never be n repeated or built on despite 
the important finding that PGs may be vital in androgen action. 
 
The main aim of the studies in this chapter was to determine if PGs are essential for 
androgen action in the MPW and for consequent male reproductive tract programming 
which occurs during this time, in the rat. This was investigated by using indomethacin to 
block PG synthesis during the MPW and to examine the outcomes in fetuses, neonates, 
pubertal animals and adult animals. 
 
One of the aims of these thesis studies is to gain insight into factors which may be 
involved in the ‘opening’ of the MPW. To determine if PGs are involved in this 
regulation and also to understand if PGs are essential prior to the MPW for later 
masculinisation, indomethacin was administered to some animals prior to the MPW 
from e11.5- e14.5 (the early window, EW) and endpoints noted in fetal, pubertal and 
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5.2 Materials and Methods 
5.2.1 Animals and treatments 
Briefly, pregnant rats were treated with indomethacin or appropriate vehicle during the 
MPW (e15.5-e18.5) or during the EW (e11.5-e14.5) (section 2.2). Initially 8 animals 
were treated with 2mg/kg indomethacin by oral gavage during the MPW. However, 
these dams became extremely ill with a 75% mortality ra e, see Table 5.1. Therefore a 
further 6 animals were treated with 1mg/kg of indomethacin, administered using 
subcutaneous injection, during the MPW. Although there were still some complications, 
sufficient data was collected to address the study aims. A further 4 litters were exposed 
in the EW to indomethacin with less complications. AGD and bodyweight was measured 
in male and female pups at e21.5 prior to the GT, gonads and ducts being dissected, in 
animals treated in the MPW or in the EW. Postnatal measurements were taken at PND8 
(MPW exposed animals only), PND25 and PND75 (section 2.3.3). Collected tissue was 
fixed in Bouins and processed for possible immunohist chemical analysis.  
 
GT were also dissected and collected from control fetuses at e14.5, e16.5, e17.5 and 
e21.5 and frozen at -80°C for RNA analysis (section 2.6) to determine if the COX1 and 
COX2 enzymes necessary to make PGs are present in the GT and if this expression 
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Table 5.1 Details of litters, treatment windows, doses and complications of indomethacin 
exposure in animal experiments in chapter 5 





17 EW / 1mg/kg Subcutaneous Injection 21 PND25 & 75
18 EW / 1mg/kg Subcutaneous Injection 21 PND25 & 75
15 EW / 1mg/kg Subcutaneous Injection 21 Culled at e21.5
16 EW / 1mg/kg Subcutaneous Injection 21 Culled at e21.5
13 MPW / 1mg/kg Subcutaneous Injection 21 PND8, 25 & 75
14 MPW / 1mg/kg Subcutaneous Injection 25 culled due to no birth
11 MPW / 1mg/kg Subcutaneous Injection 24 Culled due to no birth
12 MPW / 1mg/kg Subcutaneous Injection 22 PND8, 25 & 75
9 MPW / 1mg/kg Subcutaneous Injection 21 culled at e21. only 4 pups
10 MPW / 1mg/kg Subcutaneous Injection 21 PND8, 25 & 75
7 MPW / 2mg/kg Gavage 21 Found dead
8 MPW / 2mg/kg Gavage 21 Found dead
5 MPW / 2mg/kg Gavage 19 Found dead
6 MPW / 2mg/kg Gavage 20 Found dead
3 MPW / 2mg/kg Gavage 20 Found dead
4 MPW / 2mg/kg Gavage 19 culled at e19.5
1 MPW / 2mg/kg Gavage 21.5 Culled at e21.5
2 MPW / 2mg/kg Gavage 20 Found dead
 
5.2.2 RNA analysis: 
The mRNA level of COX enzymes in control male GT was investigated using Taqman 
(section 2.6). Briefly, RNA was isolated from frozen tissue and converted into cDNA 
and quantitative RT-PCR performed. Expression was studied before during and after the 
MPW. The genes investigated and primers used are listed n Table 5.2.  
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Table 5.2 Taqman primers and Universal probe library probes used in chapter 5 




GCT CTT CAA GGA TGG GAA 
ACT
TTC TAC GGA AGG TGG GTA 
CAA 42
COX2 CTA CAC CAG GGC CCT TCC
TCC AGA ACT TCT TTT GAA 
TCA AGG 5
 
5.2.3 Immunohistochemical (IHC) investigations 
Briefly, IHC staining (section 2.5.1) was performed on processed and sectioned fetal 
GT, gonads and ducts to determine the presence of the COX2 protein.  
Table 5.3 Details of COX2 antibody used in Chapter 5 
Primary Antibody Source Retrieval Species Dilution
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5.3 Results 
5.3.1 Expression of COX enzymes 
To determine if the COX enzymes are present in the male GT, COX mRNA levels were 
investigated in the developing GT using Taqman (Fig. 5.1) and the COX2 protein 




Similar to findings in the literature, relative mRNA COX1 was expressed at a much 
lower level in the male GT than relative COX2 mRNA. The relative mRNA of each 
enzyme showed a similar pattern, with consistent levels of expression throughout 
development from e14.5 until just before parturition when levels were found to be 




Figure.5.1 Quantitative analysis of COX1 (A) and COX2 (B) mRNA levels in the developing 
male GT.  Using one way ANOVA*** P<0.0001, in comparison to each younger age. Values are 
means ±SEM for 7-14 animals/group from a minimum of 3 litters. 
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The fetal GT at e17.5 was difficult to embed in a consistent orientation. IHC could not 
be conducted on an e17.5 male GT which would be of a precise plane within the tissue 







COX2 IHC staining was positive at e17.5 and e21.5 in the male GT. The exact location 
could not be identified at e17.5, but suggested greate  COX2 expression around the tip 
of the GT. At e21.5 the COX2 protein was nuclear and was expressed in the OS penis, 
the urothelial cells and around the blood vessels (Fig 5.2).  
 
5.3.2 Effect of indomethacin administration during the MPW 
Initially 8 animals were treated with 2mk/kg of indomethacin by gavage during the 
MPW to block PG synthesis. Due to complications with the mothers, these fetuses were 
not used for these studies. All animals thereafter w re treated with 1mg/kg of 

















Figure 5.2 Representative photomicrographs of COX2 staining (brown) in the control male 
GT at e17.5 (A) and e21.5 (B). An e21.5 negative control is shown in panel C. T = the tip of 
the GT, U = urothelial cells, O = os penis, CC = corpus cavernosum.  
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5.3.3 Effect of Indomethacin exposure on number of pups per litter 
Some literature reports that exposure to indomethacin causes an increased rate of 
resorption of pups (O’Grady et al, 1972;). In order to determine if this was true in rats 


















Using an unpaired T-test, no significant difference was found in the number of pups per 
litter between vehicle exposed and indomethacin exposed animals. However Fig 5.3 
shows a large degree of variability in the number of pups per litter from animals treated 
with indomethacin with some evidence of a decrease in two litters, so it is possible that 










Figure 5.3 Number of pups per litter in vehicle exposed and indomethacin exposed animals 
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5.3.4 Effects of indomethacin exposure on males 
To identify if exposing animals to indomethacin during the MPW was affecting 
androgen action, Bodyweight, AGD and testis weight were measured at e21.5, PND8, 







A significant reduction in bodyweight was found at e21.5 in males exposed to 
indomethacin. However by adulthood, there was a significant increase in bodyweight of 
indomethacin exposed males in comparison to respective ontrols. These opposite 
results could be due to the rather small numbers of litters or animals and or a high 
variability of bodyweight at any age. However, the results for females in Fig.5.10 
suggest that in utero indomethacin exposure does decrease bodyweight in the fetal 
period. This is discussed in more detail in section 5.4.  
Figure 5.4 Control male body weight compared with animals exposed to 1mg/kg indomethacin 
during the MPW. *** P<0.0001. Values are means ±SEM for 6-11 animals/group from a minimum 
of 2 litters. 
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There was no significant difference in the AGD of males exposed to indomethacin 
compared with respective control males. This was true in the fetal period at e21.5, in the 
neonatal period at PND8, at puberty (PND25) and in adult animals.  
To determine if indomethacin treatment during the MPW affected the testis, animals 
were examined for cryptorchidism at PND25 and adulthood. Testes were dissected, their 
weight measured and their gross cellular composition investigated. No cryptorchidism 
was found in any animals exposed to indomethacin or vehicle.  
 
Figure 5.5 AGD at different ages in control males compared against males exposed to 1mg/kg of 
indomethacin during the MPW. Values are means ±SEM for 6-11 animals/group from a minimum of 
2 litters at each age.  
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Testis weights were not significantly different betw en control animals and animals 
exposed to indomethacin in either fetal or postnatal life (Fig 5.6). In order to determine 
if there was any gross difference in cellular compositi n, testes were immunostained 






However, no gross difference in apparent germ cell numbers or distribution was found 
when comparing control animals with animals exposed to indomethacin, although germ 
cell numbers were not counted using stereology.  
A B 
Figure 5.7 Representative photomicrographs showing immunostaining for VASA (brown) in e21.5 testis 
from a control (A) and an indomethacin exposed (B) animal. 
 
Figure 5.6 Testis weights of control animals compared to animals exposed to 1mg/kg 
indomethacin during the MPW. Values are means ±SEM for 6-11 animals/group from a 
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The postnatal penis was examined for the presence of hypospadias, and its length and 
weight measured. No hypospadias was found in any of the males exposed to 














No significant difference was found in the penis length of animals exposed to 
indomethacin in comparison to control animals at PND8 and PND25. However, by 
adulthood a significant decrease in penile length was seen in animals that were exposed 











Figure 5.8 Penis length in rats exposed to either vehicle or 1 mg/kg indomethacin during the 
MPW. Usng a one way ANOVA *** P<0.0001, in comparison with respective control. Values 
are means ±SEM for 4-9 animals/group from a minimum of 2 litters 
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5.3.5 Effects of indomethacin exposure on females 
To determine if blocking prostaglandins, using indomethacin affected the development 






Similar to results for e21.5 males, there was a small but significant decrease in 
bodyweight of females exposed to indomethacin at e21.5. No significant difference in 
bodyweight was seen at puberty or in adulthood (Fig5.9). 
Figure 5.9 Female bodyweight in rats whose mothers were treated with vehicle or 
indomethacin during the MPW. *** P<0.0001, in comparison with respective control. Values 
are means ±SEM for 3-14 animals/group from a minimum of 2 litters. 
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At e21.5 and PND25 there was no significant difference in AGD between control 
females and those exposed to indomethacin during the MPW (Fig 5.10). In adulthood, 
the AGD of indomethacin exposed females was significantly reduced in comparison to 
animals exposed to vehicle. 
Figure 5.10 AGD at different ages in control females compared with females exposed to 
1mg/kg of indomethacin during the MPW.  *** P<0.0001, in comparison with respective 
control. Values are means ±SEM for 3-14 animals/group from a minimum of 2 litters. 
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No significant difference was seen in the weight of ovaries of females exposed to 
indomethacin during the MPW in comparison to respectiv  controls. However, when 
dissecting the adult ovaries, it became evident that each female exposed to indomethacin 
in utero had a slightly different position of ovaries in comparison to control females. In 
control animals, the ovaries are usually found at the distal end of the uterine horns, near 
the kidneys, at the edge of the abdominal cavity. However in adult females exposed to 
indomethacin, the ovaries in each animal studied were present at the end of the distal 
end of the uterus but were more ‘centrally located’ in the abdomen, often with the uterus 
intertwined with other organs (Fig. 5.12). The weights (Fig 5.11) and gross apprearance 
of the ovaries appeared normal but the location within he body was not. In order to 
determine if these females were fertile, timed matings were set up using three adult 
animals. Of the three animals, one did not plug at all and the two which did gave birth 
Figure 5.11 Ovary weight of female rats exposed to either vehicle or 1mg/kg indomethacin  
during the MPW. Values are means ± SEM for 3-14 animals from a minimum of 2 litters.  
Using an un-paired t-test, no significant difference was found in ovary weight at PND25  
or at PND75 between control and indomethacin exposed females 
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late. The first of these had an extended gestation period of 1 day and gave birth at e23.5 






5.3.6 Effect of indomethacin exposure prior to the MPW 
To determine if PGs play a role in regulation of the MPW or are important in the 
opening of the MPW, pregnant dams were administered 1mg/kg indomethacin from 
e11.5-e14.5 and pups examined at either e21.5 or postnatally. As androgens are 
produced from e14.5 by the fetal testis, it was unlikely that blocking PGs prior to the 
MPW would have any androgen related effect in males, and so only 2 litters of 
indomethacin exposed animals were examined at each age in this set of experiments.   
 
Figure 5.12 Position of right ovary (circled) in control female adult (A) and indomethacin exposed 
female adult (B) 
A B 
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Only minor changes in AGD, PND25 testis and body weight were seen in animals 
exposed to indomethacin, however, none of these changes were significantly different 
Figure 5.13 Bodyweight (A), AGD  (B) and testis weight (C) of males whose mothers were 
treated with vehicle or 1mg/kg indomethacin during the EW. Values are means ±SEM for 2-6 
animals/group from 2 litters. Using un-paired t-tests, no significant differences were found 
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from controls and was based on small animal numbers. Nevertheless, the results suggest 




 Figure 5.14 Bodyweight (A), AGD (B) and ovary weight (C) in females whose mothers 
were treated with vehicle or 1mg/kg indomethacin during the EW. Values are means 
±SEM for 2-6 animals/group from 2 litters. Using un-paired t-tests no significant 
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5.4 Discussion 
The aim of the studies in this chapter was to determine if prostaglandins play a role in 
androgen programming of the male fetus which occurs d ing the MPW, and if blocking 
PGs during this time (e15.5-e18.5) would affect virilisation as suggested by studies in 
mice published in the 1980’s (Gupta and Goldman, 1986; Gupta, 1989; Gupta and 
Bentlekewski). A secondary aim was to determine if PGs might be involved in 
regulation of the MPW, in particular the ‘opening’ of the window. Thus, PG synthesis 
was blocked in a small number of animals, in the period prior to the MPW, namely 
e11.5-e14.5.  
 
The primary investigation in these studies set out t  determine if the enzymes required to 
make PGs were present in the GT. COX1 and COX2 are isoenzymes and each is 
expressed on different chromosomes in the human and also in the rat (Ogawa et al, 
2001; Taketa; 1998). COX1 and COX2 proteins have 60% homology and their structure 
can be divided into three domains; an N-terminal EGF domain, a membrane binding 
domain and a catalytic site, and the latter contains the cyclooxygenase active site 
(Kurumbail et al, 1996). The binding site in COX2 for NSAIDs is reported to be larger 
than the binding site in COX1. COX1 is present in most tissues to produce 
prostaglandins which are important in regulating cell function whereas COX2 in 
postnatal life is expressed mainly in response to acute inflammation (Kurumbail et al, 
1996). In fetal life however, COX2 is more highly expressed than COX1, particularly in 
the testis but also in the reproductive tract as a whole (Kirschenbaum et al, 1999; Schell 
et al, 2007). Fitting with the literature the studies reported in section 5.3.1 found COX1 
and COX2 to be expressed in the male GT, and COX2 was expressed at higher levels 
than COX1 (Fig.5.1). Protein immunohistochemistry demonstrated the COX2 protein is 
present at both e17.5 and e21.5 in the developing male GT, most abundantly at e21.5, 
suggesting that PG synthesis and action could be important in the male GT. This fitted in 
also with analysis of mRNA expression which showed much higher levels of COX2 
mRNA in the GT at e21.5 than at earlier fetal ages.  
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Indomethacin is well established as a compound which blocks the COX enzymes non-
selectively and this inhibits prostaglandin synthesis (Dannhardt and Kiefer, 2001). 
Indomethacin binds deep into the cyclooxygenase active site of both COX1 and COX2 
proteins.  
 
The literature on the fetal effects of indomethacin are conflicting, with variation in 
effects reported according to species, doses and timing of administration (section 
1.6.1.4.1 and section 1.7.3). In the late 1980’s Gupta reported that indomethacin at 
various doses affected masculinisation of male mice. Furthermore, it was reported that 
this effect was seen when PGs were inhibited during ‘the critical period for 
differentiation’, what we now term the MPW. Indomethacin was chosen as the choice of 
PG synthesis inhibitor for the experiments in this chapter in order to determine if the 
results reported by Gupta could be repeated in the rat.  
 
A number of studies have been conducted using indomethacin in rodents, with large 
differences reported in the dose administered whereby some studies used 1mg/kg 
whereas others used up to 20mg/kg. For example, when investigating the effect of 
indomethacin on implantation sites, one study administered 3mg/kg twice daily to rats 
and reported a 77% decrease in implantation sites (Poyser, 1999). In addition, it has been 
reported that pregnant rats treated with 5mg/kg indomethacin had similar effects and 
treatment with 10mg/kg caused severe gastrointestinal bleeding and animal death 
(Sookvanichsilp and Pulbutr, 2002). However both of these studies administered 
indomethacin early in gestation from gestational days 3-5. In contrast, Randall et al 
(1987) exposed mice to either 10mg/kg or 20mg/kg indomethacin by subcutaneous 
injection and (on gestational day 10 alone) and found a slight effect on fetal body weight 
but otherwise development was normal despite toxic effects found in the dams. Of 
interest, one study tried three different routes of indomethacin administration (oral, 
subcutaneous and intramuscular) to pregnant mice from days 9-15 of gestation, with a 
dose of 7.5mg/kg and reported no teratogenic effects (Kalter et al, 1973). However when 
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Kusangi et al administered the same dose (7.5mg/kg) to mice from days 7-15 of 
gestation, using oral gavage, fetuses were reported to have fused ribs, vertebral 
abnormalities and skeletal defects (Kusangi et al, 1971). In rabbits, 8mg/kg or 16mg/kg 
(per day) of indomethacin was administered from day of mating until birth and although 
these studies found an increased resorption of developing embryos, no defects were 
found in the surviving embryos (O’Grady et al, 1972). Thus, it appears that the effect of 
indomethacin on fetuses depends on the species used, the ose administered, the route of 
administration and also the length of exposure. However, even allowing for variation in 
these parameters it appears that there is a degree of inconsistency in results obtained. 
 
For the studies reported in this chapter, an initial dose of 2mg/kg was administered by 
oral gavage. This was chosen as an initial dose for the ats as it was twice as high as the 
dose administered by Gupta to the smaller mice, and according to the literature this was 
the higher of ‘low doses’ that have been used. Gavage was chosen as the method of 
administration to mimic the oral exposure route in humans. However, dams treated 
orally with 2mg/kg indomethacin became very ill and some had difficulty giving birth. 
Upon investigation, these dams had severe intra-gastric bleeding an accepted side affect 
of non-steroidal anti-inflammatory drugs such as indomethacin. It was decided to lower 
the dose to 1mg/kg and change the route of administration to subcutaneous injection. 
This also mimicked the dose and route used in most studies by Gupta in mice.  
 
The bodyweight of both male and female fetuses was reduced at e21.5 in animals 
exposed to indomethacin in comparison to respective controls. Conversely, the 
bodyweight of indomethacin exposed adult males was increased significantly in 
comparison to respective controls. In females however no significant difference was 
seen in bodyweight at any age after fetal life. This suggests that the litters exposed to 
indomethacin have a smaller body weight prenatally but this is corrected during 
development postnatally. Furthermore, the decrease in bodyweight seen at e21.5 was not 
associated with any other defect or disorder and, i particular, the reproductive tract of 
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the males was normally developed. It is well established in the literature that intrauterine 
growth restriction can result in compensatory overgrowth postnatally, especially in 
males, and consequently an increase in bodyweight/obesity in adulthood, so it is possible 
that this may have occurred also in indomethacin-exposed males (Desai et al, 2004).  
 
When animals were exposed to 1mg/kg of indomethacin during the MPW, there was 
very little effect on the development of the male reproductive tract. AGD was unaffected 
at any age, in comparison to control males. This suggests that androgen action was not 
disrupted during the MPW. Furthermore, testis weight at each age examined and 
apparent germ cell numbers at e21.5 were similar between treated and control animals, 
demonstrating that indomethacin exposure did not induce any gross effect on the testis 
prenatally or postnatally.  
 
Male penis length at PND8 and PND25 was unaffected by indomethacin exposure in the 
MPW, however, by adulthood there was a significant decrease in penis length in animals 
exposed to indomethacin. This is an odd finding as penis length is determined during the 
MPW and to reach the programmed length, requires postnatal testosterone action, 
including during puberty (Boas et al, 2006; Van den Driesche et al, 2011). The lack of 
difference seen at PND8 and PND25 compared to the difference in adulthood suggests 
there may have been a deficit in testosterone during later puberty as the AGD results 
suggest that androgen action in the MPW was not affected (Foster and Harris, 2005; 
Welsh et al, 2008; Macleod et al, 2010). However, it should be noted that only 4 animals 
from 2 litters were examined in this group and perhaps future studies with an increase in 
animal number may alter these findings, although the reduction in penile length noted 
here was not trivial.  
 
Indomethacin exposure during the MPW had small but significant effects in adult 
females although, as these were based on small animal umbers, it is unclear if they are 
real or incidental effects. Although no difference was observed in the AGD of control 
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versus exposed female animals, at e21.5 or at PND25 there was a significant decrease in 
AGD in indomethacin-exposed females in adulthood in comparison to respective 
controls. This finding is unexplained and may simply reflect low animal numbers. The 
one finding that seems to represent a real effect was the mal-positioning of ovaries in 
indomethacin exposed females in adulthood. What determines ovarian position, other 
than their site of origin and their attachment to the abdominal wall via the cranial 
suspensory ligament, is unclear, so it is not possible to suggest how the ovarian mis-
location would have occurred, nor whether it would be of any functional consequence. 
The studies reported in this chapter were primarily designed to repeat the studies of 
Gupta et al, which suggested that PGs were important for masculinisation in mice and 
that blocking PGs by indomethacin exposure in mice, during the critical period of the 
MPW caused male reproductive tract abnormalities. In contrast, in the investigations for 
this thesis, exposing rats to 1mg/kg indomethacin during the MPW or in the period prior 
to the MPW, did not cause any significant impairment of masculinsation in males. No 
hypospadias or cryptorchidism was noted for any of the male animals and there was no 
difference in AGD at any age investigated, suggesting hat androgen action during the 
MPW was not affected. Testis weight was also comparable to controls. The only isolated 
effect found was with regard to reduced penis length in adulthood in indomethacin 
exposed animals. However, assuming that this effect is real (see above), it must reflect a 
deficiency in late pubertal or adult testosterone exposure as no effect on this parameter 
were found at earlier ages. This might indicate, for example, that development or 
function of adult Leydig cells was somehow altered by fetal indomethacin exposure, but 
the absence of any change in adult testis weight speaks against this. An alternative 
would be a defect in growth potential of the penis itself or, for example, in its ability to 
generate DHT locally for growth/size maintenance. However, as no defects in penis size 
were found at earlier ages, it is difficult to envisage how such an age-selective effect 
would occur. Overall, the results, especially those showing unaltered AGD, points to no 
impairment of androgen action in the MPW as a result of indomethacin exposure.  
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It is important to consider that transplacental transfer of indomethacin cannot be 
accurately determined. Some studies suggest that indomethacin only transfers to the 
fetus just before parturition and that exposure prior to this does not cross the placenta 
(Aselton et al, 1985; Klein et al, 1981; Traeger et al, 1973). Given the results of this 
chapter, it is difficult to determine if fetuses were actually exposed to the indomethacin, 
although bodyweight was affected; however this could have been because of a placental 
or maternal effect. It is obvious that the indomethacin affected the dams due to their 
illness and difficulty in giving birth, but just how much of the drug crossed the placenta 
to expose the fetus was not determined. On the other hand, the resorption or variability 
in the number of pups from dams treated with indomethacin and the ovary displacement 
in adult females from this group suggests that sufficient indomethacin did cross the 
placenta. Previous studies have determined the exact difference in PG expression after 
indomethacin exposure using enzyme immunoassays (Tanaka et al, 2002), and 
radioimmunoassays (Shahbazian et al, 2001), but these experiments were in the animal 
(rat in both instances) being treated with the indomethacin directly rather than 
determining fetal exposure. Attempts have been made to understand the level of 
indomethacin crossing the placenta, and it is thougt that early in gestation placental 
transfer is minimal and this increases closer to parturition in rats (Klein et al, 1981) and 
in humans (Aselton et al, 1985) Although there are publications outlining how 
indomethacin works and the various effects noted (or absent) in fetuses, not a great deal 
of advance has been made in quantifying the level of PGs which are inhibited in the 
fetus by indomethacin exposure. One method of doing this is by radioimmnoassyas 
(Jaffe et al, 1973; Oki et al, 1974; Thomas et al, 1978), however, some PGs have a very 
short half life and the accuracy of this method remains to be determined.   
 
One hypothesis which might explain the difference in results reported here and those by 
Gupta is differences in species. Gupta used mice as the rodent model and the 
experiments reported here used rats. It may also be important that Gupta did not 
investigate the effects of indomethacin directly. Rather, masculinisation was disrupted 
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using exposure to oestradiol 17-β or cyproterone acetate and arachidonic acid was then 
administered which, rescued masculinisation. It wasthi  rescuing action that was then 
blocked using indomethacin (Gupta and Goldman, 1986). In the second study, Gupta 
characterized two different PGs, namely PGE2 and 6-keto PGF1 in the fetal genital 
tracts of males and females. The study reported that both males and females had equal 
levels of expression of these PGs at the indifferent stage, however through development, 
both PGs increased in expression in the male reproductive tract and decreased in 
expression in the female reproductive tract. Gupta reported that fetal exposure to 
testosterone caused an increase in expression of PGE2 and 6-keto-PGF1 in the female 
reproductive tracts whereas exposure to cyproterone acetate (an anti-androgen, but also 
has progestational activity) decreased the expression of these PGs in the male 
reproductive tract. Moreover Gupta reported that exposure of fetuses to indomethacin 
inhibited PGE2 and 6-keto-PGF1 in the reproductive ract (Gupta, 1989). In the final 
study by Gupta, Wolffian ducts were put into culture and their testosterone dependent 
differentiation was blocked using indomethacin (Gupta and Bentlekewski, 1992). Thus 
perhaps another explanation for the differences in the results reported in this chapter and 
the results by Gupta may be due to experimental protocols. Perhaps indomethacin can 
only block masculinisation which has been rescued by arachidonic acid rather than block 
androgen mediated masculinisation in the absence of arachidonic acid. In addition, 
cyproterone acetate can also have progestagenic effe ts and so some of the effects 
reported by Gupta could have been due to blocking an oestrogen effect, which could 
decrease testosterone levels and perhaps even AR levels.  
 
In conclusion, exposing fetal rats to 1mg/kg of indomethacin prior to or during the MPW 
did not affect masculinisation of male pups. A signif cant decrease in prenatal 
bodyweight was observed in these animals although it is difficult to be certain that this 
was due to the indomethacin as opposed to reflecting variability between litters. 
Furthermore, the F1 generation of females exposed to indomethacin displayed some 
symptoms of difficulty in plugging and of the two which did, both were late in 
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parturition. The effects of PG inhibitors on pregnant females, in both rodents and 
human, are well reported in the literature as well as some of the effects on growth and 
development of the F1 generation. However, the effects on fecundity and possible 
difficulties in giving birth in the F1 generation are less well documented and merit 
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6.1 Introduction 
Hypospadias is a congenital defect of the penis which consists of an abnormal urethral 
opening, sometimes associated with abnormal prepuce and ventral penile curvature. 
Hypospadias involves abnormal location of the urethral meatus which, in relatively mild 
cases, involves the urethral opening being located on the glans of the penis, in moderate 
cases on the upper half of the penile shaft and in severe cases at the base of the penis in 
the perineal region. One cause of hypospadias is when androgen action is subnormal 
within the masculinisation programming window as reviewed in section 1.1.1.  
 
The androgen dependent molecular mechanisms involved in penis development and 
hypospadias are poorly understood, if at all (section 1.9.3). The first aim of the studies in 
this chapter was to study the anatomy of the developing rat genital tubercle (GT) in male 
and female rats through to postnatal day 25, when an adult type penis is present except 
that growth is incomplete and preputial separation has not occurred. The second aim was 
to investigate genes expressed in the GT during the MPW that might be androgen 
regulated, and to establish if they might be involved in hypospadias. The initial step of 
understanding the anatomy of the GT was undertaken so as be able to assess the cellular 
localization of expression of any androgen-regulated g nes which would allow a link to 
specific structures and events in GT development.  
 
The basic approach used in the studies described was to block androgen action in the 
MPW and to investigate changes in gene expression in the GT by microarray. This study 
was undertaken in our group by Dr David MacLeod and the microarrays were 
undertaken using Affymetrix. It was designed to identify potential androgen regulated 
genes in the MPW, by comparing the genes expressed at 17.5 in rat control (vehicle 
exposed) male GT (normal androgen action), control female GT (normal ‘absence’ of 
androgen action in females), flutamide exposed male GT (blocked androgen action) and 
testosterone exposed female GT (excess androgen actio ). Several genes were identified 
to be potentially regulated by androgens (Table 6.1). One such gene was Asporin, which 
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is a member of the small leucine-rich repeat proteoglycan (SLRP) family but with a 
unique stretch of aspartate residues (Lorenzo et al2001). Expression of ASPORIN has 
been found in various human tissues including aorta, uterus, heart and liver and also in 
mouse tissues (Lorenzo et al, 2001). Asporin has been shown to bind to TGF-β and to 
inhibit chondrogenesis, whereas supra-normal expression of Asporin has been linked to 
oesteoathritis (Nakajima et el 2007). Recent studies have shown that Asporin has the 
ability to inhibit the activation of BMP receptors (Tomoeda et al 2008) as well as being 
involved in collagen mineralization (Kalamajski et al 2009). The microarray results 
indicated that Asporin was negatively regulated by androgens.  
 
An alternative to the microarray approach was to investigate candidate genes, which 
other studies have suggested might be androgen regulat d in males. Examples of such 
genes include Slit2 and Robo1. Studies within another collaborative group in ourUnit 
had suggested that Slit2 and Robo1 may be regulated by androgens in the prostate during 
development and indeed some studies had been published outlining the effect of Slit2 
and Robo1 expression in prostate cancer cells induced in rats (Latil et al, 2003). In 
vertebrates, three slit (Slit1, 2, 3) and four Robo (Robo1, 2, 3, 4) genes have been 
identified. SLIT is the ligand for the ROBO receptor and it has been shown that the 
Slit/Robo pathway is involved in tissue growth, development and remodeling. Three 
main roles have been well documented for Slit/Robo which are i) conserved role in 
guiding axons during assembly of the nervous system (Andrews et al, 2007; Dickson et 
al 2002 Hinck et al, 2004), ii) regulating chemotaxis (Prasad et al, 2007; Wu et al, 2001), 
and iii) suppressing tumourogenesis by promoting apoptosis and inhibiting cell 
migration (Fujiwara et al 2006). Such roles would be relevant to urethral fold closure 
during penis differentiation, as this involves substantial cell migration, and thus it was 
hypothesized that androgen regulation of Robo1, and or Slit2 in the GT might be 
important in, or after, the MPW. In summary, the aim of the studies in this chapter was 
to gain an understanding of the anatomy of the developing GT and to investigate the 
potential androgen regulation of the three aforementioned genes during and after the 
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MPW. Although the GT was the primary tissue of interest, it was also important to 
establish if any identified mechanisms of androgen action within the GT might be 
common to other male (or female) reproductive tract tissues. Therefore, expression of 
the three genes of interest was also investigated in the testes, ovaries, Wolffian and 
Müllerian ducts. 
 
6.2 Materials and Methods 
6.2.1 Animals and treatments 
Briefly, pregnant rats were treated with flutamide, TP, DHT or DES or appropriate 
vehicle during the MPW (section 2.2). The genital tubercle was dissected from rat 
fetuses at e16.5, e17.5, e19.5 or e21.5, from both male and female pups. The GT was 
fixed in Bouins and processed for immunohistochemical analysis or frozen at -80°C for 
RNA analysis. 
6.2.2 Anatomical analysis 
Due to the nature of the GT tissue and its differing cellular composition throughout 
vertical planes, the most popular method of studying this tissue is to take serial sections 
from the base through to the tip of the GT. Immunohist chemistry is usually conducted 
on every 2-3 sections. This technique had not been established within our group prior to 
this PhD and optimizing the correct orientation of tissue during embedding was vital for 
identification of tissue regions and thus correct interpretation of results. This proved 
challenging and was best achieved by using a green biomarker (section 2.3.2) to mark 
the tip of the GT which was then embedded in paraffin wax in a vertical manner.  
The anatomy of the GT and flutamide effects were initially identified by simply using 
H&E staining (section 2.9).  
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6.2.3 RNA Analysis 
Briefly, RNA was isolated from frozen GT and converted into cDNA and Taqman 
quantitative RT-PCR performed to establish quantitative mRNA levels. The genes 
investigated and primers used are listed in Table 6.1. The expectation was that if any of 
the candidates were important in androgen regulated GT development, then expression 
would switch on during and / or after the MPW and this pattern would be disrupted by 
flutamide in males and induced in the GTs of females exposed to testosterone.  
Table 6.1 List of primers and probes used in Taqman-PCR analysis in chapter 6 




AAG AAA ACC TCT CTT 
CTG ACA AGG 
GCA CAC AGC CAA 
AAG CAG TA 56 
ROBO1 
GCA GAG AGG CCT 
ACA CAG ATG 
CAC TGG GCG ATT TTA 
TAG CAG 10 
SLIT2 
GCC ATT CAG GAC TTC 
ACC TG 
CGA AGG ACA ACG 
GGA GAG 108 
6.2.4 Optical Projection Tomography (OPT)  
In order to image the GT as a whole, optical projection tomography (section 2.7) was 
carried out on e21.5 control male GT. This software is attached on a CD, with 
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6.3 Results 
6.3.1 Anatomy of the GT and the postnatal day 25 penis 
In order to understand the anatomy of the rat penis u der normal conditions, two 
approaches were taken. The first of these was to serial section a male control PND25 
penis and stain using haematoxylin and eosin (H&E) (section 2.9) and image. The 
second approach used Optical Projection Tomography (OPT) to gain insight into the 3-

















Figure 6.2 Still OPT image of control e21.5 male rat GT. Urethra, corpus cavernousum and OS penis 
are clearly visible  
 
Figure 6.1 H&E stain of control male rat PND25 penis-higher power image from Fig.6.3 to clearly 
distinguish OS penis, corpus cavernosum and urethra.  
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Figure 6.3 Representative serial sections from the tip to the base of a PND25 control male penis. For 
guidance, section order is by rows, ‘O’ represent the OS penis, the urethra is indicated by an arrow 
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Serial sectioning and H&E showed the various internal structures of the fully formed 
penis, namely the OS penis, urethra, corpus cavernosum and how each structure varied 
in morphology depending on their specific location between distal and proximal regions 
(Fig 6.1 and 6.3). This information was supported by the OPT 3D reconstruction, a still 
image of which (Fig 6.2) also clearly shows how thevarious key structures within the 
developing penis. The complete imaging movie and associated software are attached in a 
CD (appendix 3).  
 
6.3.2 Effect of flutamide exposure on gross morpholgy of the penis 
To visualize the impact that androgen action had on structural development of the penis, 
pregnant animals were treated with various doses of flutamide during the MPW and the 
fetuses or offspring then studied. The dose response in Fig 6.4 illustrates the increasing 
severity of hypospadias corresponding with the increasing dose of flutamide 
administered. 
 
      
 
 
Flutamide exposure in the MPW induces hypospadias in a dose responsive manner 
(Welsh et al, 2008, 2010). When exposed in the MPW to 2mg/kg flutamide, no obvious 
defects of the penis were evident at PND25 but exposure to higher flutamide doses 
resulted in progressively worse disruption of normal penile anatomy and in particular the 
Figure 6.4 Representative penile cross sections at PND25 from animals exposed to various 
doses of flutamide during the MPW. O=OS penis, the arrow indicates the the urethra  and *= 
the bilateral corpora cavernosa. Note that as the dose of flutamide increases, the more 
superficial the urethra becomes, such that after exposure to 100mg/kg flutamide the urethra 
lies open at the surface of the penis (=hypospadias). 
2mg/kg 5mg/kg 10mg/kg 100mg/kg 
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failure of complete urethral closure (i.e. hypospadias) but also the OS penis and corpora 
cavernosa became malformed, appearing as a single rath r than a bilateral structure (Fig. 
6.4).  
 
6.3.3 Investigation of gene expression in the GT and the effects of flutamide 
6.3.3.1 Expression of Asporin 
In order to identify, with as much certainty as possible, androgen regulated genes in the 
GT four treatment groups were chosen and GTs collected on e17.5; the groups were 
control male, flutamide exposed male, control female and testosterone exposed female. 
Three GTs were pooled from three separate litters and the three pools from each 
treatment group then run on the microarray. E17.5 was chosen for study because it is 
towards the end of the MPW and should therefore capture any androgen-regulated 
change in gene expression that is specific to the MPW. The microarray results 
(affymetrix) found the following pattern of Asporin expression in rat GT at e17.5: 
 
Table 6.2 Results of affymetrix microarray results for Asporin expression in rat e17.5 GT. N=9 
from 3 different litters.  
GT comparison 
Asporin expression –fold 
change 
e17.5 Flutamide males vs e17.5 control males  +1.74 
e17.5 control females vs e17.5 control males +1.78 
e17.5 flutamide males vs e17.5 testosterone females +2.10 
e17.5 Testosterone females vs e17.5 control females -2.15 
 
Each of the comparisons of the four treatment groups investigated strongly indicated that 
Asporin may be negatively regulated by androgens in the GT during the MPW, and for 
each comparison the comparison was statistically significant (p<0.05). To validate the 
microarray results, and quantify the change in exprssion of Asporin, Taqman PCR was 
conducted on the following GT tissues at e17.5; vehicl  exposed male, flutamide 
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exposed male, vehicle exposed female and testosterone exposed female. All animals 
were exposed during the MPW and were from a separate study to those used for the 







Taqman confirmed 3 out of the 4 microarray results for e17.5 GT expression of Asporin. 
In males exposed to flutamide from e15.5-e16.5 (MPW), Asporin expression was 
significantly increased in the GT at e17.5 in comparison to the vehicle exposed males. 
E17.5 control female GTs also expressed Asporin at a higher level than did control male 
GTs, although this increase was not statistically significant. Interestingly, the results 
showed that GTs from females which had been exposed to testosterone during the 
MPW, had a significantly increased expression of asporin in comparison to vehicle 
exposed females at e17.5. This was in complete contrast o the results from the 
microarray, which showed that GTs from females which had been exposed to 
testosterone during the MPW had decreased Asporin expression in comparison to control 
females.  
Figure 6.5 Quantitative analysis of Asporin mRNA level in e17.5 rat GT. Usnig a one way 
ANOVA* P<0.01 in comparison with respective female control. *** P<0.001 in comparison to 
respective male control Values are means ±SEM for 12 animals/group from a minimum of 4 
litters.  
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In order to determine if the difference in Asporin expression between control males and 
females changed during and after the MPW, Taqman anlyses were conducted on GT 
from vehicle exposed (during the MPW) males and femal s at e16.5, e17.5, e19.5 and 
e21.5 (Fig. 6.6). Asporin expression was consistently higher in the female GT than in the 
males throughout development. Although none of the results were individually 
significantly different, a significant overall difference was found between the two sexes 
as well as a significant difference between the ages. An increase in tissue size may 
explain the increase in Asporin expression through the developing GT.  
Figure 6.6 Quantitative analysis of Asporin mRNA level in the developing male and 
female GT according to fetal age. Values are means ±SEM for 6-10 animals/group from 
a minimum of 4 litters. Using a two way ANOVA a significant difference of Asporin 
expression was observed among the four ages (P< 0.01) and between the two sexes 
(P<0.05). Bonferroni post-hoc tests showed no sex differences at any of the individual 
ages 
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The initial microarray validation experiment (Fig. 6.5) showed that Asporin expression 
increased in the e17.5 male GT when androgen action was blocked during the MPW 
using flutamide, in comparison to vehicle exposed males, when androgen action is 
normal. A similar trend of expression was found at e16.5 and also after the MPW at 
e19.5 and e21.5, and using a two way ANOVA no significant difference in Asporin 
expression was found between control and flutamide exposed fetuses but there was a 
significant difference among ages, overall, which was probably due to an increase in 
tissue size.  
 
Possible role for oestrogens  
As described above, there was considerable variability and even conflict in some of the 
results on Asporin mRNA expression after fetal exposure to flutamide and especially 
exposure to TP. In considering potential explanations, it was recognized that variable 
contribution from oestrogens or from disturbance of the androgen-oestrogen balance 
Figure 6.7 Quantitative analysis of Asporin mRNA level in the male GT from fetuses 
exposed to either vehicle or flutamide during the MPW. Values are means ±SEM for 8-10 
animals/group from a minimum of 4 litters. At no age were values for control and 
flutamide significantly different.   Using a two way ANOVA a significant difference of 
Asporin expression was observed among the four ages (P<0.05) but no significant 
difference was found between control and flutamide exposed tissue.  
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could potentially play a role, especially as the GTis an established oestrogen target 
(Kalfa et al, 2008; Yucel et al, 2003). For example, as TP can be aromatized to 
oestradiol, this could have exerted effects that were being interpreted as ‘androgenic’. 
Even the effects of flutamide could conceivably result from disturbance of the normal 
androgen-oestrogen balance, because by blocking androgen but not oestrogen action, 
this balance is automatically altered. To address some of these possibilities, pregnant 
rats were therefore dosed during the MPW with either DES (a potent, synthetic 
oestrogen) or with DHT, which is a more potent androgen than testosterone but which 






Results shown in Fig 6.8 show that Asporin expression in the male GT increased 
dramatically in DES-exposed fetuses. This increase in expression was significant when 
compared against the control male GT value, but was also significantly higher (P<0.05) 
than and the values for flutamide exposed males. Although at face value the increase in 
expression of asporin in GTs from DES exposed male fetuses suggests that oestrogens 
Figure 6.8 Quantitative analysis of Asporin mRNA level in the e17.5 GT after exposure of 
fetuses during the MPW to flutamide, DES, TP or DHT. Usnig a one way ANOVA 
**P<0.0025  in comparison to control male, flutamide male, control female, DHT and TP 
female. Values are means ±SEM for 6-8 animals/group from a minimum of 3 litters.   
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can regulate asporin expression, it may also be related to distortion of the 
androgen:oestrogen balance, which can be fundamentally important in males (see 
section 1.5). DES treatment also reduces testosterone production by the fetal rat testis 
(Haavisto et al, 2003), which means that it will sever ly distort the endogenous 
androgen:oestrogen balance by both lowering androgen action at the same time as 
elevating oestrogen action. In contrast, although flutamide reduces androgen action it 
will not elevate oestrogen levels, so that there is a smaller distortion of the 
androgen:oestrogen balance than in the case of DES. This is speculation, but would 
perhaps reconcile the flutamide and DES results in males.  
 
As found in the earlier study (Fig. 6.5), TP exposure of females increased asporin 
expression in the GT, as also did DHT (Fig. 6.8), suggesting that the effect is androgen-
mediated as opposed to alteration of the androgen:oestrogen balance, although both 
treatments will increase the androgen:oestrogen balance, if this is important in females. 
Irrespective of the explanation the fact that Asporin  expression changes in the same 
direction in females exposed to androgens as in males in which androgen action is 
decreased, points to a fundamental difference (opposite) in response between the sexes 
as far as the GT is concerned.  
 
 
Figure 6.9 Quantitative analysis of Asporin mRNA levels, at various fetal ages in the WD of 
males exposed to either vehicle or flutamide during the MPW. Values are means ±SEM for 3-5 
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animals/group from a minimum of 3 litters.  Using a one way ANOVA, no significant difference 
was found between GTs of control fetuses in comparison to those of flutamide exposed animals.    
 
In order to determine if the treatment-related changes in expression of Asporin found in 
the GT was common to other male (or female) reproductive tract tissues, the expression 
of Asporin was also investigated in the testes, ovaries, Wolffian and Müllerian ducts. No 
pattern emerged which suggested that Asporin expression may be negatively regulated 
by androgens from any of these tissues. For example, the expression of Asporin was 
similar between control fetuses and flutamide exposed fetuses in the testis and WD and 
no significant difference were found between the treatment groups or ages, an example 
of which is shown in Fig. 6.9, but other results are not presented.  
 
6.3.3.2 Investigation of SLIT2 expression in the GT 
The slit2/robo1 pathway was suggested to be androgen regulated in the prostate. 
Therefore Taqman-PCR was used to determine if either this ligand (Slit2) or its receptor 
(Robo1) are expressed in the rat GT. As the tissue for the Asporin analysis had already 
been collected and appropriate cDNA available, it was decided to use the same approach 
to investigate the expression of Slit2 and Robo1.  
 
Figure 6.10 Quantitative analysis of Slit2 mRNA level in e17.5 rat GT after exposure to vehicle, 
flutamide, or TP during the MPW.Using a one way ANOVA * P<0.01 in comparison with 
respective male control. Values are means ±SEM for 12 animals/group from a minimum of 4 
litters.  
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Expression of Slit2 increased in e17.5 male GT from fetuses that had been exposed to 
flutamide during the MPW, in comparison to the exprssion of Slit2 in GT from vehicle-
exposed e17.5 males. Furthermore, e17.5 control female GT also expressed slit2 at a 
higher mean level than did the male control tissue, although this difference was not 
statistically significant (Fig. 6.10). Mean Slit2 expression was also decreased in the GT 
of female fetuses exposed to testosterone during the MPW, in comparison to control 
females, although again this difference was not statistically significant. Nevertheless, 
viewed overall, the results suggested that Sli 2 might be negatively regulated by 
androgens. To investigate Slit2 expression further in the MPW and later, Taqman-PCR 
was conducted on the GT through development from e16.5-e21.5, in both control male 




Although this analysis showed some possible differences between Slit2 expression in 
male and female GTs, these differences were inconsistent in direction and none was 
statistically significant (Fig. 6.11). It was therefore concluded that a simple male-female 
Figure 6.11 Quantitative analysis of Slit2 mRNA expression at various fetal ages in the 
developing male and female GT. Using a one way ANOVA no significant difference was 
found between male and female GT expression of Slit2. Values are means ±SEM for 6-10 
animals/group from a minimum of 4 litters.    
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comparison does not support the notion that androgens n gatively regulate Slit2. To test 
this conclusion more directly, an age course study was undertaken comparing Slit2 







Similar to what was found in the original study (Fig. 6.10) an increase in the expression 
of Slit2 was found in the e17.5 GT of male fetuses exposed to flu amide, but this 
increase was not statistically significant (Fig. 6.12)  Additionally, no significant 
differences were found in the expression of Slit2 between control and flutamide groups 
at other ages, namely at e16.5, e19.5 and e21.5 (Fig.6.12). These results therefore seem 
to suggest that Slit2 is not androgen-regulated in the GT during or after the MPW. 
However, bearing in mind the thoughts about importance of the androgen:oestrogen 
balance discussed above for asporin expression, the effect of fetal exposure to flutamide, 
DHT, DES or testosterone, during the MPW on GT exprssion of Slit2 at e17.5 was 
investigated (Fig. 6.13).  
  
Figure 6.12 Time course quantitative analysis of Slit2 mRNA level in the male GT form vehicle 
exposed controls and males exposed to flutamide during the MPW. Values are means ±SEM for 
8-10 animals/group from a minimum of 4 litters.   Using a one way ANOVA no significant 
differences were found between control male GTs and those exposed to flutamide 
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This analysis showed a number of differences in mean Slit2 expression levels between 
males and females ± exposure to flutamide, DES, TP or DHT, but none of the 
differences were statistically significant, again not supporting the notion that Slit2 might 
be negatively regulated by androgens in either males or females, and with insufficient 
data to conclude that oestrogens might negatively regulate Slit2 expression in the male 
GT (Fig.6.13). Overall, perhaps the most reasonable conclusion is that Slit2 expression 
is naturally quite variable and that the one original results pointing to androgen 
regulation (Fig. 6.10) was simply a chance effect.   
 
6.3.3.3 Investigation of Robo1 expression in the GT 
In parallel to determining the expression of Slit2 and possible androgen regulation in the 
GT, expression of the gene for the Slit2 receptor, Robo1, was also investigated using 
Taqman-PCR. The same samples and method of investigation were used as described for 
asporin and Slit2.  
  
Figure 6.13 Quantitative analysis of Slit2mRNA levels in the e17.5 GT after exposure of fetuses 
during the MPW to flutamide, DES, DHT or TP. Usig a one way ANOVA, no significant difference was 
found between the treatment groups. Values are means ±SEM for 6-8 animals/group from a minimum 
of 3 litters.     
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Fig. 6.14 shows the Taqman-PCR results for the expression of Robo1 in e17.5 GT. 
There were no significant differences in Robo1 expression between male and female GT 
and no significant impact of flutamide or TP exposure, although there were suggestive 
trends. For example, in males when androgens were blocked in the MPW using 
flutamide, an increase in mean Robo1 expression was found in the e17.5 male GT in 
comparison to e17.5 control male GT. Another trend was an increase in expression of 
Robo1 in the GT of female fetuses exposed to testosterone during the MPW in 
comparison to control females and males. In order to follow this up, Robo1 expression 
was investigated in control male and female GT at e16.5, e17.5 and after the MPW at 
e19.5 and e21.5.  
Figure 6.14 Quantitative analysis of Robo1 mRNA level in e17.5 rat GT. Values are means ±SEM 
for 12 animals/group from a minimum of 4 litters. Using a one way ANOVA there were no 
statistically significant differences between any of the groups.    
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Taqman-PCR showed that Robo1 was expressed at similar levels between control male 
and control female GTs throughout fetal development, a d this expression was at its 
highest during the MPW at e17.5 (Fig. 6.15). In order to completely rule out the 
possibility that Robo1 was androgen regulated, Taqman-PCR was conducted on GT 
from fetuses across the fetal age range after exposure to flutamide during the MPW and 
compared to the GT of control fetuses. In addition, the effect of DES and DHT exposure 
on Robo1 expression were investigated.  
 
Figure 6.15 Time course quantitative analysis of Robo1 mRNA level in the developing male and 
female GT. Values are means ±SEM for 6-10 animals/group from a minimum of 4 litters.  Using a 
one way ANOVA there were no significant differences between males and female at any age.   
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An earlier experiment (Fig.6.15) that found a suggestiv  upward change in Robo1 
expression in e17.5 male GT after exposure to flutamide, was not confirmed in the time 
series set of experiments (Fig.6.16); in fact Robo1 was found to be expressed at similar 
levels in the GT between control and flutamide exposed fetuses at all ages, although the 





Figure 6.16 Time course quantitative analysis of Robo1 mRNA level in the male GT from control 
males and those exposed to flutamide during the MPW. Values are means ±SEM for 8-10 
animals/group from a minimum of 4 litters. Usnig a one way ANOVA was no significant effect of 
flutamide exposure at any age.    
Figure 6.17 Quantitative analysis of Robo1 mRNA levels in the e17.5 GT after exposure of fetuses 
during the MPW to flutamide, DES, DHT or TP.  Using a one way ANOVA *P<0.05 in comparison to 
control male GT. Values are means ±SEM for 6-8 animals/group from a minimum of 3 litters.     
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The results for Robo1 expression reported in Fig. 6.14, Fig. 6.15 and Fig. 6.16 were 
inconsistent and variable. However as Robo1 is the receptor for Slit2, it was of interest to 
determine if patterns of Robo1 expression in the GT were similar to that of Slit2. 
Taqman-PCR was used to investigate Robo1 expression in e17.5 from fetuses which had 
been exposed to vehicle, flutamide, DES, DHT or testosterone during the MPW (Fig. 
6.17). Consistent with what was found for Slit2 expression patterns (Fig. 6.13), DES 
exposure of males lowered Robo1 expression whereas DHT exposure lowered Robo1 
expression in female GTs (Fig. 6.17). It seems unlikely that Robo1 is androgen or 
oestrogen regulated and as postulated with the asporin results, the possibility arises that 
disruption of the androgen:oestrogen balance may affect Robo1 expression, however 
overall patterns of expression of Robo1 in the various treatment groups was not 
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6.4 Discussion 
Originally, there were three main aims to the studies in this chapter; 1) to understand the 
anatomy of the developing genital tubercle and postnatal penis, 2) to investigate if three 
candidate genes might be androgen regulated during and after the MPW in the GT and 
3) to use the understanding of the anatomy of the developing GT to asses cellular 
localization of any androgen regulated genes. These inv stigations were designed to 
better understand the specific structures and events in GT development during and after 
the MPW and to gain insight into possible androgen regulated genes within the MPW 
which might be linked to the origins of hypospadias.  
 
Two methods were used to study the anatomy of the GT; serial sectioning and OPT. 
Combined,  these provided insight into the key structures, namely the urethra, OS penis, 
corpus cavernosum, and how these structures developed within the GT over time. 
Embedding of the GT at any age before e19.5 proved to be problematic. The GT is very 
small during the fetal period and it was a difficult task to dissect and embed this tissue in 
a consistent orientation to provide reproducible results in relation to same plane of 
transverse section and orientation. The aim was to embed the tissue ‘tip’ down in a 
vertical manner to allow serial sectioning from base to tip. However, even if the GT was 
at a slight angle, the sections were not then consistent with regards to plane of section 
through the tissue, and this was potentially exacerbat d by flutamide treatment which 
can result in curvature of the GT/penis. Furthermore, during the MPW, the GT is not as 
elongated as it is after the MPW, and it was difficult to identify the tip and base from the 
almost circular structure that is the GT at e17.5 or before. Consequently, a new approach 
was taken, and this was to mark the ‘tip’ of the GTduring micro-dissection using a 
green biomarker. This approach provided good results for e19.5 and e21.5 GT; however 
it was still difficult to embed the smaller GTs from younger age animals and in a 
consistent orientation. This was also encountered when trying to embed tissue for OPT 
analysis. It was possible to embed GTs from e21.5 onwards but prior to this the 
orientation was difficult and only provided ambiguous results. OPT of e21.5 GT 
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however provided an elegant method to observe the internal morphological changes in 
structure of the intact GT from the base to the tip, and to compare against individual cut 
sections to identify the exact plane of section being investigated.  
Animals were exposed to various doses of flutamide during the MPW to determine the 
effects of blocking androgen action on the developing GT. Increasing doses of flutamide 
clearly correlated with increasing severity of hypos adias such that closure of the 
urethra was completely inhibited in the GT of males exposed to 100mg/kg flutamide but 
to a lesser (more anterior) and more variable extent at lower doses.  
 
Three genes were chosen for investigation of their expression in the GT during the 
MPW. Asporin was chosen from the genes identified through the microarray study 
which strongly suggested asporin to be negatively rgulated, in the GT, at e17.5 at least. 
Slit2 and Robo1 (ligand and receptor respectively) were chosen as the e two genes were 
also suggested to be negatively regulated by androgens in the prostate in work done by 
another Unit group. The published roles of each of the three chosen genes, and pathways 
they are involved in could be relevant to the development of the GT. Therefore their 
expression was studied primarily in GT at e17.5 during the MPW, and then extended to 
time points after the MPW. Gene expression was studied in GT of fetuses from four 
different ‘androgen’ settings; 1) in the GTs of male fetuses exposed to vehicle, in which 
androgen action is considered normal, 2) in the GT of male fetuses that were exposed to 
flutamide, in which  androgen action is blocked 3) in the GT of female fetuses that been 
exposed to vehicle and normal androgen action is con idered absent/ minimal and 4) in 
the GT of female fetuses that had been exposed to tes sterone during the MPW and in 
which androgen action is ‘enhanced’. It was not possible to validate the microarray 
results for the GTs from female fetuses exposed to test sterone during the MPW and this 
raised the possibility that testosterone exposure in the female fetuses, may be being 
aromatized to oestradiol and the changes in asporin expression might be an oestrogen 
response rather than an androgen response. Therefore it was decided to expose animals 
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to DES or DHT during the MPW to further elucidate if the observed changes in 
expression might be due to androgen or oestrogen regulation. 
   
The microarray results for Asporin expression in e17.5 GT were validated using Taqman 
RT-PCR. The validation experiments used a different s t of GTs to the samples sent for 
the microarray and also increased the ‘n’ numbers in comparison to the microarray. 
Three of the four results from the microarray were validated and these experiments 
showed the GT of control female fetuses expressed aporin at a higher level than control 
male fetuses, thus in the absence of ‘normal androgen action’ asporin expression 
increases. Furthermore, the GT of male fetuses that had been exposed to flutamide 
during the MPW, had a higher level of Asporin expression in comparison to control male 
GT. This result also suggested that in the absence of androgen action, Asporin 
expression increase in the GT. RT-PCR was used to determine if both of these results, 
which suggested that Asporin expression is negatively regulated by androgens, wa  also 
found at other ages in the developing GT. Indeed, a significant trend was found whereby 
female control GTs expressed Asporin at a higher level than male control GTs, at e16.5, 
e17.5, e19.5 and e21.5. In addition, a significant difference was also was also found in 
GTs of male fetuses that had been exposed to flutamide during the MPW which 
expressed Asporin at higher level than control male GT at e16.5, e17.5, e19.5 and e21.5. 
Thus it could be hypothesized that Asporin expression was negatively regulated by 
androgens, although the degree of androgen regulation was perhaps modest and 
somewhat inconsistent. In further studies, the GT from male fetuses that had been 
exposed to DES expressed Asporin at a significantly higher level than in any other 
treatment group investigated and this result might suggest that oestrogens can positively 
regulate asporin expression. This might explain the TP results from the validation 
experiments, whereby TP might be aromatized to oestradiol and then exert an effect. 
However, if this theory were true, it would not explain why the GT from female fetuses 
exposed to DHT also had an increased expression of Asporin in comparison to male and 
female control GTs but also to male GTs which had been exposed to flutamide, unless 
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there is an inherent difference between male and female GTs. Another possible 
explanation is that, in each of the treatment groups, the androgen-oestrogen balance was 
disturbed and in each treatment group when this balance is disturbed, asporin expression 
increases in comparison to control male and female GTs. Although these results looked 
potentially interesting, the studies were hindered by the lack of a good working antibody 
for ASPORIN in the rat, which would have established if asporin protein is expressed in 
the GT, if similar effects were seen in the various treatment groups and what cells and 
structures within the GT expressed asporin.  
 
The first Taqman-PCR experiment that investigated Slit2 mRNA expression suggested 
that it might be negatively regulated by androgens, as the GT of male fetuses exposed to 
flutamide, in which androgen action is blocked, expr ssed Slit2 at a significantly higher 
level than did control male GT. Furthermore, when exposed to androgens, in the form of 
TP, female GT had a decreased expression of Slit2 in comparison to female controls (i.e. 
changing in a ‘male’ direction). In addition, control female GTs expressed asporin at a 
higher level than did control male GTs. Thus, this expression pattern was investigated at 
different ages in the developing GT. However, Slit2 expression was not found to be 
significantly different in the GTs of control male and female fetuses at e16.5, e17.5, 
e19.5 and e21.5. Furthermore, the difference in Slit2 expression in the male and female 
control GTs, found at e17.5 in the previous experimnt, was not repeatable. Lastly, Slit2 
expression at e16.5, e17.5, e19.5 and e21.5 in the GT of male fetuses exposed to either 
flutamide or vehicle, found that Slit2 was expressed at similar levels in the control male 
GT throughout development from e16.5-e21.5, and although small increases in Asporin 
expression were found after flutamide exposure, these were only evident at e17.5 and 
e19.5 and were not statistically significant. Furthe  investigation of Slit2 expression in 
male and female fetuses exposed to DES or DHT did not provide any more conclusive 
insight. Thus, viewing results from the various separate experiments overall, it appeared 
that Slit2 expression was highly variable (at e17.5) in expression and was not obviously 
androgen-regulated.  
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A similar scenario to Slit2 was found for results for Robo1, the receptor for Slit2. The 
initial experiment investigating Robo1 expression suggested that disturbance of the 
androgen-oestrogen balance in GTs from fetuses, which had been exposed to flutamide 
or TP, increased Robo1 expression in comparison to control male GT. However further 
studies in this age group and also at e16.5, 19.5 and e21.5 found that these results were 
not repeatable and the latter experiments suggested Robo1 mRNA was expressed at 
similar levels in male and female GTs and little difference was found in Slit2 expression 
of the GT of fetuses exposed to flutamide in comparison to control males, at each age 
investigated. The final experiment investigating Robo1 mRNA expression found a 
significant decrease in the GT of male fetuses exposed to DES and in female fetuses 
exposed to DHT in comparison to control male. This finding could potentially have been 
interpreted as reflecting disturbance of the normal androgen:oestrogen balance. 
However, the fact that these results contradicted the findings of the initial Robo1 
experiment, in which flutamide exposure in the male or TP exposure in the female 
increased Robo1 expression in comparison to control males, suggested that results were 
simply variable and inconsistent. Thus similar to its ligand, Robo1 might have variable 
expression in the GT and these experiments suggest the mRNA of either Slit2 or Robo1 
are not androgen or oestrogen regulated. Similar to Asporin, further studies of Slit2 and 
Robo1 were hindered by the lack of a working antibody (which would work on rat GT) 
for immunohistochemical protein analysis.  
 
To conclude, the difficulty of investigating a tissue which has different cellular 
compositions at different planes could be addressed to some extent, by orientating the 
embedded tissue and serial sectioning. This, combined with OPT, which visualized the 
tissue in its entirety, provide good methods for studying the anatomy of the GT. 
However, to then utilize the former approach would require good working antibodies to 
localize the proteins of interest to specific cell types and to investigate the impact of 
androgen or oestrogen modulation. This was not possible for any of the three proteins 
studied in this chapter, so the approach used was restricted to investigation of gene 
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expression. Three genes were studied to determine if they are regulated by androgen 
action in the GT. Although some initial results indicated that Asporin, Slit2 and Robo1 
might be regulated by androgens, the Taqman-PCR results proved variable and not 
always repeatable. Studies in this chapter have proved that although Taqman PCR may 
give indications of mRNA expression patterns, to really understand the events within a 
tissue such as GT, in which molecular mechanisms not completely established, good 
working antibodies are an absolute requirement. Furthermore, it was very disappointing 
that even when microarray results all pointed in one direction, it was still be impossible 
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7. Final discussion 
The general aims of this thesis were to investigate what regulates the MPW, to identify 
pathways regulated by androgens during the MPW that are involved in the development 
of the male reproductive tract, and through these to further knowledge of the origins of 
TDS. To date, the studies published on the MPW have focused on the importance of this 
time frame, demonstrating that disrupted androgen action, be it through phthalates, 
oestrogens or anti-androgenic compounds, can induce TDS disorders (Clark et al, 1990; 
Foster and Harris, 2005; MacLeod et al, 2009; McIntyre et al, 2001; Welsh et al, 2008). 
Such studies have highlighted that the programming which androgens direct during the 
MPW is unique to fetal development and does not occur at any other time in life. 
Deficits in androgen action during this time cannot be compensated for later in life 
(Welsh et al, 2010; van den Driesche et al, 2011). However no studies have addressed 
the question of what makes the MPW unique, what regulates it and indeed what 
pathways are activated by androgens within it.  
 
In order to investigate these gaps in our knowledge, th  obvious starting point was to 
investigate if androgens themselves and the availability of the AR might be involved in 
opening of the MPW, which would be logical as the natural onset of testosterone 
production coincides with the onset of the MPW (chapter 3). In addition, it was 
recognized that androgens do not exert their effect alone (Heemers and Tindall, 2007; 
Heinlein and Chang, 2002) and require various biochemical associates and the 
expression of some of these were also investigated (chapter 4). Some studies published 
almost 20 years ago had defined a time frame called th  ‘critical period of development’ 
and outlined the effects of disrupted androgen action during this time, well before the 
‘MPW’ became a common definition (Gupta and Goldman, 1986; Gupta, 1989; Gupta 
and Bentlejewski, 1992). These studies highlighted the importance of prostaglandins 
during the MPW and yet no further investigations have been published either supporting 
or contradicting this. Furthermore, given the various roles PGs play in embryonic 
development, and their roles which have been defined in the testis, it would be 
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understandable if PGs were indeed vital during the MPW and this was investigated for 
the first time in the rat (chapter 5). Finally, it was hypothesized that the molecular 
mechanisms regulated by androgens during the MPW might be unique to any other time 
frame. To gain insight into genes which might be regulated during this time, a 
microarray study was conducted. This thesis investigated one of the genes from the 
microarray study as well as two further candidate gnes, each of which was 
hypothesized to be regulated by androgens in the GT (chapter 6).  
 
A majority of the studies which have been published investigating androgen action have 
used testosterone formulations as the choice of androgen. Such studies have also 
reported the testosterone can cause adverse pregnancy effects such as dystocia and fetal 
growth restriction (Wolf et al, 2002; Welsh et al, 2008, 2010). Furthermore testosterone 
can be converted to oestrodial by aromatase which can have effects on male 
reproductive development (Goyal et al, 2007) but also means it is not always clear if an 
effect seen is due to an androgen effect or an oestrogen effect. Some, however, may 
deliberate that using testosterone formulations provides a more realistic physiology as 
testosterone is the common androgen produced and acts as a precursor for both 
oestrogens and DHT in males. In the studies reported in chapter 3, to ensure any effect 
seen was that of androgen action, DHT was used; a more potent androgen which cannot 
be aromatized to oestradiol and which, as results in chapter 3 showed, does not cause 
adverse pregnancy effects. 
 
It was almost considered a given that the onset of testosterone production controls the 
‘opening’ of the MPW and consequently one of the qustions which arises from this 
theory is what might be closing the MPW as it is widely accepted that androgens and 
AR are present after the MPW. A second hypothesis which arose was that if the 
availability of androgens is the limiting factor inthe on-set of the MPW, then would 
providing androgens earlier than this, initiate theMPW early, or advance or enhance 
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masculinisation? Furthermore, would providing ‘extra’ (exogenous) androgens during 
the MPW also advance or enhance masculinisation?  
 
The studies reported in chapter 3 found that AR mRNA was present prior to the MPW, 
and the immounohistochemical studies suggested that AR protein is also available prior 
to the MPW thus the availability of AR does not appear to be a factor in regulating 
opening of the MPW. Therefore initial studies of this thesis exposed fetuses to DHT 
prior to (e11.5-e14.5) and during the MPW (e15.5-e18.5). One of the more surprising 
results of these experiments was the effects found on the female offspring. Virilisation 
of females by exposure to testosterone during the fetal period is well known and well 
documented (Rhees et al,1997; Welsh et al, 2008 Wolf et al, 2002). Primarily such 
studies used testosterone during the MPW. No studies have been published on the 
effects of androgens on females prior to the MPW. An important finding of this thesis is 
that females exposed to DHT prior to the MPW are viilised similar to females exposed 
to DHT during the MPW. In fact, certain tissues, such as the female phallus, were more 
susceptible to masculinisation when exposed to DHT prior to the MPW. These findings 
suggest the females window of sensitivity to androgens is not restricted to the MPW and 
may be wider than the MPW in males. This may be useful knowledge for scientists 
investigating female reproductive tract development if the time frame of susceptibility to 
androgen perturbations in the female development could be better defined.  
 
Exposing male fetuses to DHT prior to or during theMPW did not advance or enhance 
masculinisation or cause any detectable positive eff cts in male offspring. No early 
coiling of the WD was detectable, and the tissues of the reproductive tract known to be 
programmed by androgens during the MPW were comparable to vehicle exposed 
animals. Four conclusions can be drawn from these exp riments. First, DHT exposure 
prior to the MPW does not exert any detectable effects in the male offspring. Second, 
masculinisation is not enhanced by the early exposure to DHT. Third, endogenous 
androgens produced in the fetus are normally sufficient to maximally program 
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reproductive organ size. Fourth, it is not the avail bility of androgens that ‘opens’ the 
MPW and other factors must be involved.  
 
Other factors which are known to work with androgens are androgen co-regulators. The 
possibility of the pathways of androgen and co-regulators which might be involved in 
the MPW are vast but to narrow this down, a logical approach was taken to compare 
bioinformatics software of AR pathways with results of a microarray study designed to 
specifically recognize androgen regulated genes, in the GT, during the MPW. Two co-
regulators found by this method showed interesting patterns of mRNA expression 
around the MPW, BRG1 and CBP. Both of these co-regulators are known to work 
together to alter chromatin organization and to induce histone modifications, and both 
were expressed in the GT and within the SC, GC and interstitial cells in the fetal and 
postnatal period. Furthermore, both of these co-regulators co-localised with AR in the 
SC at PND25. BRG1 and CBP expression did not change in the testis of fetuses which 
had been exposed to DBP, DES or flutamide, suggesting that expression of the genes 
themselves is not androgen regulated. However, further studies should focus on 
determining the protein level of expression of CBP and BRG1 in the GT before and 
during the window to determine if the mRNA expression changes that were found when 
comparing before, during and after the MPW, are also seen at the protein level. One of 
the weaknesses throughout the studies in this thesis was the inability to determine 
protein expression levels before and during the MPW accurately in the GT. If this issue 
could be resolved, it would facilitate evaluation of the involvement of potential factors 
in regulation of the MPW. However, aside from regulation of the MPW, BRG1 and CBP 
expression in the testis and their co-localisation with AR warrants further investigation 
to determine what role (if any) these proteins might play in the testis in modulating AR 
activation and thus androgen action. This would be a crucial question for SC, as these 
display late onset AR expression and androgen-sensitivity and poorly understood ‘stage-
dependent’ changes in function in adulthood (Sharpe, 2005). A targeted knock-out of 
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either of these genes in SC would be most informative, and could be achieved by use of 
the Amh-Cre mouse line and generation of floxed BRG1 or CBP lines.   
 
RWDD1 expression does appear to be androgen regulatd nd RWDD1 protein 
expression was substantially reduced in the GT at e21.5 at least when androgen action in 
the MPW was blocked using flutamide. It would be interesting to determine if this effect 
is seen in e17.5 GT and if possible in earlier GT as well, especially as Rwdd1 mRNA 
expression did not change greatly across the MPW. Nevertheless, as RWDD1 showed 
impressive co-localisation with AR in the GT and testis, it is of considerable interest for 
follow-up studies. The effect of exposure to other androgen disrupting chemicals (which 
cause hypospadias) on RWDD1 expression would be useful to compare with the 
flutamide results. Detailed characterization of RWDD1 throughout the male 
reproductive tract through to adulthood in relation t  AR expression/androgen action 
should be a first step, as well as comparing expression patterns between males and 
females. Such studies require a working antibody, due to the cellular complexity of the 
tissues and the fact that not all cell types express the AR. The fact that in the present 
studies, flutamide exposure had an apparently much greater effect on RWDD1 protein 
expression than on mRNA expression reinforces this view. Unfortunately, it appears that 
current batches of the RWDD1 antibody do not work.  
 
In addition to androgen co-regulators, other methods f regulation of the MPW were 
also considered and one of these is methylation. The preliminary investigations 
conducted on the methylation regulators BORIS and DNMT3L have demonstrated 
interesting decreases in mRNA expression during the MPW. DNMT3L is a member of 
the DNMT3 enzymes which catalyze methylation reactions. Despite being a member of 
this family, however, DNMT3L does not itself catalyse methylation reactions (reviewed 
by Garcia-Carpizo et al, 2011), but is thought to regulate methylation through histone 
deacetylase activity (Aapola et al, 2002). DNMT3L expression was significantly 
decreased in the GT of fetuses exposed to flutamide during the MPW in comparison to 
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controls. A recent study has found that the methylaion enzyme DNMT3A is increased 
in expression in the foreskin of hypospadias patients i  comparison to control males 
(Vottero et al, 2011) and consequently in future studies it would be important to 
determine the expression of DNMT3L protein in flutamide exposed GT throughout 
development and also in the postnatal penis.  
 
Targeted disruption of DNMT3L in the testis has been r ported to cause hypogonadism 
and azoospermia (Bourc’his et al, 2001). Further studies of the testis in these mice 
reported the semineferous tubules to only contain SCs  and some leptotene-like cells. 
The GCs were reported to be arrested and and died around the meitoc stage (Hata et al, 
2006). This study did not report any other effect on masculinisation. Microarray 
expression profiling  found particular sex linked genes to be down regulated, such as 
Sox3, Pern, Ott each of which is gonad specific but it is unclear xactly what this means 
(Hata et al, 2006). However the relationship between xpression of DNMT3L and AR in 
control testis has not yet been reported. The studies reported in chapter 4 found that 
DNMT3L was expressed in cells of the interstitium at e21.5 and PND25 but not at 
PND4. Further studies should determine what cells of the interstitium DNMT3L is being 
expressed in, using Leydig cell-specific markers. Moreover, at PND25, DNMT3L was 
expressed in a stage specific manner in the spermatocytes and it would be interesting to 
characterize what steps of meiotic development this co ncides with, as the DNMT3L 
knockouts show a failure of GC to complete meiosis. The latter findings led the authors 
in question to conclude that it was an underlying problem with gene methylation in 
spermatocytes that caused this GC loss. However, as the present findings show that 
DNMT3L is co-expressed with AR in the SC, it is possible that deletion of DNMT3L 
perturbs normal androgen action in SC, and it is this t at is responsible for the GC loss, 
especially as SC-selective knockout of the AR (SCARKO mice) leads to a similar 
demise of GC during meiosis (de Gendt et al, 2003). Experiments to distinguish between 
these possibilities may assist our understanding of the mechanisms used by DNMT3L 
and why it’s absence causes azoospermia.  
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BORIS, an 11 zinc finger protein, has been shown to play a role in chromatin 
remodeling as well as being considered to have pro-proliferative characteristics (Nguyen 
et al, 1996). BORIS expression has only been found in the testis and studies suggest that 
DNA methylation acts as a negative regulator of BORIS expression, thus the BORIS 
gene activity is methylation controlled (Kelnova et al, 2002; Woloszynska-Read et al, 
2007). The studies in chapter 4 found that BORIS was expressed in the GT as well as in 
the testis. The expression of BORIS in the GT has not been reported before and its role 
in the GT is unknown and calls for further investiga on. Taqman-PCR suggested that 
BORIS expression is decreased during the MPW and in future studies it would be 
interesting to determine if this is reflected at the protein level. The expression of BORIS 
protein was found in the developing testis at e21.5, PND4 and PND25, in interstitial 
cells, SC and GCs and at e21.5 and PND25 in the PTM cells also. A recent study 
reported a BORIS knockout mouse model to be fertile but have small testes and impaired 
spermatogenesis, in comparison to controls (Suzuki et al, 2010); Through microarray 
analysis of the testis of the BORIS knockout model,  this group identified the down 
regulation of a transcript termed cerebroside sulfotransferase (CST), known to be 
involved in meiosis. Furthermore, the study reported BORIS can bind to and activate the 
CST promoter. This study concluded BORIS to have a critical role in transcriptional 
regulation of CST important for spermatogeneisis (Suzuki et al, 2010). Thus recent 
progress has been made in gaining insight into the mechanisms which BORIS might 
play in the testis, however many there are still many questions. Firstly, it is surprising 
that the expression of BORIS with AR in control testis has not been previously fully 
characterized. This characterization of co-expression of BORIS and AR in SC and in 
other somatic cells could be due to a functional relationship, which may result in 
deficient androgen action when BORIS is knocked out which could then causes GC 
problems as a consequence. Methylation is known to be important in GC, but it seems 
when a methylation-associated gene or protein is found to be expressed in the GCs level 
of AR activity in relation to this is not always investigated and yet this activity may 
explain (or contribute to) results of knockout and give  dramatic new insight into 
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androgen action in the testis and elsewhere. As suggested for BRG1 or CBP, a targeted 
knockout of either BORIS or DNMT3L in SC (for example via Amh-Cre system) would 
provide more precise information of the roles these genes play in the testis.  
 
Prostaglandins are known to be involved in various cellular processes in the body and 
indeed during the embryonic period (Challis et al, 2000; Lala, 1989, Norwitz et al, 
2001). Indomethacin is well established as a non-selective COX enzyme inhibitor and 
consequently blocks PG synthesis (Norton, 1997). Reports that blocking PGs during the 
MPW, using indomethacin, in the mouse could affect masculinisation were published 
over 20 years ago (Gupta and Goldman 1986; Gupta, 1989) yet the role of PGs in the 
MPW has never been fully defined or even further investigated. Studies in this thesis 
used the highest concentration of indomethacin possible, in the rat, which allowed for 
dams to avoid adverse effects and parturition to occur around about on time. Even at the 
dose used (1mg/kg) some adverse effects were noted, such as on fetal growth and 
perhaps litter size. Of interest the F1 female generation had misplaced ovaries and there 
was some suggestion of difficulties in estrus cycles and thereafter with parturition. This 
suggests the indomethacin was crossing the placenta and fetuses were being exposed, to 
some level at least. Despite this, no affect was seen on AGD or on any measured aspect 
of the reproductive tract of males exposed to indomethacin. A decrease was found in 
penile length in adult rats that had been exposed to indomethacin during the MPW, but 
this was based on small numbers of animals. Moreover, even if correct, it did not point 
to impaired androgen action in the MPW, as penis size was normal at PND25 and AGD 
and the remainder of reproductive tract development was normal in these animals. 
However, the N number for these animals would need to be increased to determine 
whether or not the effect on adult penis size is real, and such studies should also 
investigate circulating hormone levels (notably testosterone) and the expression of 5α-
reductase in the penis to see if changes in either of these might explain the findings.  
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Thus one of the important conclusions of this thesis i  that exposure of rats to 
indomethacin during the MPW, and possible blocking of PGs, does not affect 
masculinisation of the male reproductive tract, at le st in the rat. The preliminary studies 
to determine if PGs are involved prior to the MPW were also negative, suggesting that 
PGs are unlikely to be a major player in regulation of the MPW. The studies reported in 
this chapter could be strengthened by determining the level of prostaglandins in control 
fetuses and comparing this against prostaglandin production in fetuses after exposure to 
indomethacin. Radioimmunoassays for PGs have been established for many years (Jaffe 
et al, 1973; Oki et al, 1974; Thomas et al, 1978) and could therefore be used for this 
purpose. However, as prostaglandins have a relatively short half life and act over short 
distances in an autocrine or paracrine manner (Hull et a , 2004), such studies may not be 
straightforward.  
 
Development of the male GT is an androgen-dependent process and when androgen 
action is deficient during the MPW, hypospadias canoccur (Baskin et al, 2001;Yamada 
et al, 2003). Consequently it was hypothesized that studying the genes within the GT, 
under normal circumstances and when androgen action is blocked, might provide insight 
into androgen pathways functioning in the MPW, but more specifically, pathways which 
might be involved in hypospadias. Of the three genes studied, Asporin provided the most 
convincing results, whereby it showed a trend towards higher expression in control 
female GT than control male GT, throughout development. Similarly a trend was seen in 
the GT of flutamide exposed fetuses, which expressed Asporin at higher levels than 
control males throughout development. It was not clear if Asporin was either androgen 
or oestrogen regulated, however, as results tended ot to be entirely consistent. In 
attempting to reconcile the various datasets, it was postulated that if the androgen-
oestrogen balance was disturbed, Asporin expression increased. Whilst this remains a 
possibility, to take the idea further would require d termination of the androgen-
oestrogen balance and to correlate changes observed with those in Asporin expression. 
As the androgen-oestrogen balance would need to be measured either in blood (difficult 
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in the fetus because of small volumes, and probably impractical in the MPW for this 
reason) or in the GT itself, which would again pose problems based on small tissue 
amounts available. A major limiting factor in studying Asporin, is the absence of an 
antibody that works on rodent tissue. Overall, the conclusion was that asporin did not 
appear of sufficient interest to warrant further studies with any priority.  
 
It was more difficult to obtain convincing results for Slit2 and Robo1 expression in the 
GT. Initial experiments indicated that Slit2 might be negatively regulated by androgens, 
but upon repetition and increasing time points and treatment groups, the expression of 
Slit2 and actually Robo1 as well, appeared more variable. This could be due to the gene 
having variable expression or another possibility which must be considered was noise 
level within the experiment and one possibility to address this might be an increase in 
PCR cycles.  However in order to fully understand the expression of Asporin, Robo1 and 
Slit2 in the development of the GT requires an antibody which worked in the rat and 
unfortunately we could not obtain such antibodies.  
In summary, this thesis aimed to investigate the regulation of the MPW and androgen 
events which take place during and to some extent bfore the MPW. It was shown (for 
the first time) that AR is present before the MPW and vailability of androgens does not 
regulate the MPW. Furthermore, providing excess androgens either prior to, or during 
the MPW does not advance or enhance masculinisation. Another novel finding was that 
the female reproductive tract is susceptible to perturbations by androgen exposure prior 
to the MPW and thus virilisation of the female reproductive tract by excess androgen 
exposure is not limited to the MPW. Androgen co-regulators and methylation regulators 
were investigated, originally to determine if certain pathways might be involved in i) the 
regulation of the MPW or ii) events within the MPW. Although this was not achieved, 
preliminary characterization studies of 3 androgen co-regulators and 2 methylation 
enzymes in the reproductive tract was reported. It is surprising that so many known 
androgen-co regulators have not been characterized in the male reproductive tract, both 
in fetal and postnatal life. For the first time, this thesis reports that BRG1 and CBP 
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change in expression in cell types in the developing testis and co-localize with AR in 
what appears to be a stage dependent manner. Furthermore, the preliminary studies in 
this thesis suggest that RWDD1 expression is androgen regulated and future studies 
should determine if it is involved in the pathway to hypospadias. This study can also 
conclude that exposure to indomethacin during the MPW, in the rat, does not affect 
masculinisation. Although this study did not determine if PGs synthesis was blocked in 
the fetus by indomethacin and to what extent, the adverse outcomes reported in the 
female offspring suggested that fetuses were exposed and this did not affect androgen 
action during the MPW. Finally, this thesis found that investigating the development of 
the male penile anatomy is not an easy task! However using serial sectioning and OPT 
provided a good method for understanding the development of the rat GT at least from 
e19.5 onwards. Furthermore, in order to investigate p thways which are involved in the 
GT and in hypospadias almost certainly requires working antibodies for 
immunohistochemistry, as without such tools it is dfficult to draw firm conclusions. 
Protein expression and localization in the different planes of the GT is an absolute 
requirement for the understanding of the pathways involved in the development and 
disorders of the GT.  
 
The studies in this thesis have shown that certain entities are not involved in regulation 
of the MPW. However, it still remains to be determined what is regulating the MPW and 
what is unique about this time frame. Although preliminary, the results from the study of 
androgen co-regulators look promising and, irrespectiv  of their role or not in the MPW, 
further studies may lead to a better understanding of the importance of co-regulators and 
their interaction with AR in modulating androgen action in the male reproductive tract. 
This may also lead to specific pathways which are important in TDS and the MPW as 
suggested by the RWDD1 results found. In addition, investigating methylation activities 
before during and after the MPW also looks to be an important angle for future studies 
into regulation of the MPW, although this would be gr atly facilitated if methylation of 
specific genes was being investigated. One of the areas of interest for this thesis was 
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genes involved in GT development and hypospadias. Hypospadias is a disorder which 
involves both the environment as well as genetics (Kalfa et al, 2011). In order to 
investigate the molecular mechanisms of androgen action in the development of the GT 
during the MPW, which might be disrupted in the hypos adias disorder, the use of 
microarrays as a starting point may not be the most promising approach.  
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*Microarray study designed by Dr David McLeod and carried out by Affymetrix. 
GeneGo pathways established by bioinformatics student Kirstine Belling. 
 
All genes were initially investigated by Taqman, those in red showed no interesting 
patterns of expression around the MPW in the lower g nital region. The genes 
highlighted in green showed interesting patterns of expression around the MPW and 
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